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THE SEARCH FOR SMALL MOLECULE INHIBITORS OF HISTONE ACETYLATION  
By Krystle Lea Carey 
 
Histone acetylation is a key mechanism of transcriptional regulation, which is mediated by two sets 
of enzymes; HATs and HDACs. Under normal physiological circumstances there is an orchestrated 
balance between the actions of HATs and HDACs. Disruption of this balance can lead to a number 
of cellular events which can cause the onset of various diseases for example cancer and HIV. The 
search  for  small  molecule  inhibitors  of  histone  acetylation  focuses  on  anacardic  acid  and  the 
azumamides. Anacardic acid is a natural compound found in cashew nut shell liquid. Its structure 
consists of salicylic acid and a long hydrophobic alkyl tail, which suggests that the compound 
would  be rather  insoluble  and  unable  to  permeate cells.  However, it  has  been  discovered that 
anacardic acid has micro molar HAT inhibitory activity towards the HATs PCAF and p300 and is 
able to suppress cancer cell growth. In contrast, the azumamides are a series of cyclic tetrapeptides 
that were discovered in Mycale izuensis, a Japanese marine invertebrate. Azumamides A-E exhibit 
nano molar HDAC inhibitory activity and cytotoxic effects. This report details the synthesis of 
anacardic acid by Suzuki coupling and the application of the Mitsunobu synthesis to generate a 
series of anacardic acid analogues. In vitro biological assays were used to assess the potency of 
anacardic acid  and  forty  four  analogues  towards  cancer  cell  growth inhibition,  HAT,  xanthine 
oxidase, luciferase and p21 reporter activity. Analogue KC_19 was identified to inhibit HAT and 
xanthine oxidase activity with equivalent potency to anacardic acid. KC_39 (IC50 = 18.2 ± 2.6 µM) 
was the most potent analogue in the MCF7 cell growth inhibition but it showed no evidence of 
HAT inhibition. Analogue KC_14 was determined in terms of ease of synthesis, MCF7 growth 
inhibition (IC50 = 52.4 ± 4.5) and PCAF inhibition (IC50 = 31.7 ± 5.0 µM) to be the best anacardic 
acid analogue overall.  The report ends with a small investigation in the inhibition of HDACs by 
the  azumamides  A,  E  and  three  novel  azumamides.  The  azumamide  hydroxamic  acid  was 
discovered to be potent inhibitor of HeLa HDAC activity (IC50 = 7.0 ± 2.5 nM).  
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1 
1 Introduction 
 
Epigenetics and Chromatin 
Epigenetics describes the heritable and transient changes in gene expression without alteration of 
the primary DNA sequence. Epigenetic changes can occur through chromatin remodelling, DNA 
methylation  or  other  regulations  like  RNA  silencing
1-4.  Chromatin  remodelling  is  modulated 
through  covalent  modifications  of  histone tails. This  chapter  reviews  acetylation  and  how this 
dynamic process effects chromatin reorganisation, and hence gene transcription. Eukaryotic DNA 
can  be  condensed  into  a  highly  compact  structure  known  as  chromatin,  formed  by  packing 
nucleosomes  on  top  of  each  other.  Nucleosomes  are  the  basal  units  of  chromatin.  A  typical 
nucleosome is composed of an octamer of the four pairs of core histones and approximately 146 
base  pairs  of  DNA  wrapped  around  the  octamer  core.    Under  an  electron  microscope  these 
nucleosomes look like beads on a string (Figure 1.1).  
 
 
 
Figure 1.1: Pictorial representation of nucleosomes as observed under an electron microscope 
 
The four core histone pairs are H2A, H2B, H3 and H4. These histone pairs are stapled together by 
the linker histone; H1. Each histone has a long conserved, positively charged and lysine rich N-
terminal tail which extends out from the histone core with the H3 NH2 tail being the longest. These 
histone  tails  are  exposed  to  different  types  of  covalent  modifications,  including  acetylation, 
methylation, phosphorylation, SUMOylation and ubiquitination. The covalent modification of the 
histone  tails  is  essential  for  chromatin  reorganisation.  The  positively  charged  lysines  actively 
interact with the negatively charged DNA, and hence covalent modifications can effect the histone-
DNA interactions. Destabilisation of the DNA-histone interaction occurs when acetylation of lysine 
neutralises the positive charge on the ε-amino group. This causes the DNA to adopt a relaxed 
transcriptionally active state. Deacetylation restores these positive charges, DNA is condensed into 
chromatin and transcription is repressed. Besides affecting DNA-histone binding, these covalent 
modifications also influence recruitment of other proteins like accessory regulatory factors which 
indirectly influence transcription. 
 
nucleosome 
DNA  
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 Histone acetylation is reversibly catalysed by two classes of enzymes, histone acetyltransferases 
(HATs)  and  histone  deacetylases  (HDACs)
5.  HATs  covalently  modify  the  N-terminal  lysine 
residues of histones by the addition of an acetyl group from acetyl CoA, whilst HDACs catalyse 
the  hydrolysis  of  an  acetyl  group  (Figure  1.2).  Histone  acetylation  is  a  key  mechanism  of 
transcriptional  regulation.  Under  normal  physiological  circumstances  there  is  an  orchestrated 
balance between the actions of HATs and HDACs. Dysfunction of this HAT/HDAC balance is 
associated  with  various  diseases  like  cancer,  diabetes,  asthma,  cardiac  hypertrophy,  retroviral 
pathogenesis and neurodegenerative disorders. Therefore, modulation of these enzymes is being 
considered as an important therapeutic strategy. 
 
 
 
Figure 1.2: Reversible acetylation mechanism of controlling gene expression by HATs and 
HDACs. HATs catalyse the transfer of an acetyl group from acetyl CoA to lysine residues on 
histone tails.  The positive charge on the ε-amino group is neutralised and the DNA unwinds into a 
transcriptionally active state.  
 
Histone Acetyltransferases 
There are two types of HAT, nuclear A-type HATs and cytoplasmic B-type HATs. A-type HATs 
mainly carry out transcription-related acetylation events. Conversely, B-type HATs are concerned 
with acetylation events linked to the transport of newly synthesised histones from the cytoplasm to 
the nucleus
6. Nuclear A-type HATs are grouped into enzyme family classes based upon sequence 
conservation within the HAT domain and biological function. There are five major families of 
nuclear HAT and each family contains a number of well known transcriptional regulators. The 
HATs  have  been  grouped  together  on  the  basis  of  their  homology  in  several  areas  including 
sequence and structure. A new nomenclature system has been implemented for all characterised 
acetyltransferases
7.  These  enzymes  have  been  given  a  more  generic  name  that  reflects  their 
enzymatic activity and the type of residue they modify. The new names for the acetyltransferases 
are based on KAT (K-acetyltransferase). Figure 1.3 includes examples of the HATs, the family 
HAT + Ac-CoA 
HDAC + H2O 
Genes activated  Genes silenced 
DNA 
histone tail 
histone  
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they belong to and their new name. However to avoid confusion only the original HAT names will 
be used in this thesis report. 
 
Family  HAT  New Name  Organism  Function 
HAT1  KAT1  yeast, human  Histone deposition and DNA repair 
yGcn5  KAT2  yeast  Transcription activation and 
DNA repair 
hGcn5  KAT2A  human  Transcription activation 
PCAF  KAT2B  human  Transcription activation 
Elp3  KAT9  human, yeast, 
fruit fly 
Transcription elongation 
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Hpa2  -  yeast  Unknown 
TIP60/Esa1  KAT5  human, yeast, 
fruit fly 
Transcription activation and 
DNA repair 
Ybf2/Sas3  KAT6  yeast  Transcription activation and 
elongation, DNA replication 
MOZ  KAT6A  human  Transcription activation 
MORF  KAT6B  human  Transcription activation 
HBO1  KAT7  human  Transcription and DNA replication 
M
Y
S
T
 
Sas2/MOF  KAT8  yeast, fruit 
fly 
Chromatin boundaries, dosage 
compensation and DNA repair.  
dCBP/NEJ  KAT3  fruit fly  Transcription activation and DNA 
repair.  
CBP  KAT3A  human  Transcription activation 
p
3
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P300  KAT3B  human  Transcription activation 
SRC-1  KAT13A  human  Transcription activation 
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ACTR 
(SRC-3) 
KAT13B  human  Transcription activation 
TAFII  KAT4  human, yeast, 
fruit fly 
Transcription activation 
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TFIIIC90  KAT12  Human  RNA Polymerase III Transcription 
Initiation 
 
Figure 1.3: A table outlining the five HAT families and their members
7-9 
 
The  HATs  within  these  families  show  high  sequence  homology  but  there  is  little  homology 
between the families. Figure 1.4 shows the HAT domains for a representative member of each  
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HAT family. In addition to the sequence divergence within the HAT domains of different families, 
their functional roles are also different. 
 
HAT
yGCN5 439
yESA1 Zn 445
hCBP C/H-3 2441
hSRC-1 1440
hTAFII230 1875
Abbreviations
Bromo bromodomain
Chromo chromodomain
Zn zinc binding domain
C/H cys/his rich regions (1,2 and 3)
bHLH-PAS basic helix-loop and PAS A and PAS B domains
RIDs LXXLL receptor interacting motifs
HAT
Bromo C/H-2
RIDs
HAT domains in sequence
Bromo
HAT
Bromo
Bromo
HAT
HAT
HAT
Chromo
C/H-1
Kinase
bHLH-PAS
 
Figure 1.4: A bar diagram of the different HAT families and their associated domains
10 
 
The best understood set of acetyltransferases is the GCN5-related N-acetyltransferase (GNAT) 
superfamily. The first member to be discovered was Gcn5 from Saccharomyces cerevisiae (yeast). 
Other family members include, human Gcn5, PCAF and at least three more distantly related HATs, 
Hat1, Elp3, and Hpa2 (Figure 1.3). The HATs within the GNAT family function as co-activators 
and contain a C-terminal bromodomain (Figure 1.4). Bromodomains serve as acetyl-lysine binding 
domains and more is discussed about their structure later. 
 
Another  group  of  evolutionary  related  proteins  is  the  MYST  family,  named  for  the  founding 
members MOZ, Ybf2/Sas3, Sas2, and Tip60. Additional members have been identified including 
yeast Esa1, Drosophila MOF, human HBO1 and MORF.  Most MYST family members have a N-
terminal chromodomain and a small zinc binding domain within the N-terminal region of the HAT 
domain. The MYST family also share a small acetyltransferase region with the GNAT family. This 
region contains an Arg/Gln-X-X-X-Gly-X-Gly/Ala segment that has been specifically implicated in 
acetyl-CoA substrate recognition and binding
8. Although the MYST family contain regions that are 
similar in sequence, the HAT members are involved in a wide range of regulatory functions in 
various organisms. Sas2 and Sas3 are involved in transcriptional silencing. Esa1 is essential for cell 
cycle progression. TIP60 is involved in transcriptional activation and is known to interact with the 
activation domain of HIV1-1 Tat
11. MOF has an important role in the transcriptional regulation of  
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dosage compensation. HBO1 interacts with ORC1 a subunit of the origin recognition complex 
which binds to DNA replication origins and is critical for initiation of replication
12. These examples 
clearly demonstrate the diverse range of regulatory functions modulated by HATs. 
 
The nuclear receptor co-activators include the HAT proteins ACTR and SRC-1 (Figure 1.3). These 
proteins are directly implicated in transcriptional activation brought about by physiological events 
such as hormone signalling. SRC-1 has been shown to interact with numerous nuclear receptors 
including progesterone-, glucocorticoid-, estrogen-, thyroid hormone- and retinoid X- receptor
13. 
The  nuclear  receptor  co-activators  contain  an  N-terminal  basic-helix  loop  PAS  A  and  PAS  B 
region, central receptor interacting domains (RIDs) and a C-terminal HAT region (Figure 1.4)
8.  
 
The general transcription factors contain HAT proteins which are subunits of general transcription 
factors. These general transcription factors are one of the many components required for assembly 
of  the  RNA  polymerase  II  transcription  complex.  TFIID  and  TFIIIC  are  two  such  general 
transcription factors.  TFIIIC90 is a subunit of the TFIIC transcription factor. Subunits of the 
TFIID  general  transcription  factor  include  the  TAFII  (TATA-binding  protein  [TBP]-associated 
factor) proteins; TAFII 250 (human), TAFII 230 (fruit fly) and TAFII 145/130 (yeast)
14. Like Gcn5, 
PCAF and p300/CBP, TAFII 250 has a bromodomain whilst the fruit fly homolog, TAFII 230 has 
two and the yeast homolog has none. The TAFII proteins also contain a conserved central HAT 
region  with  a  potential  acetyl-CoA  binding  site
8.  The  HAT  activity  of  the  TAFII  subunits  is 
required  to  facilitate  RNA  polymerase  transcription  complex  formation.  This  is  achieved  by 
acetylating nucleosomes at the site of the promoter to facilitate access of TBP to the TATA box at 
the promoter
14. 
 
The p300/CBP family contains the transcriptional co-activators p300 and CBP. These two HAT 
proteins are often referred to as single entity ‘p300/CBP’ since the two proteins are considered 
structural  and  functional  homologs.  The  p300/CBP  HATs  contain  several  protein  domains, 
including a bromodomain, and three cysteine-hystidine rich domains (C/H-1, C/H-2 and C/H-3) 
that  are  believed  to  mediate  protein-protein  interactions
8.  p300/CBP  enhances  transcriptional 
activation through multiple pathways. One route is by assisting in the recruitment of the RNA 
polymerase II to promoters through interaction directly with polymerase II holoenzyme and general 
transcription factors. Another route is through the acetylation of nucleosomes, either directly or 
through the recruitment of additional HAT proteins, enabling access of DNA-binding proteins to 
the promoter. Lastly p300/CBP can enhance transcriptional activation through the acetylation of 
transcription factors
15. Hence, the p300/CBP members not only mediate acetylation of histones but 
facilitate the access of the transcriptional machinery and the recruitment of non-histone regulatory 
factors  too.  The  multifunctional  p300/CBP  transcription  co-activator  is  the  most  potent  of  the 
HATs and can acetylate all four core histones within nucleosomes as well as acetylate numerous  
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regulatory targets
16. Hence, the p300/CBP HATs are global transcriptional co-activators whereas 
the GNAT and MYST family members play a direct role in histone substrate binding or chromatin 
targeting. For example members of the MYST family serve as catalytic subunits in Tip60, HBO1 
and MOZ/MORF complexes
11, 12. 
 
Gcn5
Ada3
Ada2
Spt7
Spt20
Ada1
HAT
TAFII90
TAFII25
TAFII
20
TAFII60
TAFII68
Spt3
Spt8
Tra1 
Gcn5
Ada3
Ada2
Spt7
Spt20
Ada1
HAT
TAFII90
TAFII25
TAFII
20
TAFII60
TAFII68
Spt3
Spt8
Tra1 
 
Yeast SAGA complex 
 
Figure 1.5 Schematic diagram of known subunits and functions of the yeast SAGA complex
9.  
The  transcriptional  adaptor  components  (Ada2,  Ada3  and  Gcn5)  are  coloured  in  yellow.  The 
subunits coloured in blue (Ada1, Spt7 and Spt20) are required for structural integrity and overall 
function. The green Sp8 and Spt3 subunits interact with TATA-binding protein (TBP) and the red 
TAFII subunits provide TBP-binding functionality. The SAGA complex also contains the ATM/PI-
3-kinase-related  protein  Tra1,  which  is  the  yeast  homolog  of  the  human  transformation/ 
transcription domain-associated protein (TRRAP).  Last but not least the SAGA complex possesses 
HAT activity through the HAT domain of Gcn5 (coloured in purple).  
 
These  large  multiprotein  complexes  are  made  up  of  a  number  of  DNA-sequence  specific 
transcription  factors.    They  facilitate  access  to  DNA  and  recruitment  of  downstream  effectors 
through three distinct mechanisms: chemical modification of histone amino-acid residues, ATP-
dependent chromatin remodelling and histone exchange. A large number of HAT proteins have 
been  found  to  be  associated  with  large  multiprotein  complexes.  Yeast  Gcn5  is  part  of  two 
multiprotein  complexes,  SAGA  and  AGA.  SAGA  is  approximately  2.0  MDa  in  size  and  is 
composed of at least 15 subunits divided into four groups of transcription related proteins, Ada, 
Spt, TBP-associated factors (TAF), and Tra1. The known subunits and their functions in the yeast 
SAGA complex are explained in Figure 1.5. 
 
The  transcriptionally  associated  proteins  of  SAGA  enhance  the  ability  of  Gcn5  to  acetylate 
nucleosomal histones and confer upon Gcn5 the ability to acetylate an expanded set of lysine  
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residues
17. Other HAT complexes have been identified and these include histone H4-specific NuA4 
(Nucleosome  acetyltransferase  of  histone  H4),  histone  H3-specific  NuA3  (Nucleosome 
acetyltransferase of histone H3), Sas complex and Elongator complex. The catalytic subunits of 
these complexes are Esa1, Sas3, Sas2 and Elp3 respectively. These multiprotein complexes also 
contribute to the ability of HATs to acetylate nucleosomal histones (Figure 1.5).  
 
HAT H2A H2B H3 H4 Non-histones
GNAT
Gcn5 14 8, 16
PCAF 14 8 p53, MyoD, HIV-1 Tat, E2F1, HMG I (Y), HMG17, 
TFIIE and TFIIF
HAT1 12
Hpa2 14 ￿
Gcn5/ADA nucleosomes 14, 18
Gcn5/SAGA nucleosomes 9,14,18
PCAF/complex ￿ nucleosomes
Elp3 Elongator 14 8
MYST
Esa1 5 14 5, 8, 16
MOF ￿ ￿ 16
Tip60 5 14 5, 8, 12, 16
Sas3 ￿ ￿ ￿ ￿ ￿ ￿ ￿ ￿ ￿
MORF ￿ ￿ ￿ ￿ ￿
MOZ 14 5, 8, 12, 16
HBO1 ￿ ￿ 5, 12, 8, 16
Esa1/NuA4 nucleosomes ￿
Sas3/NuA3 nucleosomes
Sas2 complex 14 16
MOF/MSL nuclesomes
p300/CBP
p300/CBP
5 12, 15 14, 18 5, 8
p53, GATA-1, EKLF, dTCF, HIV Tat, HMG I (Y), SRC-
1, ACTR, TIF2, TFIIE and TFIIF
Nuclear Receptor Co-activators
SRC-1 9, 14 ￿
ACTR ￿ ￿ ￿ ￿ ￿ ￿ ￿ ￿
General Transcription Factors
TAFII230 14 ￿
TFIIIC90 14  
 
Figure 1.6: A table of the HAT subfamilies and the substrate specificity of each member
9, 11, 18-
23.  Histones that are the primary in vivo substrates for a given HAT are highlighted in bold, other 
histones listed are acetylated weakly or in a secondary manner. Where possible the specific lysines 
that have been acetylated are listed. The numbers denote the position of the lysine residue in the 
histone sequence. The tick marks indicate that the histone is acetylated by a specific HAT but the 
specific lysines have not been identified. 
 
It was mentioned that different HAT family members have different functions. In addition, the 
HAT subfamilies generally have distinct substrate specificities. For example the GNAT family has 
a preference for Histone H3 and in particular lysine 14. HAT Gcn5, PCAF, Hpa2 and the Elongator 
complex all show strong preference for histone H4 lysine 14 (Figure 1.6). Gcn5 and PCAF also 
acetylate lysines 8 and 16 on histone H4 but to a lesser degree. In contrast, all but the Sas3 member 
of the MYST HAT family show an enhanced preference for lysine residues on histone H4 over  
 
8 
those  on  histone  H3.  The  p300/CBP  family  has  no  substrate  specificity  and  as  previously 
mentioned this family of HATs are able to acetylate lysines on all four histones. The substrate 
binding specificities of the HAT proteins is broadened when they form part of the multiprotein 
HAT complexes. For example Sas2 only has HAT activity when it forms a complex with Sas4 and 
Sas5. Sas2 as the catalytic subunit is essential for HAT activity. Sas4 is thought to interact with the 
histone deposition protein Arf1, whilst Sas5 stimulates HAT activity. The Sas2 complex acetylates 
histone H4 lysine 16 and histone H3 lysine 14 with HAT activity preference for the former
19, 22. 
Other complexes show extended specificity towards nucleosomes, for example the repertoires of 
Gcn5, Esa1 and Sas3 have been increased to include acetylation of nucleosomes.  
 
Finally the HAT p300/CBP and PCAF can acetylate non-histone proteins which is phenomenon 
also  known  as  intrinsic  transcription  factor  acetyltransferase  (FAT)  activity.  These  HATs  are 
responsible for acetylating hundreds of non-histone proteins alongside their histone targets. These 
include more than sixty transcription factors and many other proteins involved in DNA repair and 
replication,  metabolism,  cytoskeletal  dynamics,  apoptosis,  nuclear  import,  protein  folding  and 
cellular signalling
24. Hence, HATs do not just play a role in transcription but in other regulatory 
processes from signalling to protein degradation.  
 
p300/CBP/ and PCAF acetylate a huge number of DNA binding transcription factors; these include 
p53, NF-κB, GATA-1 and GATA-3, MyoD and E2F. Acetylation of the DNA binding transcription 
factors within their DNA binding domains can lead to disruption or stimulation of DNA binding. 
The tumour suppressor protein p53 is a key player in cellular signalling and stress responses. It is 
responsible  for  regulating  gene  expression  concerned  with  cell  cycle  arrest,  senescence  and 
apoptosis.  Acetylation  of  p53  by  CBP  increases  its  DNA  binding  affinity  followed  by 
transcriptional activation of its target genes and consequent DNA repair. p21
 (WAF1, CDKN1) is a potent 
cyclin-dependent  kinase  inhibitor  that  belongs  to  the  Cip/Kip  family  of  CDK  inhibitors.  Its 
expression is tightly controlled at the transcriptional level by p53. Under stress conditions like 
DNA damage, p53 induces p21, which results in growth arrest
24.  
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HAT Structure  
The  HATs  from  the  GNAT  and  MYST  families  were  the  first  to  be  characterised  at  the 
biochemical and structural level. Crystal structures have been published for a number of HATs in 
complex  with  acetyl  CoA.  GCN5  is  currently  the  best  characterised  with  crystal  structures 
published  for  the  HAT  domains  of  Tetrahema,  (tGcn5),  yeast  (yGcn5)  and  human  (hGcn5) 
homologs
25-27. The crystal structure for hGcn5 HAT domain in complex with acetyl CoA was 
published in 2007 and is shown in Figure 1.7. 
 
hGcn5/acetyl CoA 
 
Figure 1.7: Ribbon structures of a hGcn5 HAT domain and acetyl CoA
27. The central core 
domain in coloured in green, the N-terminal end in blue and the C-terminal end in red. Acetyl CoA 
is represented as a ball and stick model. PDB reference 1Z4R
27. 
 
The crystal structure has a mixed α/β globular fold which consists of seven α-helices and seven β-
strands. The overall topology of the protein is shaped like a vise and the HAT domain folds around 
a central core with the N- and C-terminal ends of the protein flanking the sides. The central core 
consists  of  a  mixed  β-sheet  built  up  of  anti-parallel  β-strands  followed  by  an  α-helix  on  the 
underside of the β-sheet. This core domain corresponds to GNAT motifs D, A and B which are the 
most conserved regions amongst the GNAT family. The acetyl CoA molecule mainly binds to the 
backbone  of the  central  domain  by  hydrogen  bonds  from  the  panthothenic  and  pyrophosphate 
moieties (Figure 1.8).  
 
10 
 
O
O H
N
N
N N
N H2
O
P
O
O
O
O
P
O
O O
P
O
O O
OH
O
N
H
N
H
S
O
O
adenine                             pyrophosphate     pantothenic acid                                 acetyl  
 
Figure 1.8: Chemical structure of acetyl CoA 
 
The Gcn5 and PCAF proteins share significant sequence and structural similarity. All the proteins 
exhibit a mixed α/β globular fold, a conserved central protein core and vise-shaped topology. The 
central protein core is not only conserved amongst the GNAT family but is also shared with the 
MYST  family.  The  HAT  proteins  also  show  a  structurally  conserved  loop-β-strand  region 
immediately C-terminal to the α-helix of the A-D motif. Outside the central core, the N- and C-
terminal ends are highly divergent amongst all HATs.  Interestingly the histone H4 specific HATs 
for example Esa1 and Hat1 are more similar to each other in this region than to the H3 specific 
HATs Gcn5 and PCAF
8.  
 
Investigations  into  HAT  structure  and  substrate  specificity  have  been  made  by  Poux  et  al
28. 
Structural comparisons were made between tGcn5 and acetyl CoA in complex with varying peptide 
substrates. These included 19-residue histone H4, histone H3 and p53 and 11-residue histone H3. It 
was shown that Gcn5 exhibits substrate preference for histone H3 lysine 14 (Figure 1.6). Lysine 8 
of histone H4 and lysine 320 of p53 can also be acetylated by tGcn5 with reduced affinity.   
 
Further investigation revealed that the most significant deviation in each of the ternary complexes 
was found in the peptide substrates themselves. There was also no evidence of strictly conserved 
residues between the substrates. Thus explaining the reduced affinity of tGcn5 for histone H4 and 
p53 however, tGcn5 is still able to accommodate these substrates. Further analysis showed that 
despite  the  divergence  in  sequence  between  the  peptide  substrate,  the  same  protein  residue 
interactions were maintained. The residues at the C-terminal end of the reactive lysine are more 
ordered than the N-terminal end and hence contribute to the majority of interactions between the 
peptide and active site. It was hypothesised that residues C-terminal to the reactive lysine are 
important  for  substrate  selectivity  whilst  residues  N-terminal  to  the  lysine  influence  substrate 
affinity. It was then discovered that residues at positions +2 and +4 at the C-terminal of the active 
lysine were shown to be of a similar chemical nature across the substrates and allowed similar H-
bonding and van der Waals interactions. Hence, tGcn5 can bind to a range of substrates permitting 
the same conserved protein interactions can be made
28.  
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p300/Lys-CoA  
 
Figure 1.9: Ribbon structure of human p300 HAT domain in complex with the bisubstrate 
inhibitor Lys-CoA
29. The conserved central core domain in coloured in blue, the N-terminal end in 
green and the C-terminal end in pink. Lys-CoA is represented as a ball and stick model. Structure 
was created using PDB Workshop version 3
30. PDB reference 3BIY
29. 
 
In 2008, Lieu et al. published the crystal structure for human p300 in complex with an HAT 
inhibitor,  Lys-CoA  (Figure  1.9)
29.  The  protein  structure  shows  an  elongated  globular  domain 
containing a β-sheet made up of seven β-strands. This β-sheet is flanked by nine α-helices and 
several loops. The longest loop is 25 residues long and is known as the substrate binding loop (L1).  
This loop is a unique feature of p300/CBP HATs and is thought to bury about a third of the Lys-
CoA inhibitor in the binding site
31. Another pocket is found about 3-4 residues away from the 
lysine binding site. This second pocket is thought to be important for binding further basic residues 
(lysine or arginine) of the peptide substrate. The central core region has structure conservation with 
the Gcn5/PCAF and MYST HATs, but significant structural variances lie in the regions flanking 
the  central  core  regions.  Another  difference  is  found  in  electrostatic  potential  of  the  substrate 
binding surface. The HATs Gcn5 and Esa1 have deeper more apolar binding pockets whereas the 
p300 HAT domain features a shallow and highly acidic binding site.  The differences in structure 
between the GNAT protein Gcn5 and p300 offers some explanation towards the difference in 
substrate specificity between the two enzymes.  
 
Substrate binding loop L1 
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It was mentioned earlier that the GNAT, p300/CBP and the general transcription factor (TAFII) 
families  each  possess  a  bromodomain  (Figure  1.4).  Bromodomains  provide  further  substrate 
specificity  in  the  GNAT  and  p300/CBP  families.  They  play  an  important  role  in  chromatin 
remodelling and serve as acetyl-lysine binding domain. They are also perceived as an important 
regulator  of  HATs.  It  has  been  suggested  that  the  specific  acetyl-lysine  recognition  by  the 
bromodomains play a role in tethering HATs to specific chromosomal sites
32.  
 
 
                                PCAF/H3-K36ac                                       CBP/H4-K20ac  
 
Figure 1.10: Ribbon structures of PCAF and CBP bromodomains bound to acetylated histone 
peptides
33. The N-terminal end is coloured in blue and the C-terminal end in pink. The acetylated 
peptides are represented as a ball and stick model and are coloured by atom. The structures was 
created using PDB Workshop version 3
30. PDB references 2RNX and 2RNY
33. 
 
Zeng et al. investigated the basis for the site specific histone recognition by bromodomains
33. They 
constructed 3D solution structures for the bromodomains of PCAF and CBP complexes with their 
specific acetylated lysine histone substrates (Figure 1.10). The conformation of these structures 
shows a conserved left-handed four helix bundle with a pronounced cleft between two inter helical 
loops; ZA and ZB. The acetyl-lysine side chain intercalates deep into the hydrophobic cleft of the 
bromodomain.  A  conserved  asparagine  residue  serves  as  the  focal  point  for  acetyl-lysine 
recognition. In the side chain of asparagine, an amide hydrogen forms a hydrogen bond with the N-
ZA and ZB loops  
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acetyl carbonyl of lysine thus anchoring the peptide to the bromodomain. Hence, un-acetylated 
histones do not bind to the bromodomain of PCAF or CBP. The difference in structure between 
CBP and PCAF lies in the ZA and ZB loops that flank the binding site. Hydrophobic interactions 
between  specific  side  chains  of  the  ZA  and  ZB  loops  and  the  histone  peptide  backbone  are 
important for stabilising the bound peptide and contribute to histone selectivity. These specific 
residues vary between bromodomains, hence the distinct histone binding selectivity of PCAF and 
CBP.  
 
HAT Mechanism of Action 
HATs catalyse the transfer of the acetyl moiety from acetyl CoA to the ε-amino lysine of histones 
and  other  substrates  resulting  in  acetylated  lysine  and  CoA.  The  actual  mechanism  for  acetyl 
transfer varies slightly between the GNAT, MYST and p300/CBP families. This also mirrors the 
structural variances and difference in substrate specificity between the families. Information gained 
from the crystal structure of HAT ternary complexes along with steady state reaction kinetics and 
site directed mutagenesis have all contributed towards elucidating the HAT mechanisms of acetyl 
transfer.  
 
The  GNAT  family  member  yGcn5  employs  a  sequential  binary  mechanism  that  involves  the 
ordered binding and release of substrate and products. Tanner et al. performed a series of X-ray 
crystal structure analysis, steady state kinetics and chemical modifications to show that yGcn5 
catalyses direct transfer of acetyl CoA to the lysine molecule
34. The acetyl group is not transferred 
to the enzyme and instead a ternary complex is formed. Another crucial step in the mechanism is 
deprotonation of the ε-amino lysine group. At physiological pH, the lysine molecule would be 
protonated and unreactive. Chemical modification studies have shown that glutamate (Glu) is the 
specific base catalyst responsible. This residue is conserved across  the GNAT and MYST families, 
Glu 173, Glu 570 and Glu 338 are the base catalysts for yGcn5, PCAF and yEsa1 respectively
35, 36.   
 
In the ordered sequential binary mechanism (Figure 1.11) HAT, acetyl CoA and lysine form a 
ternary complex. A conserved glutamate residue in the HAT domain directly attacks the ε-lysine 
and  deprotonates  the  amine.  The  deprotonated  lysine  then  performs  nucleophilic  attack  of  the 
carbonyl carbon in acetyl CoA. This leads to formation of a tetrahedral intermediate, which then 
collapses to from acetylated lysine product and CoA
35.   
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A) Ordered sequential binary ternary complex mechanism 
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B) Theorell-Chance Mechanism 
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Figure 1.11: HAT mechanisms of acetyl-transfer
29, 35 
 
The  HAT  p300  employs  a  different  HAT  mechanism.  It  was  originally  suggested  that  p300 
employed  a  double  displacement  (ping  pong)  mechanism.  However,  there  have  been  some 
contradictory findings. Mutagenesis of three nucleophilic residues in close proximity to the active 
lysine failed to reduce HAT activity. Hence, HAT activity was still proceeding by some other 
mechanism. The ordered binary mechanism is also not applicable since bisubstrate analogues with 
longer  peptide  moieties  were  found  to  be  weaker  binders  to  p300  than  the  simple  Lys-CoA 
analogue. For example the 20 residue bisubstrate analogue Lys-CoA-20 inhibits p300 (IC50 = 200 
µM) about 20-fold weaker than Lys-CoA (IC50 = 0.5 µM)
37. Lys-CoA lacks the means to form 
significant interactions with the HAT domain since it does not possess the positively charged ε-
amino  group  as  found  in  histone  substrates.  If  the  ordered  binary  complex  mechanism  was 
applicable to p300 then bisubstrate analogues with authentic peptide moieties would bind more  
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efficiently than the simple Lys-CoA analogue. Hence, Liu et al. proposed that the Theorell Chance 
mechanism was a better model for p300 catalysed acetyl transfer
29.  
 
The Theorell-Chance mechanism (Figure 1.11) differs from the ordered sequential mechanism in 
that  no  stable  ternary  complex  is  formed  during  the  fast  acetyl  transfer.  Instead,  the  peptide 
substrate interacts weakly with the p300 active site, allowing the lysyl residue to protrude into the 
active site and react with acetyl CoA. Two residues have been identified in the p300 HAT structure 
that assists the fast acetyl transfer mechanism. A phenolic Tyrosine residue (Tyr1467) forms a 
direct H-bond to the sulfur atom of acetyl CoA. It plays a key orientating role as well as an acid 
which protonates the CoA leaving group. The second residue, Tryptophan (Trp1436) has an indole 
side  chain  which  forms  van  der Waals contacts  with  the  lysine side  chain,  guiding  the lysine 
molecule towards acetyl CoA attack. The carbonyl oxygen of the amide group also primes the 
lysine for attack by reducing the pKa of the ε-amine group of lysine.  
 
This  understanding  of  catalytic  mechanism  and  histone  substrate  binding  can  help  elucidate 
functional groups that are compatible and selective for HAT binding.  It is understood that although 
the HAT families exhibit significant divergence in sequence in families, the central core domain 
remain  conserved.  However  despite,  the  structural  conservation  of  the  core  domain  there  are 
differences in the specific mode of acetyl-transfer. It is these differences that determine the HAT 
specificity and selectivity for histone and non-histone substrates.  
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HATs and Cancer 
The search for small molecule modulators of histone acetylation began when it was realised that 
such inhibitors would have therapeutic potential against disease. Misregulation of HATs have been 
implicated in the onset of cancer (Figure 1.12).  
 
HAT  HAT implications in cancer 
Gcn5  Critical regulator of cell cycle and c-Myc 
PCAF  Critical regulator of cell cycle, p53, E2F and c-Myc 
p300/CBP  Translocation: MOZ-, MORF-, and MILL-p300/CBP fusions 
Mutation: Rubinstein-Taybi syndrome and epithelial cancer 
Inactivation: haematological malignancy  
TIP60  Association with androgen receptor in prostrate cancer 
MOZ  Fusions with p300/CBP and TIF2 
MORF  Fusions with p300/CBP 
ACTR  Up-regulation  in  breast  cancer  correlates  with  resistance  to 
tamoxifen.  
 
Figure 1.12: Acetyltransferases with a potential role in cancer
38 
 
HATs can function as either tumour suppressors or as tumour activators. Evidence that p300/CBP 
is a tumour suppressor has been provided by a range of studies. Point mutations in the genes 
encoding  p300  and  CBP  located  on  chromosomes  16p13.3  and  22q13.1  respectively  form  the 
genetic basis of Rubinstein-Taybi syndrome, a complex disease that includes a high incidence of 
cancer. It was discovered from studies of patients with mutations that affect the HAT domain of 
CBP that a loss of HAT activity is also sufficient to cause the syndrome
39. The genes that encode 
p300/CBP  have  been  found  mutated  in  several  human  cancers  including  glioblastoma,  breast, 
colorectal and gastric carcinomas. However, it has been deduced by Ozdag et al. that neither gene 
is commonly mutated in epithelial cancers after thorough screening of the genes in a range of 
epithelial cancer cell lines (at least 60) and primary tumors
40.   
 
Further evidence that p300/CBP proteins possess tumour suppressor activity can be gained from 
their role in regulating chromatin and tumour suppressor proteins such as p53
41. The “genome 
guardian”  is  another  name  for  p53 and its  importance  is  emphasised by  the discovery  of  p53 
mutations in more than 50% of all human cancers.  One of the key regulators of p53 function is 
acetylation.  Under  any  type  of  in  vivo  stress,  the  acetylation  levels  of  p53  are  significantly 
enhanced.  This  correlates  with  the  requirement  of  acetylation  to  enhance  stabilisation  and 
activation of p53
42.   
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Aberrant  regulation  of  HAT  targeting  and  activity  has  been  linked  to  leukemogenesis. 
Chromosomal translocation of the genes that encode p300/CBP with genes for other HAT proteins 
creates abnormal fusion proteins which can induce leukaemia. Such translocation-derived fusion 
proteins can cause either loss-of-function or gain-of-function in gene expression; in any case the 
result is aberrant cell cycle regulation and then cancer. In acute myeloid leukaemia (AML) the gene 
for CBP is translocated and fused to either the MOZ-, MORF- or to the histone methyltransferase 
MILL  gene.  For  example  MOZ  interacts  with  the  AML-1  transcription  factor  responsible  for 
simulating gene transcription and cell differentiation. MOZ and p300/CBP act as a co-activator of 
AML-1. However, t(8;16) translocation results in the expression of MOZ-CBP fusion proteins 
which targets AML-1 and induces leukemia
43.  
 
HAT  acetylation  is  not  only  implicated  in  cancer,  other  clinical  diseases  are  associated  with 
aberrant  HAT  function.  Loss  of  p300/CBP  function  is  found  to  be  associated  with  certain 
neurodegenerative diseases. Degradation of p300/CBP by caspase-6 causes a decrease in histone 
acetylation.  Reduced  acetylation  of  transcription  factors  implicated  in  neuroprotection  such  as 
phosphor-CREB leads to the onset of neuronal apoptosis
44.  
 
Some viruses encode proteins such as the adenoviral E1A, the HIV-1 Tat, or the simian virus 40 
large T protein to specifically target p300/CBP. This causes a loss of cell growth and enhances 
DNA synthesis. HAT function is essential for the replication of HIV. Upon infection of susceptible 
cells  HIV-1  is  transcribed  and  integrated  into  the  host  genome.  The  enzyme  responsible  for 
insertion, HIV-1 integrase (HIV-1 IN) is acetylated by p300 which is essential for DNA binding. 
The  HATs  p300/CBP  and  PCAF  also  play  a  central  role  in  activating  HIV  transcription  by 
regulating recruitment of HIV-1 Tat to the viral long term repeat (LTR) promoter. Tat transcription 
activity is initiated by p300/CBP acetylation of a specific lysine (lys50) in Tat followed by PCAF 
binding  to  the  acetylated  lysine  via  its  bromodomain.  This  bromodomain  mediated  interaction 
results  in  the  release  of  lysine-acetylated  Tat  from  the  LTR  promoter  and  activates  HIV-1 
transcriptional activation
32. p300/CBP also acetylate nucl, a single nucleosome which is located 
downstream of the HIV transcription start site. Hence, acetylation of nucl, HIV-1 IN and HIV-1 Tat 
by HATs are important for HIV multiplication
45.  
 
These examples clearly highlight the importance to target HAT enzymes for clinical therapy or 
development  of  molecular  tools  to  explore  the  role  of  the  physiological  pathways  in  human 
diseases.   
 
18 
HAT Inhibitors 
There is a wide range of HDAC inhibitors currently in clinical trials for the treatment of cancer. 
These include the drugs suberoylanilide hydroxamic acid (SAHA) and FK228 which have been 
clinically approved. These drugs are able to induce the repression of tumour suppressor genes in 
vivo at amounts that have little or no toxicity
46. However there are no clinically acceptable HAT 
inhibitors and certainly none of the HAT inhibitors exhibit the potency characterised by the HDAC 
inhibitors. There is substantial progress to be made in the development of potent HAT inhibitors. 
This chapter reviews current HAT inhibitors as models for improvement.   
 
Lys-CoA                                                                                          H3-Lys-CoA-20 
 
Figure 1.13: Chemical structures of peptide CoA conjugates 
 
The first reported HAT inhibitors were bisubstrate analogues that target the HAT p300 and PCAF. 
These HAT inhibitors were designed as a conjugate of the amino acid lysine and acetyl CoA, the 
two  substrates  used  by  HATs.  Several  mimics  of  the  lysine  substrate  of  the  HAT  have  been 
designed,  but  none  have  gone  through  to  clinical  trials.  Lys-CoA  (Figure  1.13)  is  a  specific 
inhibitor of p300 HAT (IC50 = 500 nM) whilst H3-CoA-20 (Figure 1.13) is a specific inhibitor of 
PCAF  (IC50  =  300  nM).  PCAF  selectively  acetylates  Lys-14  of  histone  H3  and  this  substrate 
preference  is  exploited  in  H3-Lys-CoA-20,  hence  the  potent  nature  of  this  conjugate  towards 
PCAF
37. The main failure of these substrate mimics are their low cell permeability and metabolic 
instability which decreases their suitability for investigations in vivo
2. There could also be an issue 
with  affinity  of  these  analogues  towards  other  enzymes  that  use  lysine  and  acetyl  CoA  as 
substrates.   
 
In 2003 a natural product anacardic acid (Figure 1.14) from cashew nut shell liquid was shown to 
have non specific HAT inhibitory activity towards p300 (8.5 µM) and PCAF (5.0 µM)
47. Anacardic 
acid consists of a salicylic acid with a long alkyl tail. Eliseeva et al. explored anacardic acid as a 
natural product lead and designed a series of analogues composed of substituted phenoxyacetic 
acid  ethyl  esters  (1,  R  =  C2H5),  their  corresponding  acids  (1,  R  =  H),  debenzylated  (3), 
sulphonamide (4), and amide (5) derivatives (Figure 1.14)
48. 
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Anacardic acid                                                                    CPTB 
 
 
   (1)                             (2)                                 (3)                             (4)                             (5) 
 
For (1) and (2) R1 = H, CH3, OCH3 or halide; R2 = H or Cl, R3 = C4H9, C10H21, C13H27 or C16H33. 
For (3) R3 = C4H9 or C10H21. 
 
Figure 1.14: Chemical structures of anacardic acid and current published analogues
47, 48 
 
In  total,  twenty  eight  derivatives  were  based  on  anacardic  acid  as  a  lead  HAT  inhibitor.  
Modifications included addition of a second aromatic ring, changing the position of the alkyl chain 
(2), its length (R3), making various substitutions at the second aromatic ring (R1 and R2) and 
introducing  a  polar  group  in  the  spacer between the  two  aromatic  rings  (4  and  5).  All  of the 
compounds  were  examined  for  p300  inhibitory  activity  in  HeLa  nuclear  extracts.  Only  one 
compound (1, R, R1, R2, = H, R3 = C13H27) had an IC50 of 6 µM which matched the inhibitory 
activity  of  anacardic  acid  (IC50  =  5  µM).  Experimental  findings  also  showed  carboxylic  acid 
derivatives (Figure 1.5 (1, R= H)) increased HAT inhibitory potency by ten fold compared to ethyl 
esters and derivatives that had the longest alkyl tails were less toxic to cell lines. Like anacardic 
acid,  these  compounds  suffer  from  a  very  high  lipophilicity  and  low  solubility  in  aqueous 
medium
48.  
 
Using  anacardic  acid  as  a  synthon  an  amide  derivative  of  anacardic  acid  called  CTBP  was 
synthesised  by  Balasubramanyam  et  al
49.  CTBP  (Figure  1.14)  features  a  5-amino-2-chloro-
benzyltrifluoride moiety substituted onto the benzylic acid of anacardic acid. This compound was 
shown  to  possess  exclusive  specificity  for  enhancement  of  p300  HAT  activity.  An  in  vitro 
radioactive filter binding assay showed that CPTB (275 µM) increased p300 HAT activity 4 fold 
compared to a standard DMSO control. The PCAF HAT activity remained constant in the present 
OH
OH
O
N
H
O O
CF3
Cl
OH
O R3
OH O
NH
O C10H21
OH O
S O O
Cl
N H
O C10H21
OH O
O
Cl
O
O R3
OR O
R1
R2
O
R1
R2
O
OR
O
R3 
 
20 
of CPTB
47. This selective activator of p300 may be a useful tool for finding potent and specific 
inhibitors of p300/CBP HATs. However, the reoccurring solubility problem arises since cells are 
poorly permeable to CTBP.  
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                      Garcinol                                                                    LTK-14 
 
Figure 1.15: Chemical structure of garcinol and LTK-14
45, 50 
 
Garcinol (Figure 1.15), a polyisoprenylated benzophenone derivative from Garcinia indica fruit 
rind is the first reported cell permeable HAT inhibitor. The HAT inhibitory activity of garcinol was 
assayed using baculovirus-expressed recombinant p300 and PCAF in a filter binding assay. It was 
proved  as  a  non-specific  inhibitor  of  p300  (IC50  7  µM)  and  PCAF  (IC50  5  µM)
49.  Further 
experimentation, showed that acetylation of histone H4 by p300 was more sensitive to garcinol 
compared with histone H3
49. In vivo experimentation of HAT activity in HeLa cells showed that 
Garcinol reduces HDAC inhibitor enhanced levels of histone H4 and histone H2B acetylation. 
Garcinol was also found to induce apoptosis in HeLa cells.  Apoptosis was stimulated in HeLa 
cells  with  hydrogen  peroxide  treatment  and  chromatin  fragmentation  was  analysed.  Hydrogen 
peroxide treated cells produced many small nucleosomal DNA fragments and the same effect was 
observed for HeLa cells treated with increased concentrations of garcinol. Further study of gene 
expression in garcinol treated HeLa cells using microarray analysis showed that more than 72 % of 
the genes tested including proto-oncogenes were down regulated
50.  
 
A  new  garcinol  derivative,  LTK-14  has  been  developed  by  Mantelligu  et  al.  for  inhibition  of 
p300
45,  51. LTK-14 is structurally the same as garcinol bar the introduction of cyclisation in the 
southeast corner (Figure 1.15). Unlike garcinol, LTK-14 (IC50 5-7 µM) specifically inhibits p300-
mediated  acetylation  of  histones  H3  and  H4.  PCAF  activity  remains  unaffected,  even  in  the 
presence  of  50  µM  LTK-14.  Another  experimental study  showed that  LTK-14  inhibits  HIV-1 
multiplication in T-cells and that this is partially through inhibition of histone acetylation
51.   
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Figure 1.16: Chemical structure of curcumin and cinnamoyl derivatives
52, 53 
 
Curcumin  (Figure  1.16),  a  component  of  turmeric  (Curcuma  longa),  has  been  identified  as  a 
‘potent’ p300/CBP specific inhibitor. A radioactive filter binding assay was used to assess the HAT 
inhibitory activity of Curcumin. The acetylation of histones H3 and H4 by p300/CBP was strongly 
inhibited with an IC50 of 25 µM whereas PCAF activity showed no change, even in the presence of 
100 µM Curcumin. The extent of p300/CBP inhibition was further investigated and it was found 
that  Curcumin  represses  p300  mediated  acetylation  of  p53.  Curcumin  is  also  able  to  repress 
multiplication of HIV-1 by inhibiting p300 acetylation of HIV-Tat and HIV-1 IN
52.   
 
Cinnamoyl compounds were synthesised to generate polyhydroxylated aromatic derivatives related 
to curcumin, garcinol and anacardic acid. The cinnamoyl derivatives (6 and 7, Figure 1.16) are 
based on a 3, 4-dihydroxycinnamoyl pharmacophore. The functional groups substituted onto the 
catechol ring included hydroxyl (R= OH), carboxylic acid (R = COOH), bromo (R = Br) and 
methoxy (R = OCH3). Costi et al. reported that to some extent all cinnamoyl compounds inhibit 
p300 activity. The most potent compound of the series (IC50 = 5 µM) was shown to be six times 
more active than Lys-CoA towards p300. This potent derivative is characterised by bromine atoms 
in the ortho position to the hydroxyl groups (7, R= Br, Figure 1.16)
53. 
 
Several series of novel small molecules known as the γ-butyrolactones, isothiazolones and a group 
of  quinoline  derivatives  have  been  synthesised.  Biel  et  al.  developed  a  novel,  small  molecule 
compound MB-3 (Figure 1.17) which was based around the α-methylene-γ-butyrolactone motif, a 
common substructure element found in many natural products. MB-3 features an aliphatic side 
chain to mimic the lysine substrate as seen in other HAT inhibitors like Lys-CoA. Unfortunately, 
MB-3 was proven to be a weak, cell permeable inhibitor of the human Gcn5 (IC50 = 100 µM) and 
CBP (IC50 = 500 µM)
54.   
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4-hydroxy-2-pentylquinoline-3-carboxylic acid                                                                                                    
 
Figure 1.17: Chemical structures of potent γ-butyrolactones, isothiazolones & quinolines
54-56 
 
Aryl and alkyl N-substituted isothiazolone compounds have been shown to inhibit PCAF activity. 
Compounds CCT004464 (IC50 = 3.1 µM), CCT004466 (IC50 = 5.4 µM) and CCT004467 (IC50 = 
12.4 µM) were identified in a high throughput screen of 69,000 compounds against PCAF. The 
isothiazolones are unique in that they feature a reactive S-N bond which can covalently bind to 
PCAF  resulting  in  inhibition.  Stimson  et  al.  designed  35  analogues  (27  N-aryl  and  8  N-alkyl 
isothiazolones) for PCAF inhibition. Isothiazolone CCT077791 (Figure 1.17) was the most potent 
PCAF inhibitor (IC50 = 7.3 µM) of the 35 analogues. The isothiazolones also show antiproliferative 
CCT004464                    CCT004466                    CCT004467   
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properties  against  human  colon  cancer  cell  lines  (HCT116  and  HT29).  CCT077791  inhibited 
HCT116  and  HT29  growth  with  IC50  =  3.0  µM  and  2.1  µM  respectively.  The  potency  of 
CCT077791  against  PCAF  and  the  cancer  cells  lines  are  comparable.  However,  some 
isothiazolones exert cytotoxic effects that are not associated with HAT inhibition, hence suggesting 
considerable off target effects. For example CCT077796 inhibits growth inhibition 11 times more 
potently than the HAT activity of PCAF
55. 
 
The most recent novel series of HAT inhibitors are the quinoline derivatives synthesised by Mai et 
al. Two simple quinoline derivatives were shown to inhibit Gcn5 in yeast cells and this prompted 
the design of 4-hydroxy-2-pentylquinoline-3-carboxylic acid (Figure 1.17) which features a long 
alkyl chain and the salicylic acid functionality as seen in HAT inhibitors anacardic acid and MB-3. 
The quinoline derivative was able to reduce histone H3 acetylation in human leukaemia U937 cell 
nuclear extracts to levels comparable with curcumin, anacardic acid and butyrolactone MB-3. The 
quinoline derivative showed inhibitory activity at 50 µM (30%) and 25 µM (24%) concentrations. 
Thereby, being more potent than anacardic acid (15%), curcumin (18%) and slightly less potent 
than MB-3 (44%) at 50 µM concentration
56.  
 
As most of the papers in this research field suggest, the development of small molecular weight 
HAT  inhibitors as therapeutic agents is the next step, following the HDAC inhibitors. The current 
HAT inhibitors are a step in the right direction, provided we can derive more potent, specific and 
cell permeable analogues. Hence, further modifications of these small molecular modulators could 
lead  to  the  development  of  potential  novel  drugs.  New  specific  inhibitors  would  also  help  to 
elucidate  the  molecular  mechanism  of  HAT  action.  The  focus  of  this  research  will  be  on the 
discovery  and  development  of small  molecular  modulators  of  protein  acetylation,  in  particular 
compounds that can selectively target HDACs and HATs.  
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Histone Deacetylases 
HDACs carry out the reverse action of HATs. They are associated with transcriptional repressors 
and co-repressors. Their binding to promoters correlates with loss of histone acetylation.  
 
Eighteen HDACs have been identified in mammalian cells and these have been grouped into two 
distinct families of HDACs based on their homology to yeast cells. The classical HDAC family 
uses zinc as a cofactor and is split into four phylogenetic classes, Class I, II, III and IV (Figure 
1.18). The SIR2 family contains seven different class III HDACs known as the sirtuins, which 
show homology to yeast Sir2 (silent information regulator 2). Sirtuins do not contain Zn
2+ in the 
active site and they have a different mechanism of action that uses NAD
+ as cofactor. The term 
“HDAC inhibitors” applies to compounds that target the “classical” class I, II, and IV HDACs and 
that are currently evaluated in clinical trials
57. For this reason the sirtuins will not be discussed in 
this chapter. 
 
HDACs 
Class  Enzymes  Zn
2+    Location  Expression 
I  HDAC1, HDAC2, HDAC3, HDAC8  Yes  Nucleus  Ubiquitous 
IIa  HDAC4, HDAC5, HDAC7, HDAC9  Yes  Nucleus and cytoplasm  Tissue specific 
IIb  HDAC6, HDAC10  Yes  Cytoplasm  Tissue specific 
III  Sirtuins 1-7  No  Variable  Variable 
IV  HDAC11  Yes  Nucleus and cytoplasm  Ubiquitous 
 
Figure 1.18: A table outlining the four HDAC classes and their members
58 
 
Class  I  human  HDACs  have  homology  to  yeast  HDAC  known  as  Rpd3  (reduced  potassium 
dependency 3).  There are four members and they are HDAC1, HDAC2, HDAC3 and HDAC8. 
Class II HDACs are homologous to the yeast HDAC Hda1 (histone deacetylase 1) and they have 
been split into two subclasses; Class IIa and Class IIb. Class IIa includes the enzymes HDAC4, 
HDAC5, HDAC7, and HDAC9 and Class IIb contains HDAC6 and HDAC10
59. Class IV contains 
HDAC11 only. Class IV comprises HDAC11 only. It is structurally related to both, class I and II 
HDACs
57.  
 
The main difference between these classes is the cellular location of the HDACs. Class I HDACs 
are  found  mostly  in  the  nucleus.  Class  II  and  IV  HDACs  are  larger  proteins  and  can  shuffle 
between  the cytoplasm  and  nucleus  in  response to cellular  signals.  In  order to  carry  out  their 
function, HDACs have to be present in the nucleus where their main substrates are found. Class II 
HDACs are targeted to the nucleus by a nuclear localisation signal (NLS) or they are recruited 
along with other proteins and HDACs. The Class I HDACs are already in the nucleus and for this  
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reason Class I HDACs may be the most attractive target for drug action, since they are at the centre 
of transcriptional activity.  
 
Another  difference  is  that  HDACs  of  Class  I  and  IV  are  ubiquitously  expressed,  whereas  the 
expression of Class II HDACs is more tissue restricted
60. For example, HDAC9 is expressed in 
heart cells, HDAC7 in T-cells and HDAC6 in breast cells
61. Some of the Class II HDACs exist as 
several splice variants. HDAC9 has three known splice variants and HDAC10 has two known 
splice variants. Hence, different cells express different forms of HDAC
60. 
 
Class I HDACs share homology in their catalytic domain whereas Class IIa shares homology in 
two  regions,  the  C-terminal  catalytic  domain  and  the  N-terminal  regulatory  domain.  Class  IIb 
HDACs each have two catalytic domains, one of which is specific for tubulin and not histones
46. 
The catalytic domain for Class I and Class II HDACs contains about 390 conserved amino acids 
(the deacetylase core). The active site consists of a tubular pocket with hydrophobic walls and a 
Zn
2+ cation at the base. Despite the differences all the HDACs share the same mechanism of action 
which  involves  removing  an  acetyl  group  from  the  lysine  N-terminal  tails  of  histones.  The 
acetylated  lysine  residue  is  inserted  in  the  hydrophobic  pocket  where  the  Zn
2+  catalyzes  the 
hydrolysis of the acetyl group via a charge-relay system. 
 
All of the classical HDACs are enzymatic transcriptional co-repressors. However, the HDACs 
within  each  class  form  class  specific  complexes  and  bind  to  different  co-repressors  and 
transcription factors. It is the availability of these co-repressors to form complexes that regulates 
HDAC activity.  
 
It has been shown that the HDACs classes have some differences and similarities, but it  has not yet 
been shown whether it is more desirable to develop selective inhibitors for Class I HDACs over 
Class  II  HDACs  or  vice  versa.  The  enzyme  active  site  for  all  HDACs  shows  considerable 
homology, and this makes development of selective inhibitors for each individual HDAC difficult. 
Most available HDAC inhibitors target either Class I HDACs or Class II HDACs.  
 
As seen for HATs, histones are not the only targets and HDACs are also involved in the reversible 
acetylation  of  non-histone  proteins  such  as  transcription  factors,  tumour  suppressor  genes  and 
HATs. One widely talked about non-histone substrate is α-tubulin. Hubbert et al. demonstrated that 
HDAC6 is able to deacetylate a polymerised microtubule substrate in vitro and in vivo. They also 
showed  that  the  tubulin  deacetylase  activity  of  HDAC6  enhances  microtubule  stability  and 
consequently increases chemotactic cell motility
62.  
  
 
26 
Microtubules are an important component of the cytoskeleton and mitotic spindle apparatus which 
consist  of  α-tubulin  and  β-tubulin  polymers.  They  are  required  for  the  segregation  of  the 
chromosomes during cell division of eukaryotic cells, cell migration, cellular signalling or vesicular 
transport within the cells. Not all HDACs function as α-tubulin deacetylases, only HDAC6 and 
Sirt2 are able to utilise tubulin as a substrate. Further research has shown that HDAC6 deficient 
cells are more resistant to oncogenic transformation. Lee et al. has proved that HDAC6 knock out 
mice  are  more  resistant  to  chemical  carcinogen-induced  skin  tumour  formation.  Their  study 
provided  important  evidence  that  HDAC6  is  specifically  required  for  autonomous  cancer  cell 
growth of solid tumours both in vitro and in vivo
63. Therefore this unique function of the classical 
HDAC6 makes it a desirable Class II HDAC target and several papers have described HDAC6 
selective inhibitors
64-66.  
 
p53 is another non-histone substrate that has been proved to undergo deacetylation by HDACs. p53 
is a transcription factor  that  plays a  key  part in  cell  cycle regulation.  It  is  capable  of  forcing 
damaged or stressed cells to enter programmed cell death. Juan et al. have shown that p53 can be 
down-regulated by Class I HDACs. The down-regulation of p53 is achieved by deacetylation the 
lysine rich C-terminal region of p53 and this results in decreased cell death
67. Inhibiting the Class I 
HDACs  responsible  for  p53  down-regulation  is  another  motivation  for  class  specific  HDAC 
inhibitors.  
 
Other  cell  cycle  regulators  controlled  by  HDAC  activity  include  E2F  and  the  retinoblastoma 
tumour suppressor protein (pRb). E2F co-ordinates the transcription of genes involved in cell cycle 
progression, such as cyclin E. E2F is found in complexes with pRb. Phosphorylation of pRb by 
CDK releases free E2F. E2F can then stimulate transcription of S-phase genes. The activity of E2F 
and pRb is also influenced by acetylation, and pRb controls E2F activity through the recruitment of 
HDACs. Hence, inhibition of HDACs can cause potent cell cycle effects and frequently induce 
apoptosis in tumour cells
61.  
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HDAC Inhibitors  
Compared to HAT inhibitors there is a vast amount of literature of inhibition of HDAC activity for 
cancer therapy. Especially due to development of HDAC inhibitors that are selective towards Class 
I or Class II HDACs. Many different types of HDAC inhibitors have been developed, ranging from 
complicated structures e.g. depsipeptide to the very simple butyrate. These HDAC inhibitors can be 
divided into several structural classes depending on their functional group moiety. The underlying 
similarity of most HDAC inhibitors is the adapted ‘cap’, aliphatic ‘linker’ and reactive functional 
group  structure.  The  nature  and  potency  of  binding  to  the  HDAC  active  site  depends  on  the 
differences between these structural components.  
 
Hydroxamic Acids 
The hydroxamic acids class is the most populated group of HDAC inhibitors. A common feature of 
these compounds is a hydrophobic linker between a cap and hydroxamic moiety (Figure 1.10). 
Hydroxamic acids have a high affinity to biometals, including Fe
3+, Ni
2+, and Zn
2+, which places 
great  value  on  these  agents  in  biomedicine
68.  The  hydroxamic  acids  are  based  on  the  lead 
compound Trichostatin A (TSA, Figure 1.19). TSA was the first natural product hydroxamic acid 
to be discovered that inhibited HDACs directly. It is isolated from Streptomyces hygroscopicus and 
was  originally  used  as  an  anti-fungal  agent  until  its  anti-cancer  properties  were  discovered  in 
Friend murine erythroleukemia (MEL) cells
69. Yoshida et al. showed that TSA can strongly inhibit 
HDAC activity in vitro (Ki = 3.4 nM) and that the in vivo effects of TSA on cell proliferation and 
differentiation can be unambiguously attributed to HDAC inhibition
70. TSA never entered clinical 
trials  as  a  drug  candidate  due  to  its  high  toxicity.  Instead  it  is  used  as  an  invaluable  tool  in 
validating HDAC enzymes as potential anti-cancer targets
61. 
 
Suberoylanilide  hydroxamic  acid  (SAHA,  vorinostat,  Zolinza®,  Figure  1.19),  is  a  synthetic 
hydroxamic acid, which is structurally related to TSA. SAHA has been approved by the US Food 
and  Drug  Administration  (FDA)  for  the  treatment  of  cutaneous  T-cell  lymphoma
71.  It  was 
discovered whilst screening for active inducers of differentiation in MEL cells. The first polar 
small  molecular  species  discovered  was  hexamethylene  bisacetamide  (HMBA),  a  compound 
consisting of two acetamide groups linked by a six methylene-group chain (Figure 1.19). HMBA 
inhibited MEL cell growth at 5 mM, but the molecular target has not been identified
71. Replacing 
the amide groups with hydroxamic acid led to a series of bishydroxamic acids. This series includes 
suberic bishydroxamic acid (SBHA, Figure 1.19) and m-carboxycinnamic acid bishydroxamide 
(CBHA, Figure 1.19). 
  
 
28 
TSA 
O
N
O
H
OH
N
 
 
       cap                hydrophobic     hydroxamic  
                                  linker               acid 
 
HMBA                                               SBHA 
  
N
H
N
H
O
O
O H
N
H
N
H
OH
O
O
 
CBHA 
O
N
O H
H
N
O
H
OH
 
SAHA 
N
O
H
OH N
O
H
 
 
Figure 1.19: Chemical structures of the well known hydroxamic acids 
 
SBHA and CBHA induced differentiation of MEL cells at 30 µM and 5 µM respectively
72. SBHA 
is two orders of magnitude more potent than the analogous bisamide HMBA due to the binding 
potential  of  the  hydroxamic  acid  group.  Further  investigation  with  derivatives  of  HMBA  and 
SBHA, have shown than the six methylene group chain provides the optimal spacer length and this 
spacer is also observed in SAHA. Derivatives of SBHA have been designed to include five- and 
seven- carbon spacers and these also show good activity at 40 µM and 20 µM respectively
72. 
SAHA was synthesised after it was postulated that only one hydroxamic acid group would be 
binding to the metal ion in the catalytic site. The second hydroxamic acid group was substituted for 
a hydrophobic group for possible receptor binding. As a result, SAHA has proved to be more 
potent than SBHA and induces differentiation of MEL cells at 2 µM
73. 
 
Several crystallographic studies have been published showing TSA or SAHA bound to a HDAC 
active site
74, 75.  From these studies it is inferred that TSA binds by inserting its long aliphatic linker 
into the hydrophobic pocket of the enzyme. The terminal hydroxamic acid group touches the polar  
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bottom of the pocket, where it chelates to the active site Zn
2+ in a bidentate fashion. The aromatic 
dimethylamino-phenyl  group  at  the  other  end  of  the  TSA  chain  makes  contacts  at  the  pocket 
entrance and acts as a ‘cap’. The aliphatic six methylene spacer chain also appears to be the optimal 
length  for  spanning  the  length  of  the  pocket  and  allowing  contacts  both  at  the  bottom  and 
entrance
75.  
 
SAHA binds to the enzyme active site in the same manner as TSA but it has a reduced inhibitory 
effect. This can be attributed to the few structural differences between TSA and SAHA. Finnin et 
al. showed that SAHA’s aliphatic chain sits less tightly in the pocket and makes fewer contacts to 
the  hydrophobic  walls
75.  The  saturated  aliphatic  linker  present  in  SAHA  lacks  a  double  bond 
compared to TSA and this creates more flexibility. The aromatic ‘cap’ in SAHA is an aniline amide 
which does not span the enzyme pocket to the same extent as the ‘cap’ in TSA. 
 
Cyclic Tetrapeptides 
This interesting family of HDAC inhibitors features the nonribosomal cyclic tetrapeptide natural 
products,  including  apicidin,  trapoxin  (TPX)  and  the  newly  discovered  azumamides.  These 
inhibitors  are  more  structurally  complex  and  are  capable  of  inhibiting  HDACs  at  nano  molar 
concentrations (Figure 1.20). The cyclic tetrapeptide inhibitors are distinguished by the presence of 
a  functionally  critical  Zn
2+  co-ordinating  amino  acid  side  chain  containing  a  terminal  α,  β-
expoxyketone, ethylketone, amide or carboxylic acid. There are structural similarities between the 
unnatural amino acid side chain and acetylated lysine resides (Figure 1.21). Hence, these inhibitors 
act as a functional mimic of the HDAC substrate, acetylated lysine.  
 
 
 
Compound 
 
IC50 (nM) 
 
HDAC tested 
TPX A  6.0  HDAC1 
TPX B  0.82   HDAC1 
Apicidin  0.40  HeLa cell HDACs 
reduced FK228  15  HeLa cell HDACs 
 
Figure 1.20: A table highlighting examples of the nano molar potency of cyclic tetrapeptides 
towards HDACs
76, 77 
 
TPX  A  and  B  are  naturally  occurring  cyclic  tetrapeptides  that  were  isolated  from  a  fungus, 
Helicoma ambiens (Figure 1.21). Their chemical structure contains a pipecolic acid residue (TPX 
A) or proline residue (TPX B), two phenylalanines and an unusual 2-amino-8-oxo-9,10-epoxy-
decanoic  acid  (Aoe)  side  chain
78.  The  Aoe  side  chain  contains  a  chemically  reactive  α,  β- 
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epoxyketone functional group that irreversibly inhibits HDACs by forming a covalent bond to the 
HDAC catalytic site. The epoxide is necessary for irreversible binding, as analogues containing the 
corresponding diol or methylene groups are biologically inactive
79. This epoxyketone functionality 
was initially deemed a requirement for cyclic tetrapeptide inhibitors. However, the lability of the 
epoxyketone  functionality  prevents  significant  in  vivo  activity,  which  makes  TPX  of  little 
pharmacologic interest.  Other inhibitors lacking this functional group have since been discovered.  
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Figure 1.21: Chemical structures of acetylated lysine, TPX A and B, apicidin and FK228
80 
 
Apicidin lacks the epoxyketone or hydroxamic acid functional group prerequisite for biological 
efficacy. Instead apicidin features an ethylketone moiety, the ketone group chelates the catalytic  
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Zn
2+, whilst the aliphatic chain acts as a spacer and the peptide ring is the “cap”. The structural 
similarities  between  apicidin’s  (S)-2-amino-8-oxodecanoic  acid  (Aoda)  moiety  and  acetylated 
lysine residues are highlighted in Figure 1.21. Apicidin acts as a functional mimic of the HDAC 
substrate. Unlike TPX, it reversibly induces histone hyperacetylation, and hence causes altered 
transcriptional regulation and untimely cell death
80. The peptidic nature of apicidins allows the 
chemical  synthesis  of  analogues  to  be  designed  easily  by  changing  the  amino  acids,  thereby 
facilitating  the  search  for  stronger  and  more  selective  HDAC  inhibitors
81.  Substitution  of  the 
ethylketone with a hydroxamic acid increased the potency of apicidin 5-fold against HeLa HDAC 
activity
82.  
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Figure 1.22: Chemical reduction of FK228 and Spiruchostatin A 
 
Depsipeptide (FK-228, Figure 1.22) is produced by Chromobacterium violaceum and was the first 
sulfur containing HDAC inhibitor to be discovered. Structurally FK228 is a bicyclic depsipeptide 
that  features  a  16-membered  ring  about  the  macrolactone  and  peptide  backbone  and  a  17-
membered  ring  about the ester and  disulfide linkages
76.  FK228 is  a natural pro-drug  which  is 
activated after incorporation into the cells
70. There is a marked difference in HDAC inhibitory 
activity between FK228 and redFK. A 75-fold increase in inhibitory activity against HDAC1 for 
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redFK228 (IC50 = 0.40 nM) versus FK228 (IC50 = 30 nM) has been observed
76. Activation occurs 
after cellular reduction of an internal disulphide bond which yields two free sulfhydryl groups, of 
which one strongly chelates the HDAC active site Zn
2+. One known major cellular reducing agent 
is glutathione or in can be reduced in vitro by dithiothreitol (DTT). Reduced FK-228 has a 4-
carbon long chain between one of the sulfhydryl groups and the cyclic depsipeptide core which can 
interact with the residues in the hydrophobic pocket. This chain is similar to the ‘linker’ chain seen 
in other HDAC inhibitors
77. A natural product Spiruchostatin A (SPI) isolated from a Pseudomonas 
extract shows great structural similarity to FK228
77,  83. Just like FK228, the internal disulphide 
bond undergoes reduction as shown in Figure 1.22. Both compounds are potent HDAC inhibitors 
with selectivity towards class I HDAC1 but are inactive against the class IIb HDAC6. Figure 1.23 
shows the IC50 values for these compounds against HDAC Class I and Class II. By contrast the 
hydroxamic acid, TSA is approximately equally effective versus HDAC1 and HDAC6 and hence 
shows no class specificity. 
 
   
IC50 (nM) 
Compound  HDAC1 (Class I)  HDAC6 (Class II) 
redFK288  0.40  787 
redSPI  0.61 ± 0.05  360 ± 40 
TSA  15.3 ± 1.6  61.2 ± 12.7 
 
Figure 1.23: A table highlighting the selectivity of reduced FK228 and SPI
76, 84 
 
FK228  is  currently  in  clinical  trials  for  peripheral  and  cutaneous  T-cell  lymphoma.  In  vivo 
characterization of SPI has demonstrated a profile of biological effects including growth inhibition, 
cell cycle arrest, induction of apoptosis, induction of p21
(WAF/cip1) and differentiation consistent with 
that seen of other HDAC inhbitors
84. 
 
Although the cyclic tetrapeptides have huge potential as HDAC inhibitors, they often present a 
huge synthetic challenge. Most synthetic cyclic tetrapeptides including apicidin have a strained 12-
membered peptide ring, which in itself is difficult to construct. In addition backbone isomerisation 
tends to occur to relieve the steric constraints. This isomerisation results in multiple backbone 
conformations of the cyclic tetrapeptide
82. For example apicidin is adopts multiple conformations 
(in a ratio of approximately 80:15:5) in the polar solvent DMSO. The predominant species adopts 
an  all  trans  conformation  whilst,  the  second  popular  conformation  has  a  cis-trans-trans-trans 
conformation. The cis configuration comes from the rotation of the tertiary amide bond in the 
pipecolic acid residue
85. 
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One solution is to replace an α-amino acid with a β-amino acid to yield a less sterically strained 
ring.  This  single  β-amino  acid  feature  occurs  naturally  in  the  azumamides,  showing  that  such 
backbone modifications have precedent in nature
82.  
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Figure 1.24: Chemical structures of the azumamides A-E
86 
 
The azumamides were discovered in Mycale izuensis, a Japanese marine invertebrate. They consist 
of five cyclic tetrapeptides named azumamide A-E (Figure 1.24). Their chemical structure includes 
three D-α-amino acids (Phe, Tyr, Ala, or Val) alongside the β-amino acid. Azumamides A, B and D 
share  the same  β-amino  acid;  (Z,2S,3R)-3-amino-2-methyl-5-nonenedioic-acid-9-amide  (amnaa) 
and azumamides C and E contain the β-amino acid (Z,2S,3R)-3-amino-2-methyl-5-nonenedioic 
acid (amnda)
86.  
 
Nakao et al. reported the original isolation, structure, elucidation and biological activities of these 
compounds
87. Biological studies were carried out with natural azumamide extracts against HDACs 
prepared from K562 human leukaemia cells. Azumamides A-E showed potent HDAC inhibitory 
activity with IC50 values of 0.045 to 1.3 µM. Azumamide A also showed moderate cytotoxic effects 
on WiDr human colon cancer cells and K562 cells
87. Further biological studies with azumamide A 
and E have explored anti-angiogenic effects with an in vitro vascular organisation model
88. 
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Benzamides  
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Figure 1.25: Chemical structures of the benzamides MS-275 and CI-994 
 
The benzamides are characterized by their 2'-aminoacetanilide group and two known derivatives 
include MS-275 and CI-994 (or N-acetyldinaline, Figure 1.25). MS-275 has been shown to inhibit 
HDACs in vitro at micro molar concentrations (Figure 1.26). MS-275 is a class I specific inhibitor 
and is more potent towards HDAC1 than HDAC3 and 8. It is less potent than the hydroxamic acids 
and  cyclic  tetrapeptides  and  also  bears  no  structural  similarity  to  these  inhibitors
89.  Molecular 
modelling studies have shown that the 2’-aminoacetanilide group can function as a weak zinc 
chelating group which binds to the active site, or contacts key amino acids in the active site without 
zinc  ion  co-ordination
90.  MS-275  induces  apoptosis  of  acute  myeloid,  B-chronic  lymphocytic 
leukaemia cells, Jurkat lymphoblastic T cells and prostate cancer cells. MS-275 and CI-994 have 
been used in clinical trials in combination with other anti-tumour drugs
91, 92, but CI-994 has since 
been discontinued. 
 
 
 
 
IC50 values in vitro 
Compound  HDAC1 (Class I)  HDAC3 (Class I)  HDAC4 (Class IIa) 
MS-275   0.37 µM  0.50 µM  10.7 µM 
TSA  3.87 nM  2.17 nM  9.68 nM 
 
Figure 1.26: A table comparing the selectivity of MS-275 and TSA to class I and II HDACs
89 
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Aliphatic Acids 
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Figure 1.27: Chemical structures of aliphatic acid inhibitors 
 
The Aliphatic group contains Valproic acid (VPA) 4-phenylbutyrate (PB) and butyric acid (Figure 
1.27).  The  structures  of  these  compounds  are  much  simpler  than  the  hydroxamic  acids.  For 
example VPA is a simple, eight-carbon, branched chain fatty acid. As a consequence, this is the 
least potent group of all the HDAC inhibitors, showing potency at millimolar concentrations. VPA 
inhibits HDAC1 in a dose dependent manner, with an IC50 of 0.4 mM. This is well within the 
therapeutic range of VPA (0.35 -0.70 mM in serum). VPA inhibited endogenous HDACs from 
HeLa cells including HDAC1, 2, 4 and 8 with 50 % inhibition between 0.5 and 2 mM
93. The low 
millimolar potency is probably because the aliphatic acids lack the “cap” functional moiety found 
for other HDAC inhibitors like TSA. Therefore these drugs do not interact with the HDAC active 
site as much as the hydroxamic acids. VPA is undergoing a range of clinical trails alone or in 
combination with other anti-tumour therapies. Most clinical trials evaluate VPA for treatment of 
haematological  malignancies,  however  there  is  increasing  interest  for  VPA  testing  in  solid 
tumours
94. VPA and PB have both been approved to treat epilepsy and VPA is also an established 
treatment for mania in bipolar disorder
95.  
 
All HDAC inhibitors reversibly inhibit HDAC at nano- to milli- molar concentrations, apart from 
one exception. TPX is able to covalently bind to the HDAC active site, and hence irreversibly 
inhibit the enzyme. The HDAC inhibitors share the same basic structure of a hydrophobic chain, 
with a reactive functional group on the end to chelate to Zn
2+. Some HDAC inhibitors have a bulky 
cap structure which can interact with extra residues around the active site or they do not. The range 
of potencies seen for these for the HDAC inhibitors corresponds to the various structural aspects of 
these compounds. Potent new HDAC inhibitors, especially is form selective inhibitors, would not 
only  help  expand  our  understanding  of  the  HDAC  enzymes  but  also  represent  attractive  lead 
compounds for drug design.  
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Synthesis of Anacardic Acid 
Anacardic acid synthesis studies were a primary aim in this research project alongside parallel 
synthesis of some anacardic acid derivatives. Although anacardic acid has been proven as a non-
specific  HAT  inhibitor  with  poor  cellular  permeability,  its  properties  will  still  be  useful  as  a 
standard control in the search for improved small molecule modulators of histone acetylation. 
 
Natural anacardic acid can be formed by hydrogenation of an unsaturated mixture of anacardic 
acids extracted from cashew nut shell liquid (Anacardium occidentale). This unsaturated mixture 
consists of four 6-alkylsalicylic acids bearing a C15 alkyl, alkenyl, alkadienyl or alkatrienyl group 
in the 6-position (Figure 1.28)
96.  
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Figure 1.28: Natural anacardic acids 
 
Several  synthetic  methods  for  anacardic  acids  have  been  reported  by  Tyman  et  al.  Saturated 
anacardic acid was first synthesised by thermolysis of basic copper salts of 2-alkylbenzoic acids 
(Scheme 1.1)
97.  
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Reagents and Conditions: [a] RMgX, CdCl2, 50 %; [b] NaBH4, 88 %; [c] HI, red phosphorus, 62 %; [d] i) 
KOH aq, CuSO4, 92 %; [e] PhNO2, ∆.  
 
Scheme 1.1:  Anacardic acid synthesis by thermolysis of basic copper salts
97 
 
R = (CH2)14CH3 (anacardic acid) 
R = (CH2)7CH=CH(CH2)5CH3 (ginkgolic acid) 
R = (CH2)7CH=CHCH2CH=CH(CH2)2CH3 
R = (CH2)7CH=CHCH2CH=CHCH2CH=CH2 
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Phthalic acid was treated with a dialkylcadmium reagent to yield the tautomers 2-acylbenzoic acid 
and 3-alkyl-3-hydroxyphthalide.  Reduction with sodium borohydride gave the 3-alkylphthalide 
which was further reduced to 2-alkylbenzoic acid. The preparation of the basic copper salt was 
hindered by extraction of basic and normal salts, of which the basic salt gave the salicylic acid. 
Improved  synthesis  was  achieved  by  reaction  of  n-alkyl  lithiums  with  2-fluoroanisole  via 
intermediate ayrne formation (Scheme 1.2)
98. The Wurtz reaction was used to general the desired 
n-alkyl  lithium  from  alkyl  bromide  and  lithium  which  was  then  subsequently  reacted  with  2-
fluoroanisole. The reactive intermediate, 2-methoxybenzyne was formed by displacement of the 
fluorine atom by lithium. Lithiation of 2-methoxybenzyne can occur in two different ways, hence 
after carbonation  two isomeric  acids are  formed.  The  final  step required  demethylation  of the 
methyl ether to afford anacardic acid with 42 % yield
98.  
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Reagents and Conditions: [a] RLi, Et2O, CO2, HCl, 35%; [b] i) HI, red phosphorus ii) H2O, H
+, 42 %. 
 
Scheme 1.2:  Anacardic acid synthesis from fluoroanisole
98 
 
The last reported synthesis by Tyman et al. prepared saturated and mono-unsaturated anacardic 
acids by C-alkylation of readily available methyl or ethyl 6-methyl-2methoxybenzoates (Scheme 
1.3)
99. This synthesis exploits the use of the Michael addition (step [a] Scheme 1.3) to pave the way 
for alkylation by alkenyl and alkynl halides. The alkylation of 2-methoxy-6-methyl-benzoic acid 
ethyl ester with the halide, 1-bromo tetradecane produced a moderately low yield of 34%. Other 
unsaturated anacardic acids were produced with yields between 25 and 94 %
99.  
 
Kubo et al. have also reported synthesis of anacardic acid, anacardic acid monoene and ginkgolic 
acid. Their synthesis attempt relied on introducing a side chain to the benzene ring by metallation 
followed  by  side  chain  construction  using  the  Wittig  reaction  (Scheme  1.4).  However  it  was 
documented that the method is not straightforward and the overall yield of anacardic acid was only 
17 %
100.  
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Reagents and Conditions: [a] i) NaOEt, ii) HCl, iii) Br2, ∆; [b] Me2SO4, K2CO3, Me2CO; [c] C14H29Br, 
LiNPr
i
2, -70 ºC, THF, HMPA, H3O
+ 34%; [d] LiSBu
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Scheme 1.3:  Anacardic acid synthesis by C-alkylation
99 
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Reagents and Conditions: [a] i) BuLi in hexane, THF, 0 ºC, ii) excess ethyl chloroformate, -78 ºC 1 h, 67%; 
[b] PPh3, CH3CN, 98 %; [c] i) lithum bis(trimethylsilyl) amide in hexane, THF, -78 ºC, ii) tetradecanol, 50%; 
[d] H2, 5% Pd on C, EtOAc, 61%; [e] 20 % NaOH, H2O, DMSO, ∆, 93 %; [f] boron tribromide, DCM, -40 
ºC, 86 %.  
 
Scheme 1.4:  Anacardic acid synthesis by direct alkylation using directive metallation
100 
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In many reported synthesis routes of anacardic acid, the starting material has always featured a 
benzene skeletal structure. Satoh et al. proposed a novel synthetic annelation reaction of enaminone 
derived from suitable isoxazoles, with ethyl acetoacetate as an alternative route to anacardic acid. 
However,  the  annelation  reaction  followed  by  condensation  with  the  ethyl  acetoacetate  gave 
unsatisfactory yields
101. A second improved synthesis was proposed by Satoh et al. which featured 
a 1, 2-addition with α, β unsaturated aldehyde and ethyl acetoacetate (Scheme 1.5)
102. 
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Reagents and Conditions: [a] BuLi, HMPA, THF, 92 %; [b] H3PO4, H2O, hydroquinone, dioxane, 89 %; [c] 
NaOMe, MeOH, 83 %; [d] ethyl acetoacetate, NaH, BuLi, THF, [e] KF, toluene, 72 %, [f] 10% NaOH, 81 %. 
 
Scheme 1.5:  Anacardic acid synthesis with 1,2 addition of aldehyde and ethyl acetoacetate
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Zehnter et al. proposed a different approach for the synthesis of anacardic acid. Their  method was 
based upon the reaction of 1-methoxy-1,3-cyclohexadiene with methyl 2 alkynoates at 180-200 ºC 
to give methyl-2-methoxybenzoates with variable saturated and monounsaturated alkyl chains in 
the  6-position.  Scheme  1.6  outlines  their  published  synthesis  for  anacardic  acid.  Unlike  the 
previous synthesis schemes, all the reaction steps are high yielding with 94 % anacardic acid in the 
final step
103.  
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Reagents  and  Conditions:  [a]  Et3N,  toluene,  1.5  h,  76  %;  [b]  250-270  ºC,  0.01  Torr,  2.5  h,  71  %;  [c] 
dichloromaleicanhydride, 180-200 ºC, 76 %; [d] AlI3, CS2, 0.5 h, ∆, 89 %; [e] 2M KOH, EtOH, ∆, 94 %. 
 
Scheme  1.6:    Anacardic  acid  synthesis  by  direct  conjugation  of  methyl-2-alkylnoates  to 
methoxy benzene
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Schemes 1.1 to 1.6 depict multi-step synthesis of anacardic acid with five or more steps. Two novel 
shortcut syntheses have since been published. A short synthesis by Seijas et al. utilised nucleophilic 
substitution of a methoxy group in 2-aryloxazolines by long chained Grignard reagents
104. This 
three step synthesis makes use of an initial simple transformation from 2, 6-dimethoxy-benzoic 
acid to the substituted aryloxazoline followed by nucleophilic substitution with a Grignard reagent 
at RT (steps [a] and [b], Scheme 1.7).  Subsequent cleavage of the oxazoline ring and the methoxy 
group in (step [c], Scheme 1.7) resulted in anacardic acid with 75% yield. It has been proven that a 
range of long chain Grignard reagents can be used in Scheme 1.7 to produce a range of analogues 
in good yield
104. 
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Reagents and Conditions: [a] SOCl2, H2NMe2CCH2OH, SOCl2; [b] C14H29MgCl, 64 %; [c] 57 % HI, 75 %. 
 
Scheme 1.7: Anacardic acid synthesis using long chained Grignard reagents
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Another short synthesis of anacardic acid was reported using palladium catalysed, base induced 
cross coupling of 9-alkyl-9-BBN with a triflate in the presence of 1-pentadecene (Scheme 1.8)
105. 
The ketal protecting group is cleaved to give anacardic acid in 95% yield. The salicylic acid part is 
obtained from cheap 2, 6-dihydroxybenzoic acid which is converted into triflate by formation of  
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the  isopropylidene  derivative  and  subsequent  reaction  with  triflic  anhydride  under  standard 
conditions
106.  
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Reagents and Conditions: [a] Acetone, SOCl2, DMAP, DME, 96 %; [b] Triflic Anhydride, Pyridine, 85 %; 
[c] i) 1-pentadecene, 9-H-9 BBN, THF, ii) NaOMe, PdCl2 (dppf) cat. 79 %; [d] KOH, H2O, DMSO, 95 %.  
 
Scheme 1.8: Anacardic acid synthesis via palladium catalysed Suzuki coupling
105, 106 
 
The palladium catalysed Suzuki reaction is a potential starting point for coupling modified C15 
alkyl chains to the triflate (step [c], Scheme 1.8). This Suzuki coupling has already been applied to 
synthesis of a ginkgolic acid derivative and a β-D-mannosylated compound. This Scheme 1.8 also 
features the protection of the salicylic acid moieties by a 2, 2-dimethyl-1, 3-benzodioxan-4-one 
functional group (step [a], Scheme 1.8) which is used frequently in natural product synthesis
107.  
 
In vitro studies
47, 48 have shown that cells are poorly permeable to anacardic acid and that anacardic 
acid has a lack of specificity towards HATs. However, anacardic acid still has potential as a lead 
compound.  Introduction  of  soluble,  lipophilic  functional  groups  would  be  essential  for  cell 
permeable  analogues  and  tweaking  of  the  functional  groups  could  improve  specificity. 
Optimisation of anacardic acid or any lead compound should obey Lipinski’s Rule of Five
108, 109.   
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These rules state that for a compound to have a greater likelihood of good oral absorption and 
permeability it should fit four criteria. These are: 
 
1.  Molecular weight is less than 500 g.mol
-1 
2.  Fewer than or equal to 5 hydrogen-bond donating groups 
3.  Fewer than or equal to 10 hydrogen-bond accepting groups 
4.  Calculated log P between -1 and +5.  
 
These  rules  can  be  considered  as  a  useful  guide.  They  are  not  imperative  for  the  design  of 
biologically active compounds as some active compounds do not fall within these criteria. However 
incorporating  these  rules  into  the  synthesis  of  new  analogues  can  improve  the  chances  of 
discovering biologically active compounds.  
 
A series of compounds known as the 6-oxa isosteres of anacardic acids have been synthesised 
using Mitsunobu conditions. These compounds have been tested for inhibition of bacterial histidine 
protein  kinase  (HPK)-mediated  two-component  regulatory  system  (TCS).  2-Hydroxy-6-
tetradecyloxy-benzoic acid in particular is a potent inhibitor of the bacterial TCS. Such an inhibitor 
could be an ideal therapeutic agent against virulent bacterial strains such as methicillin resistant 
Staphylococcus aureus (MRSA). Anacardic acids have been shown to exhibit antimicrobial activity 
against Gram-positive bacteria, and the structure activity relationship (SAR) data exhibited by the 
6-oxo  isosteric  anacardic  acids  is  similar  to  the  SAR  reported  for  the  antibacterial  activity  of 
anacardic acids.  The 6-oxo isosteric anacardic acids have not been tested for HAT  inhibitory 
activity
110. Since the antibacterial activity is similar to anacardic acids, there is a possibility that 
they could inhibit HAT activity. 
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Reagents and Conditions: [a] MeOH, H2SO4, ∆; [b] Diethylazodicarboxylate, Ph3P, CH3(CH2)13OH, THF, 29 
%, [c] i) 20 % KOH/EtOH, ∆, ii) 6M HCl, 73 %.  
 
Scheme 1.9: Synthesis of 2-Hydroxy-6-tetradecyloxy-benzoic acid using adapted Mitsunobu 
conditions 
 
2-Hydroxy-6-tetradecyloxy-benzoic acid closely resembles anacardic acid except for the presence 
of oxygen at the beginning of the alkyl chain. The total synthesis is outlined in Scheme 1.9. Like 
anacardic acid, it too can be made from cheap 2, 6-dihydroxybenzoic acid. The benzoic acid is  
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methylated to form the benzoate (Step [a], Scheme 1.9). This benzoate is then subjected to adapted 
Mitsunobu conditions for the selective mono-Ο-alkylation of the γ-resorcylic ester to afford 2-
Hydroxy-6-tetradecyloxy-benzoic acid methyl ester in 29% yield
110. Alkaline hydrolysis followed 
by acidification gave the free acid 2-hydroxy-6-tetradecyloxy-benzoic acid.  
 
Biological Effects of Anacardic Acid 
Anacardic acid is widely reported as a HAT inhibitor of p300 (IC50 = 8.5 µM) and PCAF (IC50 = 
5.0 µM)
47. Balasubramanyam et al. also performed a series of filter binding assays using highly 
purified HeLa core histones to characterise the specificity and nature of anacardic acid inhibition 
towards p300 HAT activity. The specificity of anacardic acid was determined by conducting a filter 
binding assay with p300 and the N-terminal peptide substrate; human histone H3. Addition of 
anacardic acid to the filter binding assay resulted in the inhibition of histone H3 acetylation. The 
nature of anacardic acid inhibition was measured by recording the rate of acetylation at different 
concentrations of anacardic acid for increasing concentrations of radiolabeled acetyl-CoA and a 
fixed concentration of core histones. From the data, it was postulated that anacardic acid is a non-
competitive p300 inhibitor
47.  
 
The HAT activity of p300/CBP has been associated with cardiomyocyte hypertrophy stimulation 
by phenylephrine (PE) and urocortin (UCN). Cardiomyocyte hypertrophy results in the thickening 
of the heart muscle (myocardium) in response to an increase in blood pressure or volume. PE binds 
to  the  α1A-adrengergic  receptor  and  the  subsequent  cellular  events  lead  to  p42/p44  MAPK 
activation of p300/CBP. The hypertrophic effect of UCN is independent of the MAPK pathway. 
However, p300/CBP plays a specific role in the induction of hypertrophy by UCN. Davidson et al. 
reported that anacardic acid prevents the stimulation of p300 by PE and UCN, hence preventing the 
induction of hypertrophy in primary neonatal cardiomyocytes
111.  
 
The inhibition of the HAT Tip60 by anacardic acid has been associated with sensitisation of HeLa 
(cervical adenocarcinoma) cells to ionisation radiation
112. Tip60 is a member of the MYST family 
and is involved in regulating the response to DNA damage by activation of ataxia telangiectasia 
mutant (ATM) protein kinase. ATM protein kinase regulates the signal-transduction pathway in 
response to DNA strand breaks
113.  ATM’s kinase activity is up-regulated in response to DNA 
strand breaks and ATM becomes autophosphorylated. The HAT activity of Tip60 is required to 
activate ATM and the subsequent DNA repair. The Tip60-dependent activation of ATM is also 
required for cells to survive exposure to ionising radiation. Sun et al. reported that anacardic acid 
inhibits  Tip60  (IC50  =  9  µM)  and  sensitised  HeLa  cells  to  the  cytotoxic  effects  of  ionising 
radiation
112. 
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Anacardic  acid  also  causes  cytotoxicity  towards  Jurkat  (T-cell  leukaemia),  U937  (human 
leukaemia),  Hs  578T  (human  mammary  ductal  carcinoma),  MDA-MB-231  (human  mammary 
adenocarcinoma), and 5637 (human primary bladder carcinoma) cells
48, 114, 115.  
 
Natural anacardic acids (Figure 1.28) have been shown to possess preventative antioxidant activity. 
Kubo et al. reported that anacardic acid can inhibit various oxidative enzymes including xanthine 
oxidase (IC50 = 51.3 µM) and lipoxygenase (IC50 = 31.5 µM)
116. The common anti-oxidant α-
tocopherol (vitamin E) is less effective than anacardic acid at inhibiting xanthine oxidase (IC50 = 
220 µM). Xanthine oxidase is a molybdenum containing enzyme that catalyzes the oxidation of 
hypoxanthine to xanthine (Figure 1.29). It can also further catalyse the oxidation of xanthine to uric 
acid.  Xanthine  oxidase  also  catalyses  the  dismutation  of  oxygen  to  superoxide  and  hydrogen 
peroxide. Uric acid accumulation is associated with gout and hyperuricemia, whilst superoxide 
anion  generation  causes  peroxidative  damage  in  cells.  Hence,  inhibitors  of  both  uric  acid  and 
superoxide anion formation are advantageous. 
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Figure 1.29: The enzymatic reaction of xanthine oxidase.  
 
A study by Masuoka et al. has found that anacardic acid inhibits xanthine oxidase activity via 
inhibition of superoxide generation and uric acid formation
117. Inhibition is caused by the anacardic 
acid binding to the xanthine substrate binding site in molybdenum region of the enzyme rather than 
influencing the oxidation process of the xanthine oxidase reaction. It was also determined that the 
long carbon chain and the salicylic acid moiety are essential for activity. 
 
It  has  been  shown  so  far  that  anacardic  acid  anti-tumour  activity,  antioxidant  activity,  HAT 
inhibitory  activity  and  sensitises  tumour  cells  to  ionising  radiation.  It  could  be  argued  that 
anacardic acid is a non-specific inhibitor and is able to target many proteins e.g. xanthine oxidase, 
lipoxygenase, p300/CBP and PCAF.  Another mechanism by which anacardic acid could exert its 
effects could be through the nuclear factor—κB (NF-κB) pathway. The transcription factor NF-κB 
is commonly found in tumourigenesis, inflammation and radiosensitisation. Sung et al. reported 
that anacardic acid suppresses NF-κB activation in response to different stimuli
118. This results in 
reduced expression of NF-κB dependent gene products which are involved in cell proliferation, anti 
apoptosis, invasion and angiogenesis. The HAT p300/CBP was identified as the molecular target  
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for suppression of NF-κB activation. Down-regulation of p300 by RNA interference abrogated the 
effect of anacardic acid on NF-κB suppression
118.  
 
Recently, anacardic acid and a structurally related analogue ginkgolic acid (Figure 1.28) have been 
discovered  to  inhibit both  in  vitro  and in  vivo  SUMOylation  but  not  in vivo  ubiquitination
119. 
Ubiquitination and SUMOylation are two of the various post-translational protein modifications 
that  also  include  phosphorylation,  methylation  and  acetylation.  SUMOylation  involves  the 
posttranslational conjugation of a small ubiquitin-related modifier protein (SUMO) to a specific 
lysine reside in a protein target. The conjugation of SUMO is mediated by an enzymatic cascade 
reaction. In the first step, SUMO proteases cleave the SUMO precursor in an ATP dependent 
manner to reveal a di-glycine motif. This motif then forms a thioester bond to a cysteine residue in 
the SUMO-activating enzyme (E1). In the second step, SUMO is passed onto a cysteine residue in 
the SUMO-conjugating enzyme (E2) through another thioester bond. In the last step of the enzyme 
cascade reaction, one of a small number of SUMO-ligase (E3) ligating proteins attaches SUMO to 
the protein target. E3 along with E2 mediates the formation of an isopeptide bond with the target ε-
amino lysine. The SUMO enzymes E1 and E2 are sufficient for in vitro SUMOylation of various 
substrates, whilst E3 interacts with E2 and facilitates both in vitro and in vivo SUMOylation. 
Fukuda et al. reported that ginkgolic acid and anacardic acid inhibited the in vitro SUMOylation of 
the  substrate  RanGAP1-C2  with  IC50  values  of  3.0  µM  and  2.2  µM  respectively
119.  It  was 
elucidated that E1 was the molecular target of ginkgolic acid and anacardic acid and that inhibition 
of E1 blocks the formation of the E1-SUMO intermediate. It was established that the long carbon 
chain and carboxylic acid moieties of the two inhibitors are essential for interaction with E1. It was 
originally postulated that the carboxylic acid forms a thioester bond with sulfhydryl of the active 
site cysteine reside E1. However, this was ruled out after it was found that a mutant E1 lacking the 
cysteine residue was still inhibited by ginkgolic acid.  
 
The papers in this field show that anacardic acid exhibits a wide range of effects, of which some 
may be linked by a common pathway i.e. NF-κB pathway. Armed with the knowledge of HATs 
and their associated inhibitors the search for small molecule modulators has focused on the natural 
product anacardic acid. The synthesis and biological studies of anacardic acid have been widely 
published by several laboratories. This report looks at anacardic acid as a lead compound in the 
search for more potent modulators of histone acetylation and the elusive specific, cell permeable 
HAT inhibitor.   
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2 Results & Discussion 
 
Organic Synthesis of Anacardic Acid & Analogues 
 
Anacardic Acid Synthesis 
The first objective was the synthesis of anacardic acid to provide sufficient material (~ 10 mg) for 
in vitro testing. The intention was to base the synthesis using the Suzuki reaction methodology 
outlined in Scheme 1.8 (Introduction). The first step of this Scheme 2.1 uses the 1,3-benzodioxan-
4-one functional group which concomitantly masks both the carboxylic acid and free hydroxyl 
moieties (Scheme 2.1)
107. It is frequently used in natural product and analogue synthesis to protect 
salicylic  acids
120.  For example  it  has been  used  in the synthesis of salicylihalamide  A  and  B, 
synthesis  of  anacardic  acid  related  benzamides  and  more  recently  the  synthesis  of  flavones, 
aurones, and acyl phloroglucinols
121-123. 
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Reagents and Conditions: [a] Acetone, SOCl2, DMAP, DME; [b] H
+/B
- hydrolysis 
 
Scheme 2.1: Proposed synthesis and cleavage of 1, 3-Benzodioxin functional group 
 
 
Rather than use this group to protect the free acid groups together, an alternative reaction route 
using  a  cheap  source  of  2,  6-dihydroxybenzoic  acid  was  sought.  It  was  chosen  to  synthesise 
anacardic  acid  (6)  via  a  benzyl  protected  derivative  as  outlined  in  Scheme  2.2.  Protection  by 
benzylation uses milder reaction conditions (step [b], Scheme 2.2) than the reaction of thionyl 
chloride and 2, 6-dihydroxybenzoic acid which requires the continuous removal of the HCl gas 
formed (step [a], Scheme 2.1). In addition the benzyl protecting group is more stable towards 
acidic/basic conditions, under which the 1-3-benzodioxin group is cleaved (Scheme 2.1). Scheme 
2.2 is one step longer than the synthetic routes in Schemes 1.7 and 1.8 due to the addition of an 
extra protecting group step. However, since the phenol group is protected separately from the 
carboxyl  group,  it  can  be  selectively  cleaved  due  to  each  protecting  group  requiring  different 
reaction conditions. The resulting free hydroxyl group or carbonyl group could be subjected to 
further coupling reactions. Hence, Scheme 2.2 has the potential to produce further anacardic acid 
analogues.  
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Reagents and Conditions: [a] MeOH, conc H2SO4, reflux, 36 h, 44 %; [b] BnBr, K2CO3, NaI, DMF, 31-56% 
%; [c] triflic anhydride, pyridine, 62 %; [d] i) 1-pentadecene, 9-H-9-BBN, THF, ii) NaOMe, cat. PdCl2 
(dppf) ∆, 5h, 8 %; [e] i) Pd on Carbon, H2, EtOAc, ii) 20 % KOH in EtOH, ∆, 43 %. 
 
Scheme 2.2: Synthesis of anacardic acid 
 
The initial step  in Scheme 2.2 involves the protection of the benzoic acid which has been achieved 
by Gennari et al
124. This involves methylation to form a methyl ester under acidic reflux conditions. 
Some problems were encountered, the methylation of 2, 6-dihydroxybenzoic acid did not always 
proceed in good yield and synthesis was slow with the reaction requiring a couple of days at reflux.   
 
This was followed by protection of a phenolic hydroxyl group with a benzyl protecting group. 
However this reaction does not selectively protect a single hydroxyl group. Ohzeki et al. reported a 
procedure for the protection of a hydroxyl group as a benzyl ether
125. The published reaction results 
in  a  mixture  of  mono-substituted  2-benzyloxy-6-hydroxy-benzoic  acid  methyl  ester  (2),  di-
substituted 2, 6-dibenzyloxy benzoic acid methyl ester (3) and starting material (1) with yields of 
48%, 24% and 25% respectively
125. 
 
The reaction  conditions  were  modified  to include addition  of  1.7  molar  equivalents  of  benzyl 
bromide and potassium carbonate reagents to the reaction mixture instead of the reported 1 molar 
equivalent of each reagent. It was hoped that this would drive the reaction to produce more mono 
and di substituted products resulting in reduced yields of left over starting material. The reaction 
was  further  modified  to  include  extraction  of  (3)  from  the  reaction  mixture  using  separation  
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techniques based upon the acidity of the products. The di-substituted product (3) was extracted 
under alkaline conditions. The mono-substituted product (2) and unreacted starting material were 
extracted under acidic conditions. The modified reaction conditions resulted in a mixture of (2), (3) 
and (1) with yields of 56%, 34% and 4% respectively. Hence, improving the yield of the desired 
mono substituted (2) product and reducing the amount of unreacted starting material (1). 
 
After protection of the free acid groups, the next step was to form the triflate from phenol (4). This 
relatively simple procedure was also reported by Ohzeki et al
125. 2-Benzyloxy-6-hydroxy-benzoic 
acid  methyl  ester  was  reacted  with  triflic  anhydride  in  pyridine  to  yield  2-benzyl-6- 
trifluoromethane-sulfonyloxy-benzoic acid (4) in 62 % yield. The triflate is a required reagent for 
the  Suzuki  coupling  reaction.  The  Suzuki  coupling  reaction  commonly  features  a  palladium-
catalysed cross coupling between organoboronic acid and halides. Other coupling reagents can be 
used too and these include organoboranes, potassium trifluoroborates or boronate esters which may 
be used in place of boronic acids. Pseudohalides (for example triflates) can also been applied in 
Suzuki couplings in place of usual halides.  
 
A  similar  Suzuki  coupling  has  been  carried  out  by  Furstner et  al. (Scheme  1.8)  to  produce  a 
pentadecyl substituted product in 79% yield
105. The first attempt with the Suzuki coupling was 
carried out with 2-benzyl-6-trifluoromethanesulfonyloxy-benzoic acid (4) and the resulting product 
(5) was only produced in 8 % yield. A significant drawback of the Suzuki reaction was the work up 
of a sticky brown crude product after the reaction. Purification of the reaction mixture required 
filtration through celite, liquid-liquid extraction and column chromatography. Product may have 
been lost during each purification step and this could partially explain the low yield of anacardic 
acid.  A second  attempt  to  repeat the reaction resulted  in base  hydrolysis  of the  triflate (4)  to 
produce (2). However, a sufficient quantity of (5) was produced from the first attempt to carry onto 
the deprotection step.  
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Reagents and Conditions: [a] i) 20 % KOH/EtOH, ∆, ii) 6M HCl 45-95 % 
 
Scheme 2.3: Saponification of benzoate
110   
 
Hydrogenolysis of (5) over palladium on carbon cleaved the benzyl protecting group and this was 
immediately followed by  alkaline hydrolysis of the benzoate. A reported set of conditions for 
saponification of methyl 6-alkoxy-2-hydroxybenzoates which produced free acids with 45-95%  
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yields was tried (Scheme 2.3)
110. The reaction conditions involved alkaline hydrolysis with 20% 
KOH  in  EtOH  under  reflux,  followed  by  acidification.  This  second  deprotection  step  was 
conducted on the crude product straight after the hydrogenolysis of (5) to minimise potential loss of 
product from any purification steps. Especially since the reaction was conducted on a very small 
scale i.e. milligrams instead of grams. The deprotection steps were relatively straightforward and 
anacardic acid (6) was produced in 43 % yield. The yield of anacardic acid is less than the yields 
reported in Schemes 1.4 to 1.9. However, enough anacardic acid (9 mg) was produced for initial 
biological testing.  
 
Later attempts to improve the overall product yield of anacardic acid investigated other palladium 
catalysed  coupling  reactions.  A  Sonogashira  coupling  reaction  with  the  triflate,  2-benzyl-6-
trifluoromethane-sulfonyloxy-benzoic  acid  (4)  and  1-pentadecyne  was  attempted  using  reaction 
conditions reported by Gallagher et al. (Scheme 2.4)
126.  
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Reagents and Conditions: [a] 1-pentadecyne, PMHS, CsF, PdCl2 (PhP3)2 (5 mol %), CuCl2 (5 mol %), NMP, 
RT. 
 
Scheme 2.4: Proposed Sonogashira coupling 1
126 
 
Unfortunately the reaction only succeeded in base hydrolysis of the triflate to form 2-benzyloxy-6-
hydroxy-benzoic acid methyl ester (3). Rather than invest time in solving the coupling reaction, 
another set of conditions was tried out, this time using the Sonogashira conditions as reported by 
Dushin  et  al.  (Scheme  2.5)
127.  This  reaction  required  the  use  of  the  1,  3-benzodioxan-4-one 
protecting group instead. 
 
Large scale protection of 2-6 dihydroxy benzoic acid with an acetal group to form the acetonide 
protected (7) in 66% yield was reported by Hadfield et al
128. However, the reaction conditions had 
to be scaled down considerably for synthesis in our laboratory. Initial attempts at this reaction 
produced product yields less than 10 % which was eventually improved to 75%. This improvement 
is attributed to maintaining the anhydrous conditions more efficiently. This was achieved by drying 
the dihydroxybenzoic acid SM under high vacuum in the presence of phosphorous pentoxide at 50 
°C before use and stirring magnesium sulphate into the reaction mixture. Vigorous removal of HCl  
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gas was also implemented by bubbling argon through the solution under a slight vacuum for the 
whole duration of the reaction rather than allowing the reaction to stir for an hour first as described 
in the reported procedure. The next step was to form the triflate from phenol (7) which gave (8) in 
99.9  %  yield  utilising  conditions  which  were  also  reported  by  Hadfield  et  al
128.  Finally  the 
Sonogashira coupling was attempted with (8), using the conditions reported by Dushin et al
127. 
Again, the reaction resulted in base hydrolysis of the triflate.  
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Reagents and Conditions: [a] Acetone, SOCl2, DMAP, DME, 75 %; [b] Triflic anhydride, Pyridine 99.9 %; 
[c] 1-pentadecyne, PdCl2(PPh3)2, DMF-Et3N (5:1), 12 h, 90 
0C. 
 
Scheme 2.5: Proposed Sonogashira coupling 2
127 
 
Despite  the  unsuccessful  attempts  to  improve  the  overall  anacardic  acid  synthetic  route  by 
repeating the Suzuki reaction and trialling two Sonogashira reaction conditions, anacardic acid was 
made  in  sufficient  quantity  for  testing.  Hence,  the main  aim  for  anacardic acid  synthesis  was 
accomplished. In addition improved yields were achieved for the synthesis of mono benzylated (2) 
and the synthesis of acetonide protected (7).   
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Synthesis of Anacardic Acid Analogues 
The main aim was to synthesise small molecular weight compounds with short hydrophilic tails. It 
is hypothesised that these compounds would be better HAT inhibitors since they would be more 
soluble  and  would  be  able  to  access  the  HAT  binding  site  more  easily.  The  analogues  are 
identifiable by the letters KC e.g. KC_01. This prefix was used to keep track of the analogues 
during the biological studies and this naming system is also used in this report.  
 
Amide Coupling 
The main aim of peptide coupling was to introduce some hydrophilic functional groups to the long 
hydrophobic  C15  alkyl  tail.  It  was  anticipated  that  the  optimal  route  would  be  to  couple  a 
carboxylic acid scaffold to the free phenolic hydroxyl group of (2) or (7). The acid product could 
then  undergo  coupling  with  peptides  using  PyBOP  and  DIPEA.  Abraham  et  al.  described  a 
procedure, where a range of phenoxyacetic acids were synthesised by deprotonation of the phenol 
with  a  strong  base;  NaH  in  THF  to  form  a  phenolate,  which  instigates  the  nucleophilic 
displacement  of  bromine  in  bromoacetic  acid
129.  The  reaction  was  carried  out  with  (7)  as  the 
deprotection reaction required to remove the acetonide protection group is quicker and easier, than 
saponification of the methyl ester and debenzylation of (2).  
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Reagents and Conditions: [a] NaH, THF, reflux, 62%; [b] NaH, THF, reflux, 28%; [c] KO
tBu, THF, reflux 
50% 
 
Scheme 2.6: Formation of acetic acid scaffold for peptide coupling  
 
Formation of the acetic acid scaffold (KC_01) via coupling of (7) with bromoacetic acid proceeded 
with a reasonable yield of 62% (Scheme 2.6). Careful monitoring of the reaction was important as 
polymerisation tended to occur and prolonged reflux caused hydrolysis of the acetal protecting 
group.  An  alternative  was  to  couple  methyl  bromoacetate  to  the  acetonide  (7)  to  avoid 
polymerisation, followed by cleavage of the methyl ester (KC_02) with base.   
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Reagents and Conditions: [a] KOH in MeOH. 46 %.  
 
Scheme 2.7:  Unexpected acetonide cleavage 
 
Conducting the coupling reaction with the NaH base (Scheme 2.6) resulted in a 28% yield of 
KC_02. The product yield was improved by substituting NaH for potassium tert-butoxide and the 
subsequent  product  yield  was  improved  to  50%.  Hence,  potassium  tert-butoxide  was  a  more 
efficient nucleophilic base. However, an additional reaction step was now required to cleave the 
methyl ester in KC_02 to produce KC_01. Khurana et al. reported a simple, rapid and efficient 
method for the hydrolysis of esters with KOH in MeOH at ambient temperature
130. Cleavage of the 
methyl ester with KOH base did not go as planned and the acetonide group was cleaved instead 
(Scheme  2.7). The resulting  product  KC_03  was  still  of interest  as a  potential  anacardic  acid 
analogue. 
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Reagents and Conditions: [a] Ethyl-4-bromobutyrate, K(O
tBu), THF, reflux, 72 h 53%; [b] i) KOH, MeOH, 
4h, ii) 2M aq HCl, 19% , 68%. 
 
Scheme 2.8:  Formation of butyric acid scaffold for amide coupling 
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These reaction conditions were exploited further to synthesise three other analogues, with a butyric 
acid ethyl ester (KC_05) or butyric acid methyl ester (KC_04 and KC_06) ‘tail’ (Scheme 2.8). 
Product KC_04 was only identified after proton NMR spectroscopy confirmed the presence of a 
similar  organic  compound  but  with  two  methyl  groups  present.  The  acetonide  and  ethyl  ester 
cleavage proceeded by hydrolysis with the base as planned, However, nucleophilic attack could 
occur with MeO
- or KOH on the carbonyl carbon of the acetonide resulting in two products (Figure 
2.1).  
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Figure 2.1: Mechanism of base hydrolysis of acetonide by KOH or MeOH.  
 
The reaction favoured the production of KC_06 with 68 % yield over KC_04 which has a 19 % 
yield. Hence, nucleophilic attack by KOH was dominant. To drive the reaction to produce only 
KC_06 in future, one only would have to substitute the MeOH solvent for THF or other suitable  
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organic solvents. The overall aim from these initial experiments was to create a carboxylic acid 
scaffold  for  coupling  peptides.  However  as  a  result  of  the  reaction  conditions,  five  additional 
anacardic acid analogues were synthesised.  
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[a] 4(2-aminoethyl morpholine, DCC, DCM, 34 %. 
 
Scheme 2.9: Amide coupling with DCC  
 
The next step involved coupling of two commercial amino acids to the acetic acid (KC_01) to form 
the morpholine (KC_07) and the acetylamino-ethyl (KC_10). Initial amide coupling reactions used 
PyBOP as the coupling reagent. This was deemed unsuccessful as separation of the products from 
PyBOP impurities was tricky. Instead DCC was used as a substitute for PyBOP. However, it was 
discovered  that  using  DCC  alone  resulted  in  formation  of  KC_09  (Scheme  2.9).  It  was 
hypothesised by mechanistic studies that coupling of KC_01 with DCC is kinetically slow and 
encourages nucleophilic attack of the acetonide group by the carboxylate to form a 7-membered 
ring anhydride (Figure 2.2). The amine then attacks the carboxyl carbon in the anhydride to form 
the ring-opened monohydride. The remaining acid then reacts with DCC in the usual way to make 
the di-amide KC_09. 
 
In order to drive the reaction in favour of KC_07 formation; HOBt was added (Scheme 2.10). The 
same conditions were then applied to the synthesis of KC_10. After trial and error of several 
deprotection conditions, cleavage of the acetonide protecting group was achieved using LiOH base 
to  afford  (KC_08)  and  (KC_11).  These  products  are  particularly  difficult  to  purify,  column 
chromatography on silica is not recommended as the products are very polar even when 10% 
NH4OH in MeOH: DCM (1:9) was used as the eluent. Attempts were made to extract each product 
from  their  impurities  by  separation.  For  example  for  (KC_08) the  basic  reaction  mixture  was 
acidified to pH5-6 and the organics were extracted with EtOAc. The separation was not efficient as 
the product (KC_08) has zwitterionic properties due to the benzoic acid and morpholine group. In 
the end the best method of extracting the product was to remove the reaction solvent in vacuo, 
dissolve the product in MeOH and filter the insoluble LiOH. The downside is that this work up can 
only work if the reaction results in one product.   
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Figure 2.2: Mechanism of DCC coupling followed by amine nucleophilic attack 
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 Reagents and Conditions: [a] 4-(-2-aminoethyl) morpholine, DCC, HOBt, DCM, 42 %; [b] 50% KOH aq, 
DMSO, reflux, 95 %; [c] N-(2-amino-ethyl)-acetamide, DCC, HOBt, DCM, 20 %; [d] 50% KOH aq, DMSO, 
reflux, 135 %. 
 
Scheme 2.10: Amide coupling with DCC and HOBt  
 
Formation of the carboxylic acid scaffold and the amide coupling reactions resulted in the synthesis 
of eleven new anacardic acid analogues. Of which KC_09 was an unexpected product due to 
nucleophilic attack by the amine at two carbonyl locations in KC_01. For all intents and purposes, 
KC_04 was also an unexpected product as MeO
- driven cleavage of the acetonide group in KC_05 
was not anticipated.  
 
A nice feature of these reactions is that synthesis of far more analogues is easily achievable by 
varying the length of the carboxylic acid scaffold or by changing the amide for a whole array of 
amino acids or other amine featuring compounds.  However a downside of these reactions is that 
the  compounds  produced  were  very  polar  and  hydroscopic.  KC_11  is  very  hydroscopic  and 
absorbs  moisture  as  reflected  in  the  experimental  yield  of  135%.  Purification  by  column 
chromatography can also be difficult due to the polar nature of these compounds.  
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Mitsunobu Synthesis 
An important criterion of this project was to synthesise low molecular weigh compounds by simple 
reproducible  reactions.  Twenty  eight  analogues  were  synthesised  using  Mitsunobu  conditions 
(Scheme 1.9, Introduction). These conditions were used instead of the Suzuki reaction, Sonogashira 
or amide synthesis for a number of reasons. The Suzuki reaction is fairly complex reaction relying 
on coupling of boronic acid or organoborane (e.g. 9-H-9-BBN) with a halide or pseudohalide (e.g. 
triflate) complex under completely anhydrous conditions. A published synthesis of anacardic acid 
used the organoborane 9-H-9-BBN to form a borane complex with 1-pentadecene
105. Which when 
recreated in our labs only resulted in a yield of 8% (Scheme 2.2). Subsequent attempts to improve 
the yield of anacardic acid with Sonogashira coupling conditions resulted in base hydrolysis of the 
triflate (Schemes 2.3 and 2.4). In addition the Suzuki and Sonogashira reaction routes are longer 
requiring protection steps and synthesis of the triflate. They also require expensive and moisture 
sensitive reagents i.e. palladium catalysts. The amide coupling conditions were not used for further 
synthesis since synthesis of a carboxylic scaffold was required for coupling amines. This required a 
protected  carboxylate  to  avoid  polymerisation  (Scheme  2.6).  However  suitable  deprotection 
conditions were not found since cleavage of the acetonide group was preferred (Scheme 2.7).  In 
addition the products of the amide coupling were often very polar and were difficult to purify. It 
was ascertained that Mitsunobu conditions would provide a milder, cleaner, two step synthesis to 
anacardic acid analogues. 
 
The first aim was to synthesis the analogue KC_19, which was also synthesised by Kanojia et al
110. 
KC_19 closely resembles anacardic acid except for the presence of oxygen at the beginning of the 
alkyl chain. The 6-oxo isosteric anacardic acids have not been tested for HAT inhibition and a 
series of these compounds was an ideal place to start. Synthesis of KC_19 was carried out using a 
reported experimental procedure (Scheme 2.11)
110, 131. The di-hydroxy-benzoate (1) was subjected 
to Mitsunobu-type conditions to form KC_18. The Mitsunobu reaction converts an alcohol into a 
variety  of  functional  groups,  such  as  an  ester,  using  triphenylphosphine  and  diethyl 
azodicarboxylate  (DEAD).  DEAD  is  no  longer  commercially  available,  hence 
diisopropylazodicarboxylate (DIAD) was used instead.  
 
The first time the reaction was carried out, 1.5 equivalents of each reagent was used as reported in 
the  experimental  procedure.  This  resulted  in  formation  of  a  di  substituted  product.  This  is 
reminiscent of the mixture of mono- (2) and di-substituted (3) benzyl protected benzoate formed in 
Scheme 2.2. It was then decided to reduce the amount of reagent and use 1.0 equivalents of DIAD, 
triphenyl  phosphine  and  1-tetradecanol.  This  resulted  in  a  mixture  of  mono-alkylated  product 
KC_18,  37%  and  di-alkylated  product  (9),  27%.  Only  29%  yield  was  reported  when  1.5 
equivalents of DEAD was used as a reagent
110. The downside of the Mitsunobu reaction is the  
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formation of by products, such as the hydrazine formed from the reduction of DIAD. The final step 
involves saponification of KC_18 which produced KC_19 in 74 % yield.   
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Reagents and Conditions: [a] 1-tetradecanol, Ph3P, DIAD, THF, 27-37%; [b] 20% KOH, EtOH, reflux 74 %. 
 
Scheme 2.11: Synthesis of  KC_19 using reported Mitsunobu conditions
110 
 
In order to avoid the synthesis of the di-substituted product in the Mitsunobu reaction, a common 
starting  material  featuring  robust  protection  of  both  hydroxy  groups  was  required.  Another 
necessity  was  facile  cleavage  of  the  protection  group.  The  acetonide  protected  compound  (7) 
fulfilled the requirements and was synthesised cheaply in bulk as the starting point for most of the 
analogues. Scheme 2.12 shows the proposed synthesis of multiple analogues. 
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Reagents and conditions: [a] acetone, SOCl2 , DMAP, DME, 75% [b] DIAD, Ph3P, R-OH, THF, 5h, 7 - 99%. 
[c] i) LiOH, H2O/THF (1:3), 0°C, ii) 6M HCl, 33 – 99.9 % 
 
Scheme 2.12: Proposed synthesis of anacardic acid analogues using Mitsunobu conditions 
 
A wide range of analogues was synthesised with different alkyl chain lengths using a range of 
alcohols from propanol to tetradecanol. The Mitsunobu synthesis is not just restricted to alkyl 
alcohols, a range of commercially available phenyloxy alcohols and heterocycles can also be used 
(Figure 2.3).  Twenty three analogues were synthesised by varying the alcohol tail. Of which five 
of these analogues were synthesised by Stuart King as part of his undergraduate organic synthesis 
project. More than three quarters of these analogues were synthesised with a yield of greater than 
60%.  This  demonstrates  the  ease  of  the  Mitsunobu  synthesis  to  produce  a  large  number  of 
analogues. The analogues with the acetonide protected groups were also submitted for biological  
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testing  alongside  the  deprotected  compounds.  It  was  envisaged  that  all  the  compounds  could 
provide  some  useful  biological  data,  and  the  acetonide  protected  compounds  would  determine 
whether the free hydroxyl and carboxylic acid had any affect on biological activity or not. 
 
 
 
                                                                                                        a compounds synthesised by Stuart King 
 
Figure 2.3: Alcohols (R-OH) used in the Mitsunobu coupling reaction (Scheme 2.12) to form a 
series  of  analogues.  The  corresponding  acetonide  protected  and  benzoic  acid  deprotected 
compounds along with their experimental yields are also detailed. 
 
In  between  organic  synthesis,  a  couple  of  preliminary  MCF7  breast  cancer  growth  inhibition 
experiments were carried out to assess the potency of analogues featuring an alkyl alcohol tail in 
vitro. These preliminary studies showed that a decrease from a C15 alkyl tail to a octyl alcohol tail 
does not greatly affect inhibition of MCF7 growth. The 6-oxa isostere of anacardic acid with a 
octyl alcohol tail (KC_14) had an IC50 of 52.4 µM ± 4.5 µM in MCF7 cells, whereas anacardic 
acid had an IC50 of 37.5 µM ± 1.2 µM. Although a marginal increase in potency has been observed 
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60 
by  shortening  the  tail,  one  of  the  project  aims  is  to  create  analogues  with  shorter  and  more 
functional tails. The long C15 alkyl tail in anacardic acid is very hydrophobic and is much longer 
than lysine side chain. Small hydrophilic tails are anticipated to be more soluble, able to get into 
cells easily and a better match for HAT binding. 
 
Bearing this biological data in mind, a series of compounds were made by coupling 1-octanol to a 
range  of  cheaply  available  heterocycles  (Scheme  2.13)  as  shown  in  Figure  2.4.  The  aromatic 
KC_30 was synthesized from a 5, 7-dihydroxy acetonide protected compound (10) synthesized by 
Lauren Sudlow (Scheme 2.14). This was then subjected to the further Mitsunobu conditions as 
outlined  in  Scheme  2.13. A  further eight analogues  were  synthesized featuring  an  octanol tail 
bringing the total number of analogues to thirty one analogues. This is a moderate number of 
analogues which can be easily increased after in vitro assays of this original series.  
 
The Mitsunobu synthesis was simple, quick and efficient. None of the reactions failed to produce 
the anticipated product as observed with the Suzuki, Sonogashira and amide coupling reactions. 
Out of all the reactions performed this was the most preferred and would be recommended for 
further synthesis of anacardic acid analogues.   
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Reagents and Conditions: [a] DIAD, Ph3P, R-OH, THF, 5h. 10 - 71 % 
 
Scheme 2.13: Synthesis of Anacardic acid analogues using 1-octanol 
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Figure 2.4: Heterocycles used in the Mitsunobu coupling reaction (Scheme 2.13) to form a series 
of analogues.  
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Reagents and Conditions: [a] DIAD (1.1 eq), Ph3P (1.1 eq), MeOH (1.1 eq), THF, 5h. 71 % 
 
Scheme 2.14: Synthesis of KC_30  
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Towards the Synthesis of CPTB Analogues 
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Reagents and Conditions: [a] DES, K2CO3, dry acetone, ∆, 4h, 76 %; [b] K
tBuO, DMSO; [c] SOCl2, DMF, 
Hexane, DCM.  
 
Scheme 2.15: Proposed synthesis of a CPTB analogue 
 
The last attempts in the chemistry laboratory were made towards the synthesis of CPTB analogues. 
CPTB  features  an  alkylated  hydroxyl  group  and  a  5-amino-2-chloro-benzyltrifluoride  moiety 
substituted onto the benzylic acid of anacardic acid (Figure 1.14, Introduction). The aim was to 
carry  out  the  same  substitutions  on  an  anacardic  acid  analogue  as  was  carried  out  by 
Balasubramanyam et al
47.  
 
Hence, the last two analogues to be synthesised were based on the anacardic acid analogue CPTB. 
Two simple reactions  were  done  with  new analogues KC_15  and  KC_29 to  alkylate  the free 
hydroxyl (Schemes 2.15 and 2.16) to mimic the functional group seen in CPTB. A trial alkylation 
of  KC_29  was  conducted  with  a  milder  reagent;  iodomethane  (Scheme  2.16).    However, 
iodomethane and NaH base failed to alkylate KC_15. Balasubramanyam et al. used diethyl sulfate 
to alkylate the hydroxyl group in anacardic acid towards the synthesis of CPTB
47. These conditions 
were applied to the synthesis of KC_44. As observed in the synthesis of CPTB, not only was 
alkylation  of  the  hydroxyl  group  observed  but  also  alkylation  of  the  carboxylic  acid.  If  more 
analogues were used to make CPTB analogues, the alkylation reaction would have to be controlled 
to favour mono-alkylation or an additional step would be required to cleave the ethyl carboxylate 
as proposed in Scheme 2.15. 
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Reagents and Conditions: [a] Iodethane, NaH, THF, 27 %;  
 
Scheme 2.16: Alkylation of KC_15 and KC_29 
 
The additional reaction steps in Scheme 2.15 were not attempted, but they would be an ideal 
starting place for some future work. Other future work could focus on the synthesis of a second 
series of anacardic acid and CPTB analogues based on the findings from the preliminary in vitro 
biological assays. 
 
To conclude, the synthesis of anacardic acid and analogues resulted in the synthesis of fifty three 
compounds. Out of these compounds forty four compounds were submitted for in vitro testing as 
analogues of anacardic acid.  It would have been relatively easy to synthesise many more analogues 
especially  with  the  Mitsunobu  conditions.  However,  it  was  important  to  gain  some  biological 
information on the potency of these compounds towards cancer cell growth inhibition and HAT 
inhibition.  The  biological  data  would  provide  useful  feedback  towards  the  design  of  further 
analogues. In particular, small, molecular weight compounds with short hydrophilic tails. Since this 
would solve the solubility problem as observed with many of the published HAT inhibitors
54.  
 
The next section reports on the range of in vitro experiments that were carried out to predominately 
investigate the effect of anacardic acid and analogues. The main aim of these experiments was to 
establish whether the compounds exhibited any reasonable potency and explore their effect on 
histone acetylation. The four main experiments carried out to explore these aims were growth 
inhibition, enzyme inhibition, western blotting and a p21 reporter gene assay. 
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Biological Studies of Anacardic Acid & Analogues 
 
Growth Inhibition 
It was reported in the introduction that misregulation of HATs have been implicated in onset of 
cancer. Growth inhibition experiments were carried out to establish whether anacardic acid and 
analogues are potent inhibitors of cancer cell growth. The in vitro cell based assay was also a useful 
medium for assessing the solubility of these compounds.  
 
Cell line evaluation was carried out to discover the most sensitive cell line for conducting anacardic 
acid growth inhibition experiments. Four different epithelial cell lines were chosen from a range of 
carcinomas.  These  were  MCF7  (breast),  PANC1  (pancreas),  PC3  (prostate)  and  HCT116 
(colorectal) cells. 
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Figure  2.5:  Comparison  of  anacardic  acid  IC50  in  different  cell  lines.  Growth  inhibition 
experiments were carried out to determine the potency of anacardic acid towards four different 
adherent  cell  lines;  MCF7  (breast  carcinoma),  PANC1  (pancreas  carcinoma),  PC3  (prostate 
adenocarcinoma) and HCT116 (colorectal carcinoma). This bar chart compares the average IC50 
values obtained for each cell line. Cells from each cell line were treated in duplicate with an 
anacardic acid concentration range of 1000 to 0.9 µM for six days at 37 °C. The IC50 values were 
calculated from the respective sigmoidal dose response curve for each experiment using GraphPad 
Prism software version 4.03. The cell line evaluation experiment was repeated twice for each cell 
line to give an average IC50 ± error. The error was calculated as the standard deviation across the 
experimental values.  
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For each cell line, the experiments were carried out in duplicate with the exception of PANC1 
where only one growth inhibition experiment was carried out.  PANC1 cells were the last cell line 
to be evaluated, and after one experiment it was identified that PANC1 cells exhibit less sensitivity 
to anacardic acid than MCF7 cells. Hence, no further experiments were conducted with the PANC1 
cell line.  
 
The results of this experiment are compared as a bar chart in Figure 2.5. The least sensitive cell line 
towards anacardic acid growth inhibition was HCT116 which had an average IC50 of 215.9 ± 139.7 
µM. This was followed by PC3 which has an average IC50 of 76.9 ± 52.8 µM. PC3 cells are more 
sensitive than HCT116 but they are not as susceptible to anacardic acid as MCF7 cells. MCF7 cells 
showed the most sensitivity with an average IC50 of 37.5 ± 1.2 µM. MCF7 cells also showed less 
variability in the results compared to the other cell lines. Thus the MCF7 breast cancer cell line was 
selected for further in vitro studies such as compound screening of all the anacardic acid analogues.  
 
Eliseeva  et  al.  conducted  a  similar  experiment  with  Jurkat  (T-cell  leukaemia),  HeLa  (cervical 
carcinoma) MCF7 and PC3 cells with anacardic acid over 48 hours. Although their finding was that 
anacardic acid was relatively more toxic to the Jurkat cell line (IC50 = 59 µM) than the other cell 
lines. MCF7 cells were only slightly less sensitive to anacardic acid (IC50 = 83 µM)
48. The IC50 
reported by Eliseeva et al. for anacardic acid is not comparable to our experimental value since our 
growth inhibition was measured over six days rather than two days.  
 
A simple compound screen was set up to assess the growth inhibition potential of anacardic acid 
and analogues in MCF7 breast cancer cells. A concentration of 250 µM was chosen for the screen. 
This  concentration  is  five  times  the  IC50  of  anacardic  acid  and  ensures  cytotoxic  effects  are 
observed by anacardic acid for comparison. It was also the maximum concentration that could be 
used before encountering solubility and DMSO side effects. At concentrations above 250 µM there 
were signs of precipitation of anacardic acid and some of analogues in the growth medium. The 
results of this screen are presented as a table (Figure 2.6). The first experiment screened analogues 
KC_01 to KC_17. Three anacardic acid analogues KC_10, KC_14 and KC_15 were identified as 
having more than 50 % growth inhibition. The second screen identified ten analogues whilst all ten 
analogues in the third screen caused more than 50% growth inhibition.  
 
In total, twenty four analogues showed more than 50 % inhibition of cell growth at a concentration 
of  250  µM.  The  remaining  twenty  one  analogues  showed  insufficient  growth  inhibition. 
Interestingly  none  of  the  analogues  that  were  synthesised  as  part  of  the  amide  coupling 
methodology (KC_01 – KC_11) showed any cytotoxic effects apart from KC_10. This could be 
attributed in part to the high hydrophobicity of the compounds. For example KC_07 and KC_08 
feature  the  hydrophobic  morpholine  group.  The  high  hydrophobicity  probably  affected  the  
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solubility of the analogues in the aqueous media and subsequently the intracellular concentration. 
On the positive note, anacardic acid and seventeen of the analogues inhibited more than 90 % of 
MCF7 cell growth at 250 µM. 
 
 
Figure 2.6: Compound screening results for anacardic acid and Analogues in MCF7 cells. A 
table listing the growth inhibition compound screen results for compounds KC_01 to KC_44 in 
MCF7 cells. Each column represents one experiment and the analogues that were screened in 
comparison to anacardic acid. Analogues highlighted in bold have an average growth inhibition 
greater  than  50  %. Three  experiments  were conducted  where up to  eighteen compounds  were 
screened per plate at a concentration of 250 µM for six days at 37 ° C. The % inhibition caused by 
the DMSO control is also listed in the table for each experiment. The DMSO control is same 
amount of DMSO added to the cells as present in the compound treatment solutions. All results are 
the mean (± SD) for triplicate determinations.  
Experiment One  Experiment Two  Experiment Three 
 
Compound 
 
% Inhibition 
 
Compound  
 
% Inhibition 
 
Compound 
 
% Inhibition 
anacardic acid  98.4 ± 0.2  anacardic acid  99.0 ± 0.0  anacardic acid  99.0 ± 0.0 
KC_01  -0.6 ± 11.4  KC_18  30.7 ± 5.4  KC_35  98.8 ± 0.3 
KC_02  2.5 ± 10.0  KC_19  98.6 ± 0.3  KC_36  57.3 ± 2.0 
KC_03  1.4 ± 6.4  KC_20  (50 µM)  23.0 ± 10.2  KC_37  99.0 ± 0.1 
KC_04  17.1 ± 2.9  KC_21  97.6 ± 0.5  KC_38  78.8 ± 3.6 
KC_05  4.3 ± 6.6  KC_22  31.0 ± 3.5  KC_39  99.2 ± 0.3 
KC_06  12.4 ± 4.6  KC_23  98.3 ± 0.4  KC_40  84.0 ± 0.3 
KC_07  13.7 ± 3.0  KC_24  61.6 ± 1.7  KC_41  97.6 ± 0.4 
KC_08  14.8 ± 1.9  KC_25  98.2 ± 0.5  KC_42  61.7 ± 0.3 
KC_09  12.9 ± 7.1  KC_26  82.9 ± 2.0  KC_43  95.2 ± 1.2 
KC_10  95.0 ± 0.2  KC_27  95.6 ± 1.0  KC_44  94.9 ± 1.6 
KC_11  5.4 ± 9.9  KC_28  54.0 ± 5.5 
KC_12  9.6 ± 7.0  KC_29  98.7 ± 0.3 
KC_13  16.2 ± 7.7  KC_30  6.5 ± 1.8 
KC_14  98.5 ± 0.1  KC_31  96.9 ± 0.5  
KC_15  97.9 ± 0.1  KC_32  47.0 ± 1.0 
KC_16  -1.5 ± 3.2  KC_33  97.8 ± 0.6 
KC_17  21.4 ± 9.4  KC_34  42.6 ± 4.7     
     
Control  % Inhibition  Control  % Inhibition  Control  % Inhibition 
1 % DMSO  15.2 ± 11.8  1 % DMSO  -2.5 ± 2.0  1 % DMSO  19.1 ± 10.0  
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The next step was to determine the IC50 of anacardic acid and the twenty three anacardic acid 
analogues by carrying out dose response growth inhibition experiments in MCF7 breast cancer 
cells. Instead of reporting all the data, four representative sigmoidal dose response curves for four 
random analogues are shown in Figure 2.7. The IC50 was calculated for each curve by plotting the 
curve of best fit. For each analogue, multiple experiments were performed to derive the mean IC50. 
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Figure 2.7: Representative growth inhibition dose response curves for four anacardic acid 
analogues.  Growth  inhibition  experiments  were  carried  out  to  determine  the  potency  of  the 
anacardic  acid  analogues  towards  MCF7  breast  cancer  cells.  For  each  growth  inhibition 
experiment,  a  sigmoidal  dose  response  curve  was  plotted  to  calculate  the  IC50.  Representative 
sigmoidal dose response curve for a four random anacardic acid analogues are shown in the figure. 
MCF7 cells were treated with a treatment concentration ranging from 1000 to 0.9 µM for six days 
at 37 °C. Two controls were also carried out in duplicate, untreated cells and one in which the cells 
were treated with the maximum amount of DMSO used in a given sample. Data shown are mean ± 
standard  deviation  for  duplicate  determinations  per  experiment.  The  growth  inhibition  data  is 
relative to the number of untreated cells and the DMSO control (▲) is shown on each plot.   
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Compound 
 
Experiment 1  
IC50 (µM) 
Experiment 2 
IC50 (µM) 
Mean (±SD) 
IC50 (µM) 
Anacardic acid  36.6  38.3  37.5 ± 1.2 
KC_10  86.3  80.5  83.4 ± 4.1 
KC_14  55.5  49.2  52.4 ± 4.5 
KC_15  149.6  154.7  152.2 ± 3.6 
KC_19  68.9  72.9  70.9 ± 2.8 
KC_21  133.2  119.0  126.1 ± 10.0 
KC_23  75.1  84.2  79.7 ± 6.4 
KC_24  157.4  125.8  141.6 ± 22.3 
KC_25  110.0  133.5  121.7 ± 16.7 
KC_26  178.4  152.0  165.2 ± 18.7 
KC_27  301.1  329.2  315.2 ± 19.9 
KC_28  203.9  163.0  183.5 ± 28.9 
KC_29  90.7  82.6  86.7 ± 5.7 
KC_31  64.3  50.6  57.4 ± 9.7 
KC_33  73.2  60.1  66.6 ± 9.2 
KC_35  55.3  74.5  64.9 ± 13.5 
KC_36  82.4  88.9  85.6 ± 4.5 
KC_37  45.3  30.6  37.9 ± 10.4 
KC_38  84.1  119.5  101.8 ± 25.0 
KC_39  20.0  16.4  18.2 ± 2.6 
KC_40  74.4  93.6  84.0 ± 13.6 
KC_41  77.0  55.1  66.0 ± 15.5 
KC_42  154.8  133.0  143.9 ± 15.4 
KC_43  217.9  347.3  282.6 ± 91.5 
KC_44  48.1  27.6  37.8 ± 14.5 
 
Figure 2.8: Average growth inhibition IC50 of anacardic acid and analogues. A table listing the 
growth inhibition IC50 results for anacardic acid and analogues KC_01 to KC_44 in MCF7 cells. 
MCF7 cells were treated with a treatment concentration ranging from 1000 to 0.9 µM for six days 
at 37 °C. The IC50 was calculated for each analogue by plotting sigmoidal dose response curves 
using GraphPad Prism software version 4.03. The dose response for each analogue was repeated 
twice  in  two  separate  experiments  and  the  average  IC50  is  the  mean  (±  SD)  for  these  two 
experiments. 
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The average IC50 results are listed in the results table found in Figure 2.8. In the cell line evaluation 
experiment  the  average  IC50  for  anacardic  acid  was  discovered  to  be  37.5  ±  1.2  µM.  Three 
analogues exhibit the same or a more potent IC50 than anacardic acid. These are KC_37, KC_39 
and KC_44, of which KC_39 is the most potent analogue of the series towards MCF7 cells with an 
IC50 of 18.2 ± 2.6 µM.  
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Figure 2.9: The three most potent anacardic acid analogues in MCF7 cells 
 
An  interesting  observation  is  that  neither  of  these  analogues  features  a  free  salicylic  acid  or 
hydroxyl group (free acid) as present in anacardic acid. KC_37 and KC_39 possess an acetonide 
which blocks the free acid groups, whereas KC_44 has an ethoxy and an ether ester group present 
(Figure 2.9). Analogue KC_40 is the free acid version of KC_39 and this analogue has an IC50 of 
84.0 ± 13.6 µM which is five times less potent than the acetonide KC_39. Likewise analogue 
KC_38 is the free acid version of KC_37 and it has an IC50 three times less potent than acetonide 
KC_37. This finding shows that the free acid groups hinder growth inhibition.  
 
The carbon alkyl tail in anacardic acid is slim line and features no other functional groups. The two 
potent analogues KC_37 and KC_39 prove that you can extend out from the tail with functional 
groups such as a benzyl group (KC_37) or an indole group (KC_39) without any repercussions. In 
addition the indole group in KC_39 provides further hydrogen bonding possibilities either through 
the lone pair on the nitrogen or via the hydrogen atom. This hydrogen bonding may be in an 
optimum location to facilitate binding of the compound to its source of inhibition.   
 
The importance of the salicylic acid group is demonstrated in the difference between analogues 
KC_43 and KC_44.  KC_43 shows that removal of the ethyl ester causes a seven fold decrease in 
potency compared to KC_44. Hence, this illustrates some importance for the salicylic acid group 
which is present in most of the analogues. On the contrary, anacardic acid analogues KC_35 and 
KC_36 were synthesised by coupling 1-octanol to 8-hydroxyquinoline and 8-hydroxycoumarin 
respectively (Figure 1.27). Neither two analogues feature the salicylic acid group as present in 
anacardic acid yet they moderately inhibit MCF7 growth inhibition.   
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Anacardic acid features a long 15 carbon tail and it was postulated that shortening the alkyl chain 
may result in more cell-permeable potent inhibitors. The three most potent analogues (Figure 2.9) 
do not possess a long 15 carbon tail as present in anacardic acid. Hence, shortening the alkyl tail 
may have improved cell permeability and the cytotoxic effects. Several analogues were synthesised 
with different alkyl chain lengths (Figure 2.3) and a comparison of their IC50 is presented in Figure 
2.10.  The  graph  also  compares  the  effect  of  free  acid  or  acetonide  moieties on  the  IC50.    As 
observed in the most potent analogues, the analogues with free acid moieties are less potent than 
the analogues with the acetonide moiety.  
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Figure 2.10: Comparison of average growth inhibition IC50 for different alkyl alcohol chain 
lengths 
 
The shortest alkyl alcohol tail that was coupled to the acetonide compound (7) in the Mitsunobu 
coupling  reaction  was  propyl  alcohol  (Figure  2.3). The anacardic  acid analogues  (KC_12  and 
KC_13) with the propyl alcohol tails showed less than 20 % growth inhibition at 250 µM in the 
compound screen (Figure 2.6). For the acetonide protected analogues, the shortest tail length, for 
which an IC50 was measured, was pentyl alcohol. The most potent tail length was an octyl alcohol 
present  in  KC_14.  Hence,  the  potency  of  the  acetonide  protected  analogues  improved  with 
increasing tail length with the exception of the heptyl alcohol tail.  
 
The optimum alkyl alcohol tail length was not established since analogues with nonyl- to tridecyl- 
alcohol tails were not synthesised. However, the acetonide KC_20 with tetradecyl alcohol tail did 
not exhibit any cytotoxic effects at 50 µM in the compound screen (Figure 2.6). Therefore, these  
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results show that the octyl alcohol tail was the optimum length but a nonyl- or decyl- alcohol tail 
may prove to be more potent. However judging by the difference in potency between the different 
tail lengths any improvement would only be marginal.  
 
The  lesser  potent  free  acid  analogues  followed  the  same  trend,  the  potency  of  the  free  acid 
analogues  improved  with  increasing  tail  length.  IC50  values  were  not  measured  for  analogues 
featuring a propyl or pentyl alcohol tail since these compounds were not cytotoxic at 250 µM.  
Unlike the acetonide analogues, the most potent free acid analogue had a tetradecyl alcohol tail 
which is the same length as anacardic acid’s pentadecyl tail. It was concluded that shortening the 
alkyl tail in free acid analogues conferred no improvement in potency compared to anacardic acid. 
In fact the potency of the free acid analogues decreased two-fold or more. These IC50 results show 
some correlation between potency and tail length for acetonide protected compounds. It was also 
shown that anacardic acid analogues with a propyl, pentyl, hexyl and heptyl alcohol tails showed 
no improvement in potency. The optimum tail length for acetonide protected compounds was an 
octyl alcohol tail. The optimum tail length for free acid analogues was the tetradecyl alcohol tail 
which is equivalent to anacardic acid’s pentadecyl tail.  
 
In addition to shortening the alkyl tail in anacardic acid other modifications included introducing 
other functional groups to create more hydrophilic, cell permeable analogues. Introduction of other 
elements such as oxygen to the alkyl tail had some effect on potency. The best example is when 
anacardic acid is compared to analogue KC_19. The alkyl tail in KC_19 is the exact same length 
as anacardic acid except an oxygen atom is present at the beginning of the tail as characterised by 
the Mitsunobu synthesis. Incorporating this oxygen atom resulted in a two fold reduced potency of 
KC_19. The effect of adding extra oxygen atoms to the alkyl tail can be observed for analogues 
KC_16 and KC_17. The tail features the alcohol, di (ethylene glycol) methyl ether, which contains 
an extra two oxygen atoms. Unfortunately these analogues did not inhibit MCF7 cell growth at 250 
µM. It was concluded that introduction of hydrophilic elements can have a negative effect on 
MCF7 growth inhibition.   
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Radioactive HAT Assay 
Following on from the MCF7 growth inhibition experiments, forty four compounds were screened 
for potential HAT inhibition. It was important to establish whether there is any correlation between 
the cytotoxic effects observed towards MCF7 breast cancer cells and PCAF inhibition. An in vitro 
radioactive HAT flashplate assay was used to screen the compounds against PCAF
132. The relative 
enzyme activity for all the anacardic acid analogues was determined in three separate experiments 
and the results are presented in Figures 2.11, 2.12 and 2.13. The anacardic acid analogues were 
screened at two concentrations (10 µM and 100 µM) in order to identify a benchmark from which 
to  proceed  with  IC50  determinations.  Only  analogues  that  showed  more  than  25  %  enzyme 
inhibition at 100 µM were evaluated further.  
 
The first two experiments screened the analogues KC_01 to KC_18 (Figure 2.11). Out of the 
eighteen analogues only KC_14 and KC_15 showed more than 25 % enzyme inhibition at 100 
µM.  Experiments  three  and  four  investigated  the  anacardic  acid  analogues  KC_19  to  KC_38 
(Figure 2.12). In experiment three, analogues KC_19, KC_25 and KC_29 met the inhibition cut-
off, whilst in experiment four all the analogues met the inhibition requirements apart from KC_34 
and KC_36.  In the final compound screen (Figure 2.13) only KC_44 showed enzyme inhibition.   
 
There is a discrepancy that occurs between each of the five experiments. For each screen, the 
inhibition of anacardic acid varies between 47% and 99% enzyme inhibition at 100 µM and this 
can be contributed to the variability in solubility for anacardic acid. The problematical solubility of 
anacardic acid and analogues can also be viewed when comparing the inhibition results between 10 
and 100 µM. For example, analogue KC_25 shows the same enzyme inhibition at 10 and 100 µM 
and some analogues (e.g. KC_39) show more inhibition at 10 µM rather than 100 µM. 
 
In the enzyme inhibition compound screen, nine anacardic acid analogues were identified to inhibit 
more than 25% PCAF activity at a concentration of 100 µM. Further dose response experiments 
were carried out to determine the IC50 of these compounds in the radioactive HAT assay.  
 
The compound screening experiment indicated that the IC50 of these analogues is higher than 100 
µM. Initial experiments were set up to measure the dose response of the analogues with an upper 
concentration of 400 µM, followed by six concentration points with two fold intervals. Out of the 
nine analogues profiled, only three analogues KC_14, KC_15 and KC_19 yielded a measurable 
dose response profile (Figure 2.14). For the other six compounds, there was no identifiable dose 
response profile with the enzyme activity values remaining unchanged across the concentration 
range (results not shown).  
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Experiment Two
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Figure 2.11: % Inhibition of GST PCAF by anacardic acid and analogues. Two bar charts 
depicting  the  radioactive  flash  plate  assay  screen  results  for  analogues  KC_01  to  KC_10  and 
KC_11 to KC_18. Each chart represents one experiment that was carried out individually. Each 
compound was screened in triplicate at a concentration of 10 µM (blue bar) and 100 µM (red bar). 
All results are the mean (± SD) of triplicate determinations, and they were expressed relative to the 
total enzyme activity with no added inhibitor.  
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Experiment Three
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Experiment Four
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Figure 2.12: % Inhibition of GST PCAF by anacardic acid and analogues. Two bar charts 
depicting  the  radioactive  flash  plate  assay  screen  results  for  analogues  KC_19  to  KC_32  and 
KC_33 to KC_38. Each chart represents one experiment that was carried out individually. Each 
compound was screened in triplicate at a concentration of 10 µM (blue bar) and 100 µM (red bar). 
All results are the mean (± SD) of triplicate determinations, and they were expressed relative to the 
total enzyme activity with no added inhibitor.   
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Experiment Five
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Figure  2.13:  %  Inhibition  of  GST  PCAF  by  anacardic  acid  and  analogues.  A  bar  charts 
depicting the radioactive flash plate assay screen results for analogues KC_39 to KC_44. The chart 
represents  one  experiment  that  was  carried  out  individually.  Each  compound  was  screened  in 
triplicate at a concentration of 10 µM (blue bar) and 100 µM (red bar). All results are the mean (± 
SD) of triplicate determinations, and they were expressed relative to the total enzyme activity with 
no added inhibitor.  
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Figure 2.14: PCAF inhibition dose response curves of anacardic acid and analogues. Enzyme 
inhibition experiments were carried out to determine the potency of anacardic acid and analogues 
towards  the  histone  acetyltransferase  PCAF.  Figure  2.14  shows  four  graphs  showing  the 
representative sigmoidal dose response curves plotted for anacardic acid and the analogues KC_14, 
KC_15 and KC_19. Each curve was obtained from one individual experiment from which the IC50 
could be calculated. A maximum of seven concentration points with 2-fold intervals were used. 
The concentration range for KC_14 was 200 to 3.1 µM and whilst KC_15 was 400 to 6.3 µM. The 
concentration range for both anacardic acid and KC_19 was 50 to 1.6 µM. Data shown are mean ± 
standard deviation for duplicate determinations per experiment and the enzyme inhibition data is 
relative to the total enzyme activity with no added inhibitor. The values were evaluated using 
GraphPad Prism software version 4.03 and sigmoidal dose response curves were assigned to the 
data to calculate the IC50 for each experiment. 
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Figure 2.14 shows a representative dose response curve for each analogue and anacardic acid. It is 
apparent that the analogues KC_14 and KC_15 do not adopt the traditional sigmoidal dose curve 
shape. The non-traditional curves appear when the maximum inhibitor concentration does not equal 
100 % enzyme inhibition. For analogue KC_14, the enzyme inhibition plateaus at approx 70 % 
whilst KC_15 plateaus at approximately 60 % enzyme inhibition. The steepness of the sigmoidal 
curve can also be measured using the hill coefficient and a value less than one can indicate negative 
co-operatively  between  the  inhibitor  and  the  enzyme.  The  sigmoidal  dose response  curves  for 
KC_15, KC_19 and anacardic acid have a hill coefficient less than one and this indicates an odd 
mechanism of action by the inhibitor. 
 
The average IC50 results are listed in Figure 2.15. A published experimental PCAF inhibition IC50 
of 8.5 µM for anacardic acid was reported by Balasubramanyam et al
47.  This published value is 
very close to the PCAF inhibition IC50 = 6.0 µM determined in the radioactive HAT flash plate 
assay. It could be argued that the later IC50 is more accurate since the former IC50 was determined 
using  a  filter  binding  HAT  assay.  A  filter  binding  assay  utilises  phospho  cellulose  discs  to 
preferentially bind acetylated histones. Radioactivity is incorporated into the acetylation histones 
upon HAT catalysed transfer of radio-labelled acetyl-CoA and the ration of bound and unbound 
molecules can be measured. However, extensive washing is required to remove the unincorporated 
acetyl-CoA  before  the  bound  radioactivity  is  measure  by  liquid  scintillation  counting
133.  In 
addition, the filter binding assay is more time consuming and less automated than the radioactive 
flash plate. 
 
Compound  Experiment 1  Experiment 2  Average IC50 
Anacardic acid  6.3 µM  5.7 µM  6.0 ± 0.4 µM 
KC_19  5.7 µM  11.2 µM  8.4 ± 3.9 µM 
KC_14  28.2 µM  35.2 µM  31.7 ± 5.0 µM 
KC_15  51.4 µM  94.7 µM  73.1 ± 30.6 µM 
 
Figure 2.15: Average PCAF inhibition IC50 of anacardic acid and analogues. A table listing the 
enzyme inhibition IC50 results for anacardic acid and analogues KC_14, KC_15 and KC_19. The 
IC50 was calculated for each analogue by plotting sigmoidal dose response curves using GraphPad 
Prism  software  version  4.03. The  dose response  for  each  analogue  was  repeated twice in  two 
separate experiments and the average IC50 is the mean (± SD) for these two experiments. 
 
The radioactive HAT flash plate assay showed that anacardic acid is the most potent HAT inhibitor 
towards PCAF inhibition, closely followed by KC_19. The negligible fold change in IC50 between 
the two HAT inhibitors is interesting particularly as KC_19 is essentially anacardic acid apart from 
the presence of an oxygen atom at the beginning of the alkyl tail. The growth inhibition data  
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showed a two fold difference in IC50 between the two compounds. Whereas the enzyme inhibition 
data shows that introduction of oxygen to the alkyl tail also has no effect on potency.  
 
KC_15 has the same functional groups as KC_19 but it has a shorter octyl alcohol tail compared to 
the tetradecyl alcohol tail in KC_19. KC_15 is the least potent out of the three analogues and 
shortening  the  tail  results in  a  decrease  in  potency compared  to KC_19. The  same  trend  was 
observed for the growth inhibition data.   
 
KC_14 has the same octyl alcohol tail as KC_15, but it does not feature the free benzoic acid or 
hydroxyl group as present in the other analogues. Instead KC_14 comprises an acetonide group 
which blocks the free acid groups. The inclusion of the acetonide group results in a two fold 
increase in potency when KC_14 is compared to KC_15. However the same logic does not apply 
to the acetonide KC_20 when compared to KC_19, since KC_20 does not inhibit PCAF activity. 
The results imply that the free acid group could hinder enzyme inhibition but this trend needs to be 
observed for a larger group of analogues.  
 
The growth inhibition data indicated that introducing a large functional group such as a benzyl 
group  (KC_37)  and  an  indole  group  (KC_44)  can  improve  potency.  However  none  of  the 
analogues that exhibit enzyme inhibition feature such groups. This suggests that the present of 
bulky functional groups are unfavourable and this implies that the binding site within the enzyme 
cannot accommodate such groups.  KC_37, KC_39 and KC_44 were identified as the most potent 
anacardic acid analogues towards MCF7 growth inhibition, but they lack the ability to inhibit 
PCAF.  There  is  no  correlation  between  their  cytotoxicity  to  MCF7  cells  and  HAT  inhibition. 
Hence, their mechanism of inhibition must lie within another biochemical pathway.  
 
Xanthine Oxidase Assay 
The xanthine oxidase assay was carried out to probe the anti-oxidant properties of anacardic acid 
and analogues. A study by Masuoka et al. established that anacardic acid inhibits xanthine oxidase 
activity via inhibition of superoxide generation and uric acid formation
117.  
 
There  are  two  assays  available  for  measuring  xanthine  oxidase  activity,  either  by  uric  acid 
formation  or  superoxide  anion  generation.  Uric  acid  formation  is  quantified  by  measuring  the 
increase  in  absorbance  of  invisible  light  at  293  nm  for  the  catalysed  oxidation  of  xanthine. 
Superoxide anion generation is measured by the reduction of yellow nitro blue tetrazolium dye to 
an insoluble blue formazan product from which the change absorbance of light can be measured. 
Either method gives reproducible results, but the visible light of blue formazan is quicker, cheaper 
and easier to measure.  
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The published experimental procedure is designed for use with plastic cuvettes, which requires a 
large reaction volume, hence more reagents
117. Thus the reaction was trialled in a plastic cuvette 
and then was scaled down six-fold for use in a 96-well plate. The results of this experiment are 
displayed  in  Figure  2.16.  For  both  reaction  formats  a  steady  rate  of  change  in  absorbance  is 
observed.  The change in absorbance for the 96-well plate format is not as substantial as the change 
observed with the cuvette format. Nevertheless, the advantage of reducing the reaction volume, the 
ease  of  carrying  out  many  samples  on  one  plate,  and  the  ability  to  carry  out  duplicate 
determinations favoured the 96-well plate format.   
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Figure 2.16: The effect of reaction volume on the xanthine oxidase assay. This graph illustrates 
the total activity results gained for experiments carried out in a cuvette or scaled down (6-fold) for 
use in a 96 well plate. The assay measures the xanthine oxidase (3.33 mg/ml) catalysed generation 
of superoxide anion via the reduction of yellow nitro blue tetrazolium dye to an insoluble blue 
formazan.  The  change  in  absorbance  can  be  measured  at  560  nm  using  a  UV  spectrometer 
(Varioskan Flash).  The graph charts the absorbance of blue formazan at 5 second intervals over a 
course of 90 seconds. The blank absorbance was measured using the 96 well plate format. Only the 
total activity and blank experiments conducted in the 96 well plates were carried out in duplicate 
and the results are the mean (SD) of n =2.  
 
Once it was proved that the xanthine oxidase assay is amenable to the 96 well plate format, an 
experiment  was  planned  to  measure  the  reaction  rate  for  different  concentrations  of  xanthine 
oxidase. The aim was to find the optimum concentration of xanthine oxidase for the activity of the 
enzyme  can  vary  between  batches  and  different  suppliers.  The  results  of  this  experiment  are  
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presented in Figure 2.17. The bar chart shows that the rate of the enzyme reaction increases with 
enzyme concentration. From this experiment it was decided that the optimum concentration of 
enzyme was 2 mg/ml.   
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Figure 2.17: The effect of enzyme concentration on xanthine oxidase reaction rate. This graph 
charts the velocity for different concentrations of Xanthine Oxidase. The velocity was calculated 
from the change in absorbance of blue formazan (560 nm) over 900 seconds for each concentration 
of enzyme. Note the velocity of the reaction is equal to the change in absorbance divided by change 
in time (∆A/∆t) since the absorbance is directly proportional to the concentration of product. 
 
The achievements from the two preliminary experiments meant that the 96 well plate assay could 
be  used  to  screen  the  forty  four  anacardic  acid  analogues  for  inhibition  of  xanthine  oxidase 
(2mg/mL).  Each  analogue  was  assayed  in  duplicate  at  100  µM  alongside  anacardic  acid  for 
comparison. This concentration was also used to screen the analogues in the radioactive HAT flash 
plate assay and was used in this assay for consistency. The results are presented in Figures 2.18 and 
2.19.  
 
Figure 2.18 shows the results for analogues KC_01 to KC_15. This compound screen does not 
identify any potential xanthine oxidase inhibitors. The second compound screen (Figure 2.19) only 
identified one inhibitor of xanthine oxidase. KC_19 inhibited 84.6 % of xanthine oxidase activity. 
Figure 2.19 also shows the results for the analogues KC_31 to KC_44 and like the first experiment 
no potential xanthine oxidase inhibitors were identified.  
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Figure 2.18: Xanthine oxidase compound screening of anacardic acid analogues. Two bar 
charts depicting the xanthine oxidase compound screen results for analogues KC_01 to KC_15 and 
KC_16 to KC_30. Each sample was carried out in triplicate and the average change in absorbance 
for each concentration was plotted against time. The data was fixed using a linear line of regression 
to calculate the slope which equates to the change in absorbance. The inverse reciprocal of the 
slope was calculated for each sample and was expressed relative to the total enzyme activity. The 
red dotted line marks the cut off point and any compounds with a % total activity below 50% was 
identified as having more than 50% enzyme inhibition at 100 µM.   
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Figure 2.19: Xanthine oxidase compound screening of anacardic acid analogues. A bar chart 
depicting the xanthine oxidase compound screen results for analogues KC_31 to KC_44. Each 
sample was carried out in triplicate and the average change in absorbance for each concentration 
was plotted against time. The data was fixed using a linear line of regression to calculate the slope 
which equates to the change in absorbance. The inverse reciprocal of the slope was calculated for 
each sample and was expressed relative to the total enzyme activity. The red dotted line marks the 
cut off point and any compounds with a % total activity below 50% was identified as having more 
than 50% enzyme inhibition at 100 µM.  
 
Dose response experiments were carried out to determine the IC50 of KC_19 and anacardic acid. 
The representative sigmoidal dose response curves for anacardic acid and KC_19 is presented in 
Figure 2.20. The average IC50 for anacardic acid was 45.0 ± 7.1 µM and the average IC50 for 
analogue KC_19 was 50.5 ± 8.1 µM. As observed for the radioactive HAT flash plate assay data 
there  is  a  negligible  fold  change  between  two  the  IC50  values.  Hence,  the  xanthine  oxidase 
inhibition is not influenced by introduction of an oxygen atom to the alkyl tail. 
 
Xanthine  oxidase  was  not  inhibited  by  KC_14  and  KC_15  at  100  µM.  However,  these  two 
analogues inhibit PCAF activity at 31.7 ± 5.0 µM and 73.1 ± 30.6 µM respectively. Although not 
potent inhibitors of PCAF, they are more selective towards PCAF than KC_19 and anacardic acid. 
Hence, the first two selective PCAF inhibitors may have been identified. These analogues are also 
the result of shorting the long hydrophobic tails in KC_19 and anacardic acid to a shorter heptyl 
alcohol tail. Hence, it could be argued that shortening the tail improves selectivity.  
  
 
83 
Anacardic Acid
1.3 1.4 1.5 1.6 1.7 1.8 1.9 2.0 2.1 2.2
0
25
50
75
100
125
Log10 Concentration µ µ µ µM
%
 
E
n
z
y
m
e
 
 
A
c
t
i
v
i
t
y
KC_19
1.3 1.4 1.5 1.6 1.7 1.8 1.9 2.0 2.1 2.2
0
25
50
75
100
125
Log10 Concentration µ µ µ µM
%
 
E
n
z
y
m
e
 
 
A
c
t
i
v
i
t
y
 
 
Figure 2.20: Xanthine oxidase dose response curves for anacardic acid and analogue KC_19. 
A graph showing the sigmoidal dose response curve plotted for anacardic acid and the analogue 
KC_19. The graph shows three curves which were obtained from three individual experiments 
from which the average IC50 was calculated. The average IC50 was calculated from the mean (±SD) 
for triplicate determinations. A maximum of eight concentration points with 1.2-fold intervals were 
used. The concentration range for anacardic acid was 90 to 25.1 µM and the concentration range 
for KC_19 was 120 to 33.5 µM.  The assay measures the xanthine oxidase (2 mg/ml) catalysed 
generation  of  superoxide  anion  via  the  reduction  of  yellow  nitro  blue  tetrazolium  dye  to  an 
insoluble blue formazan. This change in absorbance of blue formazan (560 nm) was measured at 10 
second intervals over a course of 300 seconds using a UV spectrometer (Varioskan Flash). The 
resulting  %  total  activity  was  calculated  using  the  linear  regression  of  the  slope  charting  the 
absorbance of blue formazan for each concentration against the total activity control. The % total 
activity values were then evaluated using GraphPad Prism software version 4.03 and sigmoidal 
dose response curves were assigned to the data to calculate the IC50 for each experiment.  
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Luciferase Counter Screen 
Anacardic  acid  and  analogues  were  screened  for  firefly  luciferase  inhibition  using  an  in  vitro 
counter screen. This counter screen was set up to identify whether anacardic acid or any of the 
analogues exhibit non-specific activity. There are concerns that anacardic acid exhibits non-specific 
activity due to its ability to inhibit PCAF, xanthine oxidase, lipoxygenase and cycloxygenanse
118. 
Artifactual causes of non-specific inhibition can range from molecules that chemically interfere 
with the assay, chemically modify the target, or form colloidal aggregates. The most common 
mechanism  for  non-specific  inhibition  is  the  congregation  of  organic  molecules  into  colloidal 
aggregates, which non-specifically inhibit enzymes
134, 135. The luciferase counter screen can be used 
to screen for promiscuous small molecule inhibitors. It is hypothesised that unless anacardic acid 
and analogues form aggregates in solution, luciferase activity will not be inhibited.  
 
Anacardic acid and each anacardic acid analogue was screened at 100 µM, the same concentration 
used in the radioactive HAT flashplate and xanthine oxidase assays. The luciferase compound 
screen results are shown in Figure 2.20. Both compound screens show that neither anacardic acid 
nor any of the analogues inhibit firefly luciferase. Therefore anacardic acid and the analogues do 
not exhibit non-specific activity. It can be also be deduced that anacardic acid and analogues do not 
form aggregates in solution.   
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Figure 2.21: Luciferase compound screening of anacardic acid and analogues. Two bar charts 
depicting the luciferase compound screen results for analogues KC_01 to KC_44. Each sample was 
carried out in duplicate. The average luminescence was calculated for each sample and expressed 
as a percentage of the luminescence observed for the total enzyme activity with no added inhibitor. 
All results are the mean (± SD) for duplicate determinations  
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Western Blotting  
To evaluate whether treatment with HAT inhibitors causes changes in protein acetylation in vivo, 
western blotting was employed to measure acetylated histone protein levels in protein extracts from 
MCF7 cells. A HAT inhibitor like anacardic acid would reduce the levels of acetylated histones 
thereby  making  it  difficult  to  detect  and  quantify  the  acetylation.  Hence,  an  experiment  was 
designed to enhance the acetylated histone levels.   
 
 
Figure 2.22: A diagram outlining the basic principle of SAHA and Anacardic acid mediated 
histone acetylation 
 
Figure 2.22 shows a schematic diagram for the experimental concept of treating MCF7 cells with 
SAHA and anacardic acid. SAHA is a histone deacetylase inhibitor and thus prevents deacetylation 
of  the  histone  tails,  resulting  in  enhanced  levels  of  acetylated  histone  proteins  which  can  be 
detected by western blotting. Specific antibodies for acetylated histone H4 are commonly available 
and an experiment was designed to look at the levels of acetylated histone rather than deacetylated 
histone. The idea of the experiment was to decrease the level of acetylated histone H4 by treating 
the cells with the HAT inhibitor anacardic acid in the presence of SAHA.  
 
A similar experiment has been carried out by Balasubramanyam et al. in HeLa cells
50. Histone 
acetylation  was  stimulated  by  TSA  and  sodium  butyrate.  In  comparison  HeLa  cells  were  also 
treated simultaneously with TSA, sodium butyrate and the HAT inhibitor garcinol. The results 
showed that garcinol significantly reduced the enhanced acetylation of H4 and H2B. 
 
An initial experiment was set up to determine the minimum concentration of the HDAC inhibitor 
SAHA required to observe acetylated histone H4 on a western blot. It was important to establish 
the minimum concentration as the cells would be treated with both SAHA and anacardic acid. 
Hence, to avoid cytotoxic effects, the concentration of SAHA was kept to a minimum. The digital 
image of the western blot is shown in Figure 2.23. SAHA has HDAC inhibitory activity, hence an 
increased  level  (more  intense  band)  of  acetylated  histone  will  be  observed  for  increasing 
↑ acetylated Histone H4 
deacetylated Histone H4 
S SA AH HA A      
a an na ac ca ar rd di ic c   a ac ci id d   
 
h hi is st to on ne e   t ta ai il l   
N H2
O
NH3
+ 
 
Protein detected by specific antibody  
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concentrations of SAHA. The results show quite clearly that SAHA treatment causes an increased 
level  of  acetylated  histone  H4  proteins  compared  to  untreated  MCF7  cells.  The  highest 
concentration  of  SAHA  (5  µM)  shows  a  more  intense  band  and  hence  an  increased  level  of 
acetylated  histone  H4  proteins. The bands  become  less intense  as  the  concentration of  SAHA 
decreases. The lowest concentration of SAHA (0.5 µM) still shows a strong band of acetylated 
histone, hence this concentration was chosen for future experiments. A blot for PCNA is also 
included in Figure 2.17. PCNA is a reference protein that acts as a standard, if there are consistent 
PCNA levels for each band then the experiment is validated. It is clear that in this experiment, the 
PCNA levels do not change in appearance.  
 
 
 
 
 
Figure  2.23:  Effect  of  SAHA  on  histone  H4  acetylation.  This  experiment  investigated  the 
minimum concentration of SAHA required to observe histone acetylation. The diagram shows two 
western blot images for acetylated histone H4 (lysine 8) and proliferating cell nuclear antigen 
(PCNA) following 2 hour treatment of MCF7 breast cancer cells with SAHA. The experimental 
concentrations of SAHA chosen were 5, 4, 2, 1 and 0.5 µM. The control cells are on the left hand 
side for comparison, these are the untreated MCF7 cells and the 0.5 % (v/v) DMSO treated cells. 
The DMSO control is the maximum amount of DMSO present in any one sample. The blot is 
presented as a digital image of the chemiluminescence emitted from the HRP bound immuno-
complex for each of the specific proteins.  
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Figure 2.24: Anacardic acid reversion of SAHA generated acetylation. The diagram shows two 
western blot images for acetylated histone H4 (lysine 8) and proliferating cell nuclear antigen 
(PCNA) following 2 hour treatment of MCF7 cells. On the right hand side, cells were treated with 
anacardic acid ranging from 100 to 12.5 µM with two fold intervals in the presence of 0.5 µM 
SAHA. The concentration of anacardic acid decreases from left to right. On the left had side are the 
control cells for comparison, these are the untreated MCF7 cells, 0.5 % DMSO (v/v), 100 µM 
anacardic  acid  and  0.5  µM  SAHA.  The  blot  is  presented  as  a  digital  image  of  the 
chemiluminescence  emitted  from  the  HRP  bound  immuno-complex  for  each  of  the  specific 
proteins.  
 
The main experiment investigated the anacardic acid dose response reversion of SAHA initiated 
histone acetylation and the digital image of the western blots produced is presented in Figure 2.24. 
The  results  show  that  by  decreasing  the  anacardic  acid  concentration,  the  level  of  histone 
acetylation is increased as the SAHA mediated histone acetylation is no longer repressed. This is 
increase is validated by the consistent PCNA levels shown on the right hand side of the blot. 
Another observation is that anacardic acid alone does not decrease the level of acetylated histone 
proteins. The band for 100 µM anacardic acid control is of the same intensity as the band for the 
untreated and DMSO controls. However these results are complicated by the anomaly in the 0.5 
µM SAHA control for the acetylated histone H4 blot. If you compare the intensity of this band with 
the  0.5  µM  SAHA  band in  Figure  2.23  it is  apparent  that  the  band  has  a  noticeably  reduced 
intensity. The reduced intensity in band is also present in the PCNA blot. This suggests that under 
loading of sample might explain the reduced intensity. Repeated attempts of this experiment to 
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reproduce the results in Figure 2.24 without the SAHA anomaly have failed to generate the same 
outcome. 
 
Consequently the increase in acetylated histones with decreasing anacardic acid has been difficult 
to  recreate.  This  places  lack  of  confidence  in  these  results  but  the  solubility  problems  with 
anacardic acid shouldn’t be undermined. The radioactive HAT flash plate assay also encountered 
problems with anacardic acid solubility. Anacardic acid and analogues suffer from a very high 
lipophilicity  and  low  solubility  in  the  aqueous  cell  culture  medium.  Attempts  to  establish  the 
optimum conditions for the HAT inhibitor reversion of SAHA may be more successful when the 
solubility issues have been addressed.  
 
p21 Promoter Assay 
The p21 reporter assay was used to explore whether anacardic acid and analogues influence p21 
programmed cell cycle arrest. It is widely known that the HDAC inhibitor SAHA induces cell cycle 
arrest  and  apoptosis  in  MCF7  cells  via  up-regulation  of  the  cyclin-dependent  kinase  (CDK) 
inhibitor p21
136. In this experiment, MCF7 cells were transfected with pGL2 vectors containing a 
p21 promoter fused to a firefly luciferase reporter gene
137. The transfected cells were then treated 
with range of experimental conditions for 24 hours and the Bright-Glo
TM luciferase assay system 
(Promega) was used to quantify the enzymatic activity of the reporter protein firefly luciferase.  
 
Compound screening of anacardic acid and five analogues was carried out to assess their effect on 
p21  reporter activity.  The  five  analogues; KC_19, KC_21, KC_23, KC_39 and  KC_41  were 
chosen for their cytotoxic effects. They all have an MCF7 growth inhibition IC50 less than 100 µM 
like anacardic acid. Out of these analogues only KC_19 inhibits HAT activity, hence it would be 
interesting to see if the other analogues had an effect of p21 reporter activity. The results of the 
compound screen are displayed as a bar chart in Figure 2.25. The results indicated that anacardic 
acid and the five anacardic acid analogues can reduce the relative p21 reporter activity in the 
presence  of  SAHA.  Secondly  anacardic  acid  or  analogue  alone  does  not  induce  p21  reporter 
activity.  There  is  also  no  correlation  between  HAT  inhibition  and  p21  reporter  activity.  The 
analogues that don’t inhibit PCAF can reduce p21 reporter activity to the same extent as anacardic 
acid and KC_19. 
 
A dose response profile of anacardic acid in the presence of 1 µM SAHA was developed to assess 
whether the p21 reporter activity fluctuates with a change in anacardic acid concentration. Figure 
2.26 shows two separate bar charts for p21 transfected cells and pGL2 transfected cells. The pGL2 
luciferase reporter vector has essentially the same backbone as the p21 reporter vector except it 
does not contain the p21 promoter gene. The pGL2-control vector contains a SV40 promoter and 
enhancer sequences which induces strong expression of luciferase in eukaryotic cells. Hence, this  
 
90 
plasmid is useful for monitoring general transfection efficiency. The dose response profile for 
pGL2  transfected  cells  shows  a  similar  pattern  in  p21  reporter  activity  as  observed  for  p21 
transfected cells.  The control reporter activity is induced less than the p21 reporter activity by the 
HDAC inhbititor SAHA. Therefore the p21 promoter activity is highly inducible by SAHA. With 
respect to anacardic acid, the p21 reporter activity increases with anacardic acid concentration 
between 100 and 0.1 µM before the relative activity starts to plateau or decrease. This experimental 
observation indicates that anacardic acid may have a non-specific effect on p21 reporter activity. 
Since, there is no robust correlation between anacardic acid concentration and p21 reporter activity. 
The pattern of reporter activity is also very similar between the two reporters. Therefore, it is 
highly probable that the repression of p21 reporter activity is due to the cytotoxic effect of two 
inhibitors in the assay.  
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Anacardic acid/analogue plus SAHA Anacardic acid/analogue only  
 
Figure 2.25: Compound screening of anacardic acid and analogues towards p21 expression. 
This experiment looks at the two HAT inhibitors anacardic acid and KC_19 plus four non-HAT 
inhibitors which have similar MCF7 growth inhibition dose responses. Each bar is representative of 
the  two  different  treatment  conditions.  The  red  bands  are  representative  of  cells  that  were 
simultaneously treated with 1.0µM SAHA and 100 µM anacardic acid or analogue. The blue bands 
show the level of expression caused by 100 µM anacardic acid/analogue treatment only. The grey 
band depicts relative p21 reporter activity by SAHA alone for comparison. The relative increase in 
p21 promotion was calculated by subtracting the background level of p21 reporter activity from 
untreated  non-transfected  cells  and  then  expressing  the  corrected  luminescence  relative  to  the 
untreated p21 transfected cells. All results are the mean (SD) of n = 2. 
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Figure 2.26: Dose response of anacardic acid in p21 and pGL2 transfected cells. Each graph 
depicts a dose response profile of varying anacardic acid concentration in the presence of a fixed 
amount of SAHA (1 µM). The blue bands represent the cells that were treated with both SAHA and 
anacardic acid. The red bands show p21 reporter activity caused by 100 µM anacardic acid and 1 
µM SAHA treatment alone. The p21 reporter activity observed in p21 transfected cells is shown in 
the top chart and the pGL2 control transfected cells in the bottom chart. The relative increase in 
p21 activity was calculated by subtracting the background level of p21 expression from untreated  
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non-transfected cells and then expressing the corrected luminescence relative to the untreated p21 
transfected cells. All results are the mean (SD) of n = 2. 
 
Biological Studies of the Azumamides 
In vitro experiments were carried out to characterise the effects of four azumamides on MCF7 
breast cancer growth inhibition and histone acetylation. The five azumamides include the known 
azumamides A and E and three novel azumamides which feature a hydroxamic acid, benzyl ester 
and a tri-chloro ethyl ester (Figure 2.27). The synthesis of these azumamides and their HDAC 
inhibitory  IC50  values  were  published  by  Wen  et  al
138.  These  azumamides  exhibit  the  classic 
pharmacophore for HDAC inhibitors: a ‘warhead’ binging the active site zinc, linked by a spacer 
mimicking  the  lysine  substrate  and  a ‘cap’  spanning  the  enzyme  binding  channel  and  making 
extensive  contacts  with  the  enzyme  ‘rim’.  Each  of  the  four  azumamides  contains  a  different 
‘warhead’. It was hypothesised that the hydroxamic acid warhead would have a stronger binding 
affinity to the zinc atom, hence creating a more potent azumamide analogue. 
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Azumamide A  NH2 
Azumamide E  OH 
Azumamide hydroxamic acid  NH-OH 
Azumamide benzyl ester  O-Benzyl 
Azumamide tri-chloro ethyl ester  O-CH2CCl3 
 
Figure 2.27: Azumamides 
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The  azumamides  also  have  a  different  cyclic  tetrapeptide  scaffold.  The  peptide  backbone  is 
different to the depsipeptide backbone featured in FK228 and SPI.  In the azumamides the peptide 
backbone  is  composed  of  D-amino  acids  (D-Phe,  D-Ala  and  D-Val).  The  side  chain  of  the 
azumamides possesses the opposite absolute configuration by expansion of one α-amino acid to a 
β-amino acid. This special structural feature of the azumamides releases the steric strain of an all 
D-configuration as observed in the cyclic tetrapeptide, apicidin
76. Despite the difference in cyclic 
tetrapeptide scaffold between azumamides and the depsipeptides it hoped that the azumamides will 
exhibit the same high degree of potency as HDAC inhibitors when tested in the HDAC Fluor de 
Lys assay (BIOMOL
®, Exeter, UK) 
 
Growth Inhibition  
In vitro experiments in MCF7 breast cancer cells were carried out to determine the IC50 of four 
azumamides. Previous studies on HDAC inhibitors have shown these compounds to have strong 
cytotoxic effects in MCF7 breast cancer cells. For example HDAC inhibitor SPI has an IC50 of 5.7 
± 0.7 nM
84. Nakao et al. reported that azumamide A showed moderate cytotoxic effects towards 
WiDr (human colon cancer) cells (IC50 = 5.8 µM) and K562 (human leukaemia) cells (IC50 = 4.5 
µM)
87. 
 
An assumption was made that the azumamides would exhibit potency at less than 100 µM and 
initial  growth  inhibition  experiments  profiled  a  range  of  ten  concentrations  under  100  µM. 
Subsequent dose response profiles were fine tuned to verify the IC50 for each azumamide. The 
representative sigmoidal dose response plots for each azumamide are presented in Figure 2.28. The 
dose response profile for azumamide A was not characterised as it is not potent in MCF7 breast 
cancer cells at less than 10 µM (data not shown). This result compared with the cytotoxic effects 
reported by Nakao et al. indicates that MCF7 cells are less sensitive towards azumamide A than 
WiDr and K562 cells.  
 
The respective IC50 values for the other azumamides are reported in Figure 2.29. Azumamide E and 
the esters have similar IC50 values between 10 and 4 µM whereas azumamide hydroxamic acid 
(IC50 = 163.7 ± 8.7 nM) is the most potent. Only the IC50 of azumamide hydroxamic acid is in the 
nano molar region as observed for other HDAC inhibitors including SPI, FK228, SAHA and TSA 
(Figure 2.30). The IC50 of azumamide hydroxamic acid lies between the published IC50 values for 
the hydroxamates SAHA and TSA. This is a reassuring observation as azumamide hydroxamic acid 
contains the same functional hydroxamic acid warhead as SAHA and TSA.  
 
In  addition,  the  peptide  backbone  of  an  azumamide  is  similar  to  the  depsipeptide  cap  which 
enhances binding interactions with the HDAC. This enhanced binding interaction contributes to the 
stronger potency of FK228 and SAHA. The same potency is observed for azumamide hydroxamic  
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acid. Hence, switching from a depsipeptide backbone to the natural peptide backbone doesn’t have 
any repercussions provided there is a strong binding affinity between the warhead and zinc atom.  
 
These results  confirm  that  the  hydroxamic  acid is  the  more  potent  warhead as  predicted. The 
growth inhibition results also show that a carboxylic acid warhead is more potent than an amide 
warhead. However, the affinity of these last two zinc binding warheads is not strong enough to 
compensate for the weaker peptide backbone binding with the enzyme active site.  
 
Azumamide benzyl ester
-2.0 -1.5 -1.0 -0.5 0.0 0.5 1.0 1.5 2.0
25
50
75
100
125
Log10 Concentration µ µ µ µM
%
 
 
C
e
l
l
 
N
u
m
b
e
r
Azumamide tri-chloro ethyl ester
-2.0 -1.5 -1.0 -0.5 0.0 0.5 1.0 1.5 2.0
25
50
75
100
125
Log10 Concentration µ µ µ µM
%
 
 
C
e
l
l
 
 
N
u
m
b
e
r
Azumamide E
-2.0 -1.5 -1.0 -0.5 0.0 0.5 1.0 1.5 2.0
25
50
75
100
125
150
Log10 Concentration µ µ µ µM
%
 
C
e
l
l
 
N
u
m
b
e
r
Azumamide hydroxamic acid
-3.0 -2.5 -2.0 -1.5 -1.0 -0.5 0.0 0.5 1.0
100
200
300
400
500
Log10 Concentration µ µ µ µM
%
 
 
C
e
l
l
 
N
u
m
b
e
r
 
Figure  2.28:  Azumamide  growth  inhibition  dose  response  curves.  Growth  inhibition 
experiments were carried out to determine the potency of the azumamides towards MCF7 breast 
cancer cells. Representative sigmoidal dose response curves for azumamide E, the two esters and 
hydroxamic  acid  for  one  experiment  are  shown  above.  MCF7  cells  were  treated  with  a  ten 
concentration point dose profile ranging in-between 100 µM and 0.01 µM. Cells were incubated for 
six days at 37ºC prior to quantification of cell number utilizing the CyQuant® Kit. Two controls 
were also carried out, untreated cells and cells treated with the maximum amount of DMSO used in 
a given sample. Data shown are mean ± standard deviation for duplicate determinations. The % cell 
number is relative to the number of untreated cells and the DMSO control (▲) is shown on each 
plot.   
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Compound 
 
Experiment 1 
IC50  
Experiment 2 
IC50  
Mean (± SD) 
IC50 
Azumamide E  13.4 µM  3.5 µM  8.5 ± 7.0 µM 
Azumamide benzyl ester  5.2 µM  3.1 µM  4.2 ± 1.5 µM 
Azumamide tri-chloro ethyl ester  6.5 µM  13.3 µM  9.9 ± 4.8 µM 
Azumamide hydroxamic acid  157.5 nM  169.8 nM  163.7 ± 8.7 nM 
 
Figure 2.29: Average growth inhibition IC50 for the azumamides.  
A table listing the growth inhibition IC50 results for the azumamides in MCF7 breast cancer cells. 
MCF7 cells were treated with a ten concentrations ranging in-between 100 µM and 0.01 µM for 
six days at 37ºC. The IC50 values were derived from duplicate data points, and nonlinear regression 
was performed to create sigmoidal dose response curves using GraphPad Prism Software version 
4.03. The dose response was repeated twice in two separate experiments and the average IC50 is the 
mean ± standard deviation for these two experiments.  
 
 
   
FK228 
 
SPI 
 
 
TSA 
 
SAHA 
 
IC50 
 
0.8 ± 0.2 nM
 
 
5.7 ± 0.7 nM 
 
44 ± 7 nM 
 
500 ± 42 nM 
 
Figure 2.30: Mean IC50 of HDAC inhibitors in MCF7 breast cancer cells
84. Data are mean IC50 
(nM) ± standard deviation for a minimum of two separate experiments.  
 
HDAC Inhibition  
The HDAC inhibitory potential of the azumamides was also characterised using a HDAC Fluor de 
Lys
® fluorescence assay. Total HDACs in HeLa cell extracts were subjected to inhibition by the 
azumamides and the results are presented in Figure 2.31. An IC50 was not determined for the 
azumamide tri-chloro ethyl ester as it did not inhibit HDAC activity at 10 µM. Interesting the 
azumamide tri-chloro ethyl ester exhibited moderate cytotoxic effects (IC50 = 9.9 ± 4.8 µM). It 
could be argued that the cytotoxic effect of azumamide tri-chloro ethyl ester is not specific for 
histone acetylation.  
 
As observed for the growth inhibition data, azumamide hydroxamic acid (IC50 = 7.0 ± 2.5 nM) is 
the  most  potent,  followed  by  azumamide  E,  azumamide  benzyl  ester  and  azumamide  A 
respectively. This is consistent with anticipated zinc binding affinities of the warhead. Maulucci et  
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al. has also published HeLa HDAC inhibition values for azumamide E (IC50 = 134 ± 24 nM) and 
these are consistent with our values.   
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Figure 2.31: Average HDAC inhibition IC50 for the azumamides. A bar chart and a table of 
results  are  included  in  Figure  2.31  to  compare  the  HDAC  inhibition  IC50
  (nM)  data  for  the 
azumamides. HDAC inhibition was analysed using a Fluor de Lys
® assay which measures total 
HDAC activity in HeLa cell extracts upon treatment with azumamide. The IC50 was calculated 
from five concentration points performed in duplicate and a non-linear line of regression was fitted 
to the data using GraphPad Prism software version 4.03.  The HDAC inhibition profile for each 
azumamide was repeated a minimum of two times and the IC50 is the mean ± standard deviation.  
 
The hydroxamic acid warhead has the strongest binding affinity towards the zinc atom. Substituting 
the carboxylic acid warhead in the azumamide E with the hydroxamic acid has resulted in a 15-fold 
increase in potency towards HeLa HDAC activity. A similar observation was made by Meinke et 
al. when they substituted the ethylketone in apicidin with a hydroxamic acid. A two fold increase in 
potency of apicidin (IC50 = 240 pM) was observed for the hydroxamic acid analogue (IC50 = 400 
pM) towards HeLa HDAC activity
80. 
 
The  biological  activity  of  the  natural  azumamides  A  and  E  is  significantly  weaker  than  the 
depsipeptide FK228. The same Fluor de Lys
® assay was used to determine the potency of FK228 
(IC50 = 15 ± 9 nM) towards HeLa HDAC activity
83.  This suggests the depsipeptide backbone  
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makes for a more potent inhibitor than the peptide backbone in the azumamides.  However the 
azumamide  hydroxamic  acid  (IC50  =  7.0  ±  2.5  nM)  has  an  equivalent  IC50  to  FK228.  This 
demonstrates  that  reduction  in  potency  due  to  switching  from  the  depsipeptide  to  the  peptide 
backbone can be overcome by increasing the affinity of the zinc-binding warhead. 
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3 Conclusions 
A number of conclusions can be made from the search for small molecule inhibitors of histone 
acetylation. The natural product anacardic acid was chosen as the lead compound for synthesis of 
further analogues. It has been reported to be non-specific HAT inhibitor of PCAF and p300 but 
there are issues with solubility due to its long hydrophobic C15 alkyl tail
47. To improve the HAT 
inhibitory activity of anacardic acid, a series of anacardic acid analogues were synthesised with 
modifications  made  to  the  alkyl  tail  in  an  attempt  to  create  more  potent  and  cell  permeable 
anacardic acid analogues.  
 
Anacardic acid was synthesised using a Suzuki coupling that was almost identical to published 
experimental conditions bar the introduction of alternative protecting groups. It was anticipated that 
by  protecting  the  phenol  and  salicylic  acid  moieties  separately,  selective  cleavage  of  their 
respective protecting groups could be utilised to create further analogues by specific substitution.  
Unfortunately,  anacardic  acid  synthesis  by  the  Suzuki  coupling  was  hindered  by  the  long 
complicated anhydrous palladium chemistry resulting in a low yield of anacardic acid. This led to 
the use of alternative reaction routes to produce anacardic acid analogues.  
 
The first alternative reaction route was amide coupling of commercially available peptides. Eleven 
anacardic  acid  analogues  were  created  via  formation  of  a  carboxylic  acid  scaffold  and  the 
subsequent  amide  coupling  and  deprotection  steps.    The  amide  coupling  reaction  was  easily 
amenable to synthesis of further analogues by coupling a whole array of commercially available 
amino acids or other amine compounds. Although the synthesis involved in the amide coupling was 
relatively  straightforward,  problems  such  as  polymerisation  and  hydroscopic  compounds  were 
encountered. Instead efforts were focus on the facile Mitsunobu synthesis to provide a milder, 
cleaner, two step synthesis to anacardic acid analogues.  
 
The  Mitsunobu  synthesis  was  used  to  generate  a  wide  range  of  analogues  with  varying  tails. 
Analogues  were  synthesised  with different alkyl  chain lengths  using  a  range  of alcohols from 
propanol  to  tetradecanol.  Phenyloxy  and  aromatic  alcohols  were  also  used  to  introduce  some 
functionality to the alkyl tails. Preliminary MCF7 breast cancer cell growth inhibition data showed 
that moderate cytotoxic effects were still achievable upon decreasing the alkyl tail from C15 to an 
octyl alcohol tail. Hence, further analogues were synthesised by coupling 1-octanol to a range of 
heterocycles. Thirty one analogues were synthesised with relative ease and moderate yields. Two 
further analogues were generated from the brief foray into synthesis of CPTB analogues bringing a 
total number of forty four anacardic acid analogues.  
 
A  review  of  the  literature  showed  that  the  biological  effects  of  anacardic  acid  have  been 
investigated  in  a  wide  range  of  assays  from  in  vitro  enzyme  assays  to  cell  inhibition  assays.  
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Anacardic acid has been associated with anti-tumour activity, antioxidant activity, HAT inhibitory 
activity and sensitisation of tumour cells to ionising radiation. The HAT and xanthine oxidase 
assays were used to confirm the biological effects of anacardic acid and compare the activity with 
the anacardic acid analogues.  
 
To explore the cytotoxic effects of anacardic acid and analogues, an assay was set up to explore 
growth inhibition in an epithelial carcinoma.  MCF7 (breast), PANC1 (pancreas), PC3 (prostate) 
and HCT116 (colorectal) epithelial cells were compared for sensitivity towards anacardic acid. 
MCF7 cells were found to be the most sensitive cell line and the IC50 of anacardic acid (IC50 = 37.5 
± 2.5 µM) was determined. The ability to inhibit MCF7 breast cancer cell growth was screened for 
all the anacardic acid analogues. Only three compounds, KC_37, KC_39 and KC_44 were found 
to more potent than or equivalent to anacardic acid in MCF7 breast cancer cells. The most potent 
analogue was KC_39 (IC50 = 18.2 ± 2.6 µM) which is two times more potent than anacardic acid. 
 
A  number  of  conclusions  were  made  from  comparing  the  IC50  values  of  the  anacardic  acid 
analogues but the important findings are as follows. The phenol and salicylic acid moieties hinder 
growth inhibition and cause at least a two-fold reduction in potency. For example, KC_40 is the 
free acid version of KC_39 and this analogue has an IC50 of 84.0 ± 13.6 µM which is five times 
less potent than the acetonide KC_39. Despite the salicylic acid hindering growth inhibition, it was 
discovered that removing the salicylic acid group completely can also result in reduced potency.  
KC_43 lacks the salicylic acid moiety and this loss resulted in a seven fold decrease in potency 
compared to KC_44. This suggests that when synthesising further anacardic acid analogues the 
structure must feature a salicylate ester at minimum. This suggestion is also backed up by the 
finding that the acetonide analogues are more potent than the free acid analogues. 
 
Twelve analogues (KC_12-15 and KC_19-26) were synthesised with varying tail lengths. Growth 
inhibition  data  from  these  analogues  showed  that  a  decrease  in  tail  length  conferred  no 
improvement  in  the  potency  of  the  anacardic  acid  analogues  featuring  the  free  hydroxyl  and 
salicylic acid moieties. However for the more potent acetonide protected compounds, the octyl 
alcohol tail was the optimum length. Thus, reduction in tail length can be tolerated.  
 
Introduction of oxygen atoms into the alkyl tail had a negative effect on MCF7 growth inhibition. 
Analogues KC_16 and KC_17 were synthesised with a di (ethylene glycol) methyl ether tail and 
these failed to inhibit MCF7 cell growth at 250 µM. Analogues with an indole group (KC_39) or a 
benzyl (KC _37) group in the tail region fared better. These analogues were found to be more 
potent than or equivalent to anacardic acid.  
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One analogue was of particular interest. The analogue KC_19 is essentially anacardic acid bar a 
tetradecyl alcohol tail rather than a pentadecyl alkyl tail. It was hoped that this analogue would 
have the same cytotoxic effect as anacardic acid, not only due to similarities but because KC_19 is 
much easier to synthesise using the facile Mitsunobu conditions. KC_19 would then be better 
synthetic substitute for anacardic acid to probe the cytotoxic and inhibitory effects of anacardic 
acid. However, in the growth inhibition assay, KC_19 (IC50 = 70.9 ± 2.8 µM) had an IC50 that was 
two times less potent than anacardic acid. In the grand scheme of things this small fold change in 
potency does not hamper the benefits that the Mitsunobu synthesis brings when the aim is to 
produce a large number of analogues.  
 
The ability of the anacardic acid and analogues to inhibit PCAF activity in vitro was assessed in a 
radioactive HAT flash plate. Three anacardic acid analogues were shown to be inhibitors of PCAF 
whilst,  the  remaining  anacardic  acid  analogues  showed  insufficient  inhibition  at  100  µM.  As 
observed  for  the  MCF7  growth  inhibition,  the  salicylic  acid  and  hydroxy  moiety  can  have  a 
detrimental effect on PCAF inhibition since the acetonide protected analogue KC_14 is far more 
potent than KC_15. The number of analogues that show PCAF inhibition is insufficient to make 
some  robust  structure  activity  relationships,  thus  highlighting  the  need  to  synthesise  more 
compounds that can inhibit PCAF activity. On a positive note, the analogue KC_19 possesses the 
same PCAF inhibitory effect as anacardic acid. The addition of an alcohol tail rather than an alkyl 
tail has no profound effect on PCAF activity. Thus this encourages further synthesis of anacardic 
acid analogues by the facile Mitsunobu synthesis. 
 
The inhibitory activity of anacardic acid and analogues towards p300 was not analysed, however it 
is  known  from  the  literature  that  anacardic  acid  inhibits  p300  with  similar  efficacy  to  PCAF 
inhibition. The radioactive HAT flash plash assay could be easily optimised for use with p300 and 
future work could investigate whether the HAT inhibitors identified in this project target p300.  
 
Anacardic acid has been shown to inhibit other enzymes besides PCAF, although with much lower 
efficiency. The IC50 of anacardic acid towards PCAF (IC50 = 6.0 ± 0.4 µM) is more potent than 
towards  xanthine  oxidase  (IC50  =  45.0  ±  7.1  µM).  This  suggests  that  anacardic  acid  is  more 
selective towards PCAF inhibition. KC_19 was also shown to both inhibit PCAF (IC50 = 8.4 ± 0.4 
µM) and xanthine oxidase (IC50  = 50.5 ± 8.1 µM). However the possibility  of complete non-
specificity and formation of aggregates in solution could be discounted due to inability of anacardic 
acid and KC_19 to inhibit luciferase activity. KC_14 and KC_15 do not inhibit xanthine oxidase 
nor  luciferase  activity,  hence  suggesting  that  they  may  be  more  specific  towards  PCAF  than 
KC_19 and anacardic acid.  It can be concluded that in terms of ease of synthesis, MCF7 growth 
inhibition (IC50 = 52.4 ± 4.5) and PCAF inhibition (IC50 = 31.7 ± 5.0 µM), the analogue KC_14 is 
the best all rounder.   
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The intracellular effects of HAT inhibition of anacardic acid upon acetylated histone H4 and p21 
levels were investigated. Histone acetylation was explored using western blotting to investigate the 
anacardic acid dose response reversion of SAHA initiated histone acetylation. Anacardic acid was 
shown to decrease histone acetylation with increasing concentration (up to 100 µM) in the presence 
of SAHA. However, this result was not reproducible due to solubility issues with anacardic acid 
and the cytotoxic effect of two inhibitors in the assay. Eliseeva et al. have reported an alternative 
method  to  analyse the change  in acetylation  of  histone  H4
48.  Rather than  simultaneously  treat 
MCF7 breast cancer cells with HDAC inhibitor and HAT inhibitor. The level of histone acetylation 
was enhanced by treating the cells with HDAC inhibitor for 1h after treatment with the HAT 
inhibitor. Eliseeva et al. showed that treatment with the HDAC inhibitor TSA (200 nM) alone 
caused  significant  increase  in  acetylated  histone.  Pre-treatment  with  anacardic  acid  (90  µM) 
resulted in a decreased level of acetylated histone
48. It would be worth repeating the western blot 
experiment using these conditions reported by Eliseeva et al. There would be no conflict between 
the  HAT  and  HDAC  inhibitors  upon  histone  acetylation  and  the  cytotoxic  effect  from  two 
inhibitors would be reduced.  
 
The observation that anacardic acid reduces p21 reporter activity in the presence of SAHA may 
have to be discounted as it is evident that the repression of p21 reporter activity may be due to non-
specific activity or cytotoxic effects. Eliseeva et al. also reported that prolonged treatment (24 
hours) with HAT inhibitors caused high toxicity and complicated normalisation of the assay data
48. 
Their experimental set up involved MCF7 cells transiently transfected with p21 promoter and the 
full-length p300 acetyltransferase. To overcome the cytotoxic effects, p21 reported activity was 
determined  over  a  shorter  period  of  time.  It  was  demonstrated  that  anacardic  acid  (90  µM) 
significantly inhibited p300 (80% inhibition) as measured by p21 reporter activity after six hours. It 
would be worth investigating the time dependent dose response of anacardic acid and analogues 
upon p21 reporter assay for a future experiment since the current results were obtained from cells 
that had been treated for 24 hours.  
 
In  addition  to  the  synthesis  and  biological  effects  of  anacardic  acid  and  analogues,  a  short 
investigation was carried out on the azumamides. The potency of the azumamides was assessed in a 
MCF7 cell inhibition assay and HDAC assay. Both assays showed that the order of potency was as 
follows; azumamide hydroxamic acid > E > A and this correlated with the binding affinity of zinc 
binding warhead. The natural product azumamides A and E were discovered to be less potent than 
the natural product depsipeptide FK228. This was explained by the different in cyclic tetrapeptide 
scaffold between the azumamides and depsipeptides. However a novel, synthetic azumamide, with 
a hydroxamic acid warhead is more potent than FK228. The hydroxamic acid warhead was able to 
compensate for discrepancies in structure between a peptide and depsipeptide backbone.   
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The main aim behind the search for small molecule inhibitors of histone acetylation was a simple 
proof of principle study to explore different structural analogues of anacardic acid. A great deal of 
knowledge  can  be  gained  from  the  experimental  findings  and  lessons  learned  in  the  organic 
synthesis and biological studies. The growth inhibition data has provided a wealth of information 
regarding structural and activity relationships. An indication of the specificity of anacardic acid and 
the three analogues, KC_14, KC_15 and KC_19 were gained from enzyme studies. However, this 
information was limited by the paucity of HAT inhibitors. Despite the lack of HAT inhibitors, the 
information  gained  from  the  growth  inhibition  experiments  regarding  tail  length,  hydrophilic 
elements and important structural elements can be used to synthesise new, improved analogues in 
future. KC_14 was recommended as the best anacardic acid analogue and perhaps this analogue 
could be used as a new structural lead. Another highlight of this project is the novel and potent 
azumamide hydroxamic acid. By modifying the warhead element of a cyclic tetrapeptide inhibitor 
it has been shown that compounds can be selectively manipulated to create better and more potent 
analogues. 
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4 Experimental Methods 
 
Organic Synthesis of Anacardic Acid & Analogues 
 
General Organic Synthesis Information 
 
NMR data were recorded on a Bruker AV300/1 NMR spectrometer (operating at 300 MHz for 
1H 
and at 75 MHz for 
13C) or a Bruker DPX400/1 NMR spectrometer (400 MHz for 1H). Proton and 
carbon NMR were taken in CDCl3 with tetramethylsilane as an internal standard unless otherwise 
stated. Multiplicities are described using the following abbreviations s, singlet; d, doublet; t, triplet; 
q, quartet and m, multiplet. Coupling constants are reported to the closest 0.1 Hz as measured in the 
spectrum.  Mass  Spectra  were  obtained  on Thermoquest Trace MS  and Micromass  Platform  II 
instruments.  Infrared  spectra  were  recorded  using  a  Nicolet  380  Fourier  transform  infrared 
spectrometer equipped with a Golden Gate Single Reflection Diamond ATR. The single intensities 
are described using the following abbreviations s, strong; m, medium; w, weak; v, very and br, 
broad. 
 
Column chromatography was carried out with MN Kieselgel 60, 0.04-0.063 mm 230-400 mesh 
silica. All reactions were monitored by thin layer chromatography using pre-coated aluminium 
backed sheets coated with Sil G/UV254 0.14 mm Silica gel 60. They were visualised with UV light 
and a ceric dip.  All solvents and reagents were used directly as supplied unless stated otherwise.  
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2, 6 Dihydroxybenzoic acid methyl ester (1)  
 
OH
OH
OH
O OH
O
O
OH
i)
2,6 dihydroxybenzoic acid                                    (1)  
 
i) H2SO4, MeOH, reflux  
Synthesised according to literature procedure
124 
     
A solution of 2, 6-dihydroxybenzoic acid, (10.9 g, 0.07 mol) in MeOH (26.0 mL, 0.6 mol) was 
refluxed for 45 h in the presence of concentrated H2SO4 (2.6 mL, 0.05 mol). The reaction mixture 
was concentrated in vacuo and the crude product was recrystallised from hexane to give (1) as a 
white crystalline solid (5.20 g, 44 %).  
 
Data for (1): 
 
1H NMR (300 MHz, CDCl3) δ ppm 9.66 (br. s, 2 H), δ 7.32 (t, J = 8.3 Hz, 1 H), δ 6.50 (d, J = 8.2 
Hz, 2 H), δ 4.09 (s, 3 H) 
 
13C NMR + DEPT (75 MHz, CDCl3) δ ppm 170.0 (C), 160.8 (C), 136.7 (CH), 108.3 (CH), 100.0 
(C), 52.8 (CH3) 
 
EI MS m/z (%): 168 ([M
+.] 40%), 154 (48%), 111 (42%) 
 
M.P 58 - 60 °C reported M.P = 57 – 58 
°C
124 
 
The 
1H NMR spectra corresponded to the reported data
124.  
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2-Benzyloxy-6-hydroxy-benzoic acid methyl ester (2) & 2, 6-dibenzyloxy 
benzoic acid methyl ester (3)  
 
OH
O
O
O
OH
O
O
OH
O
O
O
O
+
(1)                                            (2)                                     (3)
i)
 
 
i) Benzyl bromide, K2CO3, NaI, DMF, 0 ºC - RT 
Synthesised according to literature procedure
125 
 
To an ice cold suspension of (1) (5.00 g, 0.03 mol), K2CO3 (6.89 g, 0.05 mol) and NaI (2.48 g, 0.02 
mol) in DMF (12.41 mL) was added benzyl bromide (6.01 mL, 0.05 mol). The mixture was stirred 
for 30 mins at 0 °C followed by 6 h at RT.  The mixture was basified with 1M NaOH (aq) and 
extracted with ether. The organic layer was successively washed with water and brine and dried 
with MgSO4 and concentrated in vacuo. The residue was purified by column chromatography (10% 
EtOAc in Hexane) to yield the di-benzyl product (3) as colourless oil (5.80 g, 56 %). The alkaline 
layer was acidified with 2M HCl (aq) and the mono-benzyl product (2) was extracted with ether. 
The ether layer was successively washed with H2O and brine, dried with MgSO4 and concentrated 
in vacuo to yield orange oil. The oil was purified by column chromatography (10% EtOAc in 
Hexane) and the solid fractions were recrystallised from hexane to yield (2) (2.40 g, 31 %) and 
recovered (1) (0.22g, 4 %). 
 
Data for (2): 
 
1H NMR (300 MHz, CDCl3) δ ppm 11.49 (s, 1 H), δ 7.53-7.38 (m, 5 H), δ 7.34 (t J = 8.3 Hz, 1 H), 
δ 6.64 (dd, J =8.4, 1.0 Hz, 1 H), δ 6.50 (dd, J =8.3, 0.9 Hz, 1 H), δ 5.14 (s, 2 H), δ 3.96 (s, 3 H) 
13C NMR + DEPT (75 MHz, CDCl3) δ ppm 171.6 (C), 163.6 (C), 159.9 (C), 136.7 (C), 135.1 
(CH), 128.4 (CH), 127.8 (CH), 126.8 (CH), 110.4 (CH), 103.8 (CH), 103.6 (C), 70.8 (CH2), 52.3 
(CH3) 
 
M.P 69 - 71 °C (hexane), reported M.P 69.0 – 70.5 °C (hexane)
125  
IR (neat) 2950 (br), 1658 (s), 1602 (s), 1578 (s) cm
-1 
 
The IR and 
1H spectra corresponded to the reported data
125.  
 
106 
2-Benzyl-6-trifluoromethanesulfonyloxy-benzoic acid (4)  
 
O
O
OH
OBn
O
O
O
SO2CF3
OBn
Bn = 
(2)                                             (4)
i)
 
 
i) Triflic anhydride, pyridine, 0 ºC 
Synthesised according to literature procedure
106 
 
Under anhydrous conditions, triflic anhydride (0.98 mL, 6.00 mmol) was added to solution of (2) 
(1.29 g, 5.00 mmol) in pyridine (5 mL) at 0 °C. The mixture was stirred for 3 h. The reaction was 
diluted with EtOAc (5 mL). The organic layer was successively washed with saturated CuSO4 (aq) 
(10 mL), water (2x 10mL), brine (2 x 10 mL) and dried over MgSO4. After removing the solvent in 
vacuo the yellow crude oil was purified by column chromatography (25% EtOAc in Hexane) to 
yield a colourless oil (1.20 g, 62%). 
 
Data for (4): 
 
1H NMR (300 MHz, CDCl3) δ ppm 7.46-7.29 (m, 6 H), 7.00 (d, J = 8.5 Hz, 1 H), 6.96 (d, J = 8.6 
Hz, 1 H), 5.18 (s, 2 H), 3.95 (s, 3 H) 
 
13C NMR + DEPT (75 MHz, CDCl3) δ ppm 163.4 (C), 157.4 (C), 146.9 (C), 135.7 (C), 131.8 
(CH), 128.7 (CH), 128.2 (CH), 126.9 (CH), 120.6 (CF3), 118.1 (CF3), 116.4 (CF3), 113.8 (CH), 
112.9 (CH), 112.1 (C), 71.2 (CH2), 52.7 (CH3)  
 
ES
+ MS m/z (%) 381 ([M+H]
+ 10%), 413 ([M+Na]
+ 100%) 
 
IR (neat) 1737 (m), 1614 (m) cm
-1 
 
Known compound but no spectroscopic data reported in the literature
139.  
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2-Benzyl-6-pentadecyl-benzoic acid methyl ester (5) 
 
O
O
O
SO2CF3
OBn
O
O
(CH2)14CH3
OBn
Bn =
(4)                                                     (5)
i) ii)
  
 
i) 1-pentadecene, 9-H-9 BBN, THF, ii) NaOMe, PdCl2 (dppf) cat 
Synthesised according to literature procedure
105 
 
A solution of 1-pentadecene (0.29 mL, 1.05 mmol) and 9-H-9-BBN (2.10 mL 0.5 M in THF, 1.05 
mmol) was stirred at RT for 1 h. This solution was reacted with NaOMe (57 mg, 1.05 mmol) and 
the reaction mixture was stirred at RT for 0.5 h. The resulting reaction mixture was refluxed with 5 
(0.37 g, 0.95 mmol) and PdCl2 (dppf) (20 mg) for 5 h. The solvent was removed in vacuo and the 
brown crude oil was partitioned between EtOAc and water. The organic layer was washed with 
brine and dried with MgSO4. The solvent was removed in vacuo. The brown precipitate formed 
was filtered through celite with ice-cold hexane. The filtrate was reduced in vacuo to yield yellow 
oil which was purified by column chromatography (hexane/EtOAc 75:25). This yielded 6 (37 mg, 
8%) as a colourless oil. 
 
Data for (5): 
 
1H NMR (400 MHz, CDCl3) δ ppm 7.33-7.11 (m, 6 H), 6.76 (td, J =7.4, 0.8 Hz, 1 H), 6.72 (dd, J 
=18.1, 7.9 Hz, 1 H), 5.01 (s, 2 H), 3.80 (s, 3 H), 2.48 (t, J= 7.8 Hz, 1 H), 1.55-1.45 (m, 2 H), 1.37-
1.28 (m, 1 H), 1.17 (br.s, 22 H), 0.80 (t, J=7.0 Hz, 3 H)  
 
13C NMR + DEPT (75 MHz, CDCl3) δ ppm 168.9 (C), 155.5 (C), 141.6 (C), 137.0 (C), 130.2 
(CH), 128.5 (CH), 127.7 (CH), 126.9 (CH), 126.7 (CH), 121.9 (CH), 120.6 (C), 110.1 (CH), 70.5 
(CH2),  52.0  (CH3),  33.5  (CH2),  31.9  (CH2),  31.6  (CH2),  31.2  (CH2),  29.7  (4  CH2  coincident 
signals), 29.6 (2 CH2 coincident signals), 29.5 (CH2), 29.4 (CH2), 29.4 (CH2), 22.7 (CH2), 14.1 
(CH3)  
  
ES
+ MS m/z (%) 453 ([M+H]
+ 80%), 475 ([M+Na]
+ 48%) 
 
IR (neat) 2922 (s), 2852 (m), 2359 (s), 1733 (s), 1586 (m) cm
-1  
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2-Hydroxy-6-pentadecyl-benzoic acid (6)  
 
O
O
(CH2)14CH3
OBn
OH
O
(CH2)14CH3
OH
Bn = i) ii)
(5)                                            (6)  
 
i) Pd on Carbon, H2, EtOAc, ii) 20% KOH, EtOH, reflux 
Synthesised according to literature procedure
110, 125.  
 
Pd on Carbon (10%, 0.13g) was added to a solution of 5 (27 mg, 0.06 mmol) in EtOAc (0.48 mL) 
and stirred under H2 for 2 h. The reaction was diluted with EtOAc and was filtered through celite. 
The solvent was removed in vacuo to yield colourless oil (31 mg). The crude was immediately 
carried on to the next step. A solution of crude oil (19 mg) in 20% KOH in EtOH (1 mL) was 
refluxed overnight for 16 h. The reaction was quenched with 6 M HCl (aq) (2 mL) and the aqueous 
solution was extracted with EtOAc (2 x 2 mL). The combined organic phases were washed with 
water and brine respectively and dried over MgSO4. The solvent was reduced in vacuo to leave an 
orange crude oil which was purified by column chromatography (hexane/EtOAc 9:1) to yield a pale 
yellow solid. Recrystallisation in hexane afforded (6) as white crystals (9 mg, 43 %). 
 
Data for (6): 
 
1H NMR (400 MHz, CDCl3) δ ppm 7.36 (t, J = 8.0 Hz, 1 H), 6.87 (dd, J = 8.3, 1.1 Hz, 1 H), 6.77 
(dd, J = 7.5, 1.0 Hz, 1 H), 2.97 (t, J = 7.8 Hz, 2 H), 1.65-1.54 (m, 3 H), 1.41 – 1.20 (m, 24 H), 0.93 
– 0.86 (m, 3 H). 
 
13C NMR + DEPT (75 MHz, CDCl3) δ ppm 176.3 (C), 163.6 (C), 145.3 (C), 135.3 (CH), 122.7 
(CH), 115.8 (CH), 110.7 (C), 32.1 (CH2), 31.2 (CH2), 29.8 (CH2), 29.7 (6 CH2 coincident signals), 
29.5 (CH2), 29.5 (CH2), 29.4 (CH2), 29.3 (CH2), 22.7 (CH2), 14.1 (CH3). 
 
ES
+ MS m/z (%) 347 ([M-H]
-
, 100%) 
 
M.P 67 - 70 °C (recrystallised from hexane); reported MP 84 - 86 °C
101 
 
The 
1H and 
13C spectra corresponded to the reported data
103, 105.  
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5-Hydroxy-2, 2-dimethyl-1, 3-benzodioxin-4-one (7) 
OH
OH O
OH
O O
OH
O
2,6 dihydroxybenzoic acid                  (7)
i)
 
 
i) Acetone, SOCl2, DMAP, DME.  
Synthesised according to literature procedure
128 
 
To an anhydrous solution of 2, 6-dihydroxybenzoic acid (6.0 g, 0.04 mol) in DME (13.1 mL), was 
added DMAP (0.2 g 2.00 mmol) and acetone (3.7 mL, 0.05 mol). The solution was cooled to 0 °C 
before a solution of SOCl2 (4.0 mL, 0.06 mol) in DME (0.2 mL) was added dropwise over 2 h. The 
yellow  reaction  mixture  was  stirred  for  1  h  and  excess  HCl  was  removed  by  bubbling  argon 
through the solution under a slight vacuum. After 0.5 h, the solvent was removed in vacuo. The 
crude product was purified by column chromatography (hexane/DCM 1:1) and was recrystallised 
from hexane to yield (7) as a pale yellow crystalline solid (4.40 g, 75%). 
 
Data for (7):   
 
1H NMR (300 MHz, CDCl3) δ ppm 10.34 (s, 1 H), 7.41 (t, J = 8.4 Hz, 1 H), 6.63 (dd, J = 8.6, 0.9 
Hz, 1 H), 6.44 (dd, J = 8.2, 0.9 Hz, 1 H), 1.75 (s, 6 H).  
 
13C NMR + DEPT (75 MHz, CDCl3) δ ppm 165.4 (C), 161.4 (C), 155.6 (C), 137.9 (CH), 110.8 
(CH), 107.2 (C), 107.11 (CH), 99.4 (C), 25.6 (CH3), 
 
ES
-- MS m/z (%): 193 [M - H], 20) 
 
ES
+ MS m/z (%): 214 ([M + Na]
+
, 29), 411 ([2M + Na]
+, 7) 
 
M.P 57 - 58 °C (hexane); reported M.P 64 - 65 °C (cyclohexane)
140.  
 
The 
1H and 
13C NMR spectra corresponded to the reported data
128. 
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Trifluoro-methanesulfonic acid 2, 2-dimethyl-4-oxo-4H-benzo [1, 3] 
dioxin-5-yl ester (8)  
 
O O
OH
O
O O
OTf
O i)
(7)                                         (8)  
 
i) Triflic anhydride, pyridine, 0 ºC 
Synthesised according to literature procedure
106 
 
Under anhydrous conditions, triflic anhydride (0.1 mL, 0.62 mmol) was added to a solution of (7) 
(100 mg, 0.51 mmol) in pyridine (1 mL) at 0 °C. The mixture was stirred for 0.5 h. The reaction 
mixture was quenched with saturated aqueous NaHCO3 (2 mL). The organic layer was extracted 
with ether (3x 4 mL), and washed with water (2x 4mL), brine (2x 4 mL) and dried (MgSO4). The 
solvent  was  removed  in  vacuo  to  yield  a  crude  cream  solid.  This  was  purified  by  column 
chromatography (hexane/DCM 1:1) to yield a cream crystalline solid (165.7 mg, 100%). 
 
Data for (8):   
 
1H NMR (300 MHz, CDCl3) δ ppm 7.59 (1 H, t, J = 8.4 Hz), 7.06 (1 H, dd, J = 1.1, 8.4 Hz), 7.00 
(1 H, d, J = 8.4), 1.76 (6 H, s).  
 
13C NMR + DEPT (75 MHz, CDCl3) δ ppm 157.5 (C), δ 157.0 (C), δ 148.7 (C), δ 136.2 (CH), δ 
117.8 (CH), δ 116.5 (CH), δ 108.3 (C), δ 106.8 (C), δ 25.5 (CH3),  
 
ES
+MS m/z (%): 365 ([M + K]
+
, 4), 675 ([2M + Na]
+
, 5).   
 
M.P 109-110 °C (hexane); reported M.P 115 - 117 °C (hexane)
141. 
 
The 
1H and 
13C NMR spectra corresponded to the reported data
106.  
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(2, 2-Dimethyl-4-oxo-4H-1, 3-benzodioxin-5-yloxy)-acetic acid (KC_01) 
 
O
OH
O
O
O O
O
O
OH
O
i)
(7)                                KC_01  
 
i) Bromoacetic acid, NaH, THF 
Synthesised according to literature procedure
129 
 
To a solution of 7 (0.20 g, 1.0 mmol) and bromoacetic acid (0.14 g, 1.0 mmol) in dry THF (1.5 
mL) was gradually added NaH (0.09g, 2.2 mmol as a 60% oil dispersion). The reaction mixture 
was refluxed for 16 h. The solvent was removed in vacuo and to the cream residue was added water 
(5 mL). The organic impurities were extracted with Et2O (3x 10 mL). The aqueous layer was 
acidified  with  6M  HCl  and  the  organics  extracted  with  Et2O  (3x  10  mL).  The  organics  were 
combined, dried (MgSO4) and the solvent was removed in vacuo to leave a solid residue. This was 
filtered and washed with cold Et2O to yield KC_01 as a cream solid (0.16 g, 60 %). 
 
Data for KC_01: 
 
1281H NMR: (300 MHz, CDCl3) δ ppm 7.55 (t, J = 8.2 Hz, 1 H), 6.72 (dd, J = 8.4, 0.7 Hz, 1 H), 
6.63 (dd, J = 8.4, 0.7 Hz, 1 H), 4.76 (s, 2 H), 1.77 (s, 6 H) 
13C NMR + DEPT (75 MHz, CDCl3) δ ppm 168.6 (C), 160.4 (C), 158.9 (C), 157.6 (C), 137.5 
(CH), 111.6 (CH), 108.5 (CH), 106.6 (C), 103.8 (C), 67.7 (CH2), 25.5 (CH3) 
 
ES
- MS m/z (%): 251 [M - H], 21) 
 
M.P 154 – 156 °C 
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(2, 2-Dimethyl-4-oxo-4H-1, 3-benzodioxin-5-yloxy)-acetic acid methyl 
ester (KC_02) 
 
OH
O
O
O
O
O
O
O
O
O
i)
(7)                                           KC_02  
 
i) methyl bromoacetate, KO
tBu, THF, RT. 
 
To a solution of 7 (2.79 g, 14.37 mmol) in THF (9 mL) was added methyl bromoacetate (2.0 mL, 
22.08  mmol).  Upon  dropwise  addition  of  KO
tBu  (4.05  g,  36.08  mmol)  in  THF  (20  mL),  the 
reaction mixture became exothermic. After continuous stirring at RT for 4 h, the reaction mixture 
was quenched with water (20 mL). The organic product was extracted from the aqueous layer with 
EtOAc (3x 20 mL). The organic extracts were combined, washed with brine (20 mL) and dried 
with MgSO4. The crude was purified by flash column chromatography (EtOAc/Hexane 1:1). The 
fractions were collected and the solvent was removed in vacuo to yield KC_02 (1.92 g, 50%) as a 
pale yellow solid. 
 
Data for KC_02: 
 
1H NMR (300 MHz, CDCl3) δ ppm 7.43(t, J= 8.4 Hz, 1 H), 6.63 (dd, J= 8.3 Hz, 1 H), 6.50 (d, J= 
8.4 Hz, 1H), 4.80 (s, 2 H), 3.81 (s, 3 H), 1.72 (s, 6 H) 
 
13C NMR + DEPT (75 MHz, CDCl3) δ ppm 168.6 (C), 159.6 (C), 157.9 (C), 157.8 (C), 136.2 
(CH), 110.6 (CH), 107.0 (CH), 105.4 (C), δ 104.1 (C), 66.2 (CH2), 52.3 (CH2) 25.6 (CH3) 
 
ES
+ MS m/z (%) 267 ([M+H]
+ 6%), 289 ([M+Na]
+ 35%), 555 ([2M+Na]
+ 100%) 
 
M.P 108 - 110°C 
 
IR (neat) 1724 (s), 1607 (m), 1584 (s), 1470 (s), 1452 (w) cm
-1 
 
.  
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2-Hydroxy-6-methoxycarbonylmethoxy-benzoic acid (KC_03) 
 
O
O
O
O
O
O
O
OH
O
OH
O
O
i)
KC_02                                           KC_03  
 
i) KOH, MeOH, ~35
°C 
Synthesised according to literature procedure
130 
 
The methyl ester KC_02 (1.82 g, 6.84 mmol) was dissolved in MeOH (5.5 mL) and to this solution 
was  added  KOH  (0.77  g,  13.69  mmol).  Upon  addition  of  base  the  reaction  mixture  became 
exothermic and the solution turned yellow in colour. The reaction mixture was left to stir overnight 
for 16 h and was quenched with water (10 mL). Impurities were removed by extraction with EtOAc 
(3 x 15 mL). The aqueous layer was acidified to pH 2 by dropwise addition of 2M aq HCl. The 
organic product was extracted with EtOAc (3x 15mL). The extracts were collected, washed with 
brine and dried with MgSO4. The solvent was removed in vacuo to yield a crude yellow solid. This 
was purified by flash column chromatography (2-16% isopropanol in DCM). The product KC_03 
was isolated as a white crystalline solid (0.80 g, 46%).  
 
Data for KC_03: 
 
1H NMR (300 MHz, CDCl3) δ ppm 11.12 (s, 1 H), 7.39 (t, J= 8.4 Hz, 1 H), 6.73 (dd, J= 8.4 Hz, 1 
H), 6.36 (d, J= 8.2 Hz, 1 H), 4.69 (s, 2 H), 4.03 (s, 6 H) 
 
13C NMR + DEPT (75 MHz, CDCl3) δ ppm 169.8 (C), 168.8 (C), 163.6 (C), 157.6 (C), 135.7 
(CH), 112.5 (CH), 104.1 (CH), 103.2 (C), 66.4 (CH2), 53.1 (CH3) 
 
ES
+ MS m/z (%) 227 ([M+H]
+, 6%), 249 ([M+Na]
+ 100%), 475 ([2M+Na]
+ 4%)  
 
IR (film) 2937 (br) 1746 (m), 1712 (m), 1656 (s), 1607 (s), 1580 (m), 1440 (s) cm
-1 
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2-Hydroxy-6-(3-methoxycarbonyl-propoxy)-benzoic acid methyl ester 
(KC_04) and 2-Hydroxy-6-(3-methoxycarbonyl-propoxy)-benzoic acid 
(KC_06) 
 
O
O
O
O
O
O
O
OH
O
O
O
O
O
OH
O
OH
O
O
+
i) ii)
KC_05                                                          KC_04                                              KC_06
 
i) KOH, MeOH, 4h, ii) 2M aq HCl 
 
To a solution of ethyl ester KC_05 in MeOH (6mL) was added KOH (0.73 g, 13.08 mmol). The 
reaction  was  slightly  exothermic  and  the  solution  turned  pale  brown  in  colour.  After  4  h  the 
reaction mixture was quenched with water (10 mL). The non-basic products were extracted with 
EtOAc (3x 20 mL). The aqueous layer was acidified to pH 2 using 2M aq HCl and the organic 
product was extracted with EtOAc (2 x 20 mL). The organic extracts were washed with brine (100 
mL) and dried with MgSO4. The solvent was removed in vacuo to yield a cream crude solid. The 
crude  was  purified  by  flash  column  chromatography  (0-12%  isopropanol  in  DCM)  and  two 
products, a clear oil KC_04 (0.34 g, 19 %) and a white solid KC_06 (1.13 g, 68 %) were isolated.  
  
Data for KC_04: 
 
1H NMR (300 MHz, CDCl3) δ ppm 11.45 (s, 1 H), 7.31 (t, J= 8.4 Hz, 1 H), 6.59 (d, J= 8.4 Hz, 1 
H), 6.38 (d, J= 8.3 Hz, 1 H), 4.04 (t, J= 5.9 Hz, 2 H), 3.95 (s, 3 H), 3.70 (s, 3 H), 2.60 (t, J= 7.3 
Hz, 2 H), 2.20-2.09 (m, 2 H) 
 
13C NMR + DEPT (75 MHz, CDCl3) δ ppm 173.6 (C), 171.6 (C), 163.6 (C), 160.1 (C), 135.1 
(CH), 110.1 (CH), 103.2 (C), 103.1 (CH), 67.5 (CH2), 52.2 (CH3), 51.6 (CH3), 30.3 (CH2), 24.6 
(CH2) 
 
ES
+ MS m/z (%) 269 ([M+H]
+, 2%), 291 ([M+Na]
+, 100%) 
 
IR (film) 2952 (w), 1739 (s), 1652 (s), 1610 (s), 1584 (m), 1444 (s) cm
-1 
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Data for KC_06: 
 
1H NMR (300 MHz, CDCl3) δ ppm 11.45 (s, 1 H), 7.31 (t, J= 8.3 Hz, 1 H), 6.60 (dd, J= 8.4, 0.8 
Hz, 1 H), 6.39 (d, J= 8.4 Hz, 1 H), 4.07 (t, J= 5.9 Hz, 2 H), 3.95 (s, 3 H), 2.67 (t, J= 7.3 Hz, 2 H), 
2.21-2.10 (m, 2 H) 
 
13C NMR + DEPT (75 MHz, CDCl3) δ ppm 179.2 (C), 171.6 (C), 163.6 (C), 160.0 (C), 135.1 
(CH), 110.2 (CH), 103.2 (C), 103.1 (CH), 67.3 (CH2), 52.3 (CH3), 30.3 (CH2), 24.4 (CH2) 
 
ES
+ MS m/z (%) 255 ([M+H]
+, 8%), 277([M+Na]
+, 100%) 
 
IR (neat) 2956 (br), 1716 (s), 1656 (s), 1599 (m), 1580 (m), 1436 (s) cm
-1 
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4-(2, 2-Dimethyl-4-oxo-4H-1, 3-benzodioxin-5-yloxy)-butyric acid ethyl 
ester (KC_05)
 
 
OH
O
O
O
O
O
O
O
O
O
i)
(7)                                   KC_05  
 
i) Ethyl-4-bromobutyrate, K(O
tBu), THF, reflux, 72 h. 
 
To a solution of acetonide 7 (4.68 g, 0.024 mmol) in THF (48 mL), KO
tBu (2.98 g, 0.027 mmol) 
was added in portions. Once the exothermic reaction had subsided, ethyl-4-bromobutyrate (3.8 mL, 
0.027 mmol) was added and the reaction mixture was warmed to reflux. After 72 h reflux the 
reaction was quenched with water (25 mL) and sat NH4Cl (25 mL). The organic product was 
extracted with EtOAc (3x 50 mL). The organic extracts were combined, washed with brine (150 
mL) and dried with MgSO4. The solvent was removed in vacuo to yield a brown crude oil. The 
crude was purified by flash column chromatography (0-25% EtOAc in Hexane) to yield KC_05 
(3.91g, 53%) as a colourless oil.  
 
 Data for KC_05: 
 
1H NMR (300 MHz, CDCl3) (300 MHz, CDCl3) δ ppm 7.40 (t, J= 8.3 Hz, 1 H), 6.60 (d, J=8.5 Hz, 
1 H), 6.52 (dd, J= 8.2, 1 H), 4.17-4.08 (m, 4 H), 2.63 (t, J= 7.2 Hz, 2 H), 2.23-2.12 (m, 2 H), 1.69 
(s, 6 H), 1.24 (t, J= 7.1 Hz, 3 H) 
 
13C NMR + DEPT (75 MHz, CDCl3) δ ppm 173.3 (C), 160.7 (C), 157.8 (C), 136.2 (CH), 109.1 
(CH), 106.5 (CH), 105.1(C), 103.6 (C), 68.0 (CH2), 60.3 (CH2), 30.4 (CH2), 25.6 (CH3), 24.3 
(CH2), 14.2 (CH3) 
 
ES
+ MS m/z (%) 331 ([M+Na]
+ 35%), 639 ([2M+Na]
+ 100%) 
 
IR (film) 2994 (w), 1739 (s), 1610 (m), 1584 (m), 1482 (m), 1467 (m) cm
-1  
 
117 
2- (2, Dimethyl-4-oxo-4H-1, 3-benzodioxin-5-yloxy)-N-(2-morpholin-4-yl-
ethyl)-acetamide (KC_07) 
 
O
O
O
O
OH
O
O
O
O
O
N
H
O
N
O
i)
KC_01                                                     KC_07  
 
i) 4-(2-aminoethyl) morpholine, HOBt, DCC, DCM 
 
To a solution of KC_01 (0.10 g, 0.41 mmol) in DCM (2 mL) was added DCC (93.0 mg, 0.45 
mmol), HOBt (64 mg, 0.47 mmol) and 4-(2-aminoethyl) morpholine (0.06 mL, 0.45 mmol). The 
reaction mixture was stirred for 4 h. The insoluble urea side product was filtered and the solvent 
was removed in vacuo. The crude was purified by flash column chromatography (0-10% MeOH in 
DCM). The product KC_07 was isolated as a pale yellow solid (62 mg, 42 %).  
 
Data for KC_07: 
 
1H NMR (300 MHz, CDCl3) δ ppm 8.27 (br. s, 1 H), 7.47 (t, J= 8.4 Hz, 1 H), 6.61 (d, J= 8.3 Hz, 1 
H), 6.53 (d, J= 8.4 Hz, 1 H), 4.55 (s, 2 H), 3.69 (t, J= 4.6 Hz, 4 H), 3.53-3.42 (m, 2 H), 2.56 (t, J= 
6.6 Hz, 2 H), 2.48 (t, J= 4.6 Hz, 4 H), 1.72 (s, 6 H) 
 
13C NMR + DEPT (75 MHz, CDCl3) δ ppm 167.8 (C), 159.2 (2 C coincident signals), 158.2 (C), 
137.4 (CH), 110.8 (CH), 106.9 (CH), 106.3 (C), 103.7 (C), 68.2 (CH2), 67.3 (CH2), 57.7 (CH2), 
53.9 (CH2), 36.6 (CH2) 26.0 (CH3)  
 
ES
+ MS m/z (%) 365 ([M+H]
+ 100%), 387 ([M+Na]
+ 32%) 
 
M.P 110 – 112 °C 
 
IR (film) 3300 (w), 3002 (w), 2531 (w), 1716 (w), 1678 (br s), 1610 (m), 1588 (w), 1482 (m) cm
-1 
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2-Hydroxy-6-[(2-morpholin-4-yl-ethylcarbamoyl)-methoxy]-benzoic acid 
(KC_08) 
 
 
O
O
O
O
N
H
O
N
O
O
OH
O
OH
N
H
O
N
O
i)
KC_07                                                               KC_08  
 
i) aq LiOH, THF, 0°C 
 
The acetonide protected KC_07 (29.15 mg, 0.08 mmol) was dissolved in THF (4 mL) and cooled 
to 0 °C. To this solution, LiOH (3.7 mg, 0.15 mmol) in H2O (0.37 mL) was added dropwise. The 
reaction mixture was warmed to RT and was stirred for 20 h. The solvent was removed in vacuo to 
leave an oily, yellow crude precipitate. The precipitate was dissolved in MeOH and the LiOH solid 
was removed by filtration. The filtrate was concentrated in vacuo to yield KC_08 (28 mg, 95%) as 
a yellow solid.  
 
Data for KC_08: 
 
1H NMR (300 MHz, MeOD) δ ppm 7.10 (t, J= 8.2 Hz, 1 H), 6.46 (d, J= 8.3 Hz, 1 H), 6.30 (d, J= 
8.1 Hz, 1 H), 4.54 (s, 2 H), 3.64 (t, J= 4.7 Hz, 4 H), 3.44 (t, J= 6.8 Hz, 2 H), 2.54 (t, J= 6.9 Hz, 2 
H), 2.48 (t, J= 4.6 Hz, 4 H) 
 
13C NMR + DEPT (75 MHz, MeOD) δ ppm 175.0 (C), 172.2 (C), 165.3 (C), 159.9 (C), 132.4 
(CH), 113.0 (C), 112.6 (CH), 103.6 (CH), 69.4 (CH2), 67.7 (CH2), 58.4 (CH2), 54.6 (CH2), 37.0 
(CH2) 
 
ES
- MS m/z (%) 323 ([M-H]
- 100%) 
 
M.P 190 – 192 °C 
 
IR (film) 3274 (br), 2941 (w), 2824 (w), 1629 (m), 1580 (s), 1459 (s) cm
-1 
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2-Hydroxy-N-(2-morpholin-4-yl-ethyl)-6-[(2-morpholin-4-yl-
ethylcarbamoyl)-methoxy]-benzamide (KC_09) 
 
O
O
O
O
OH
O
O
OH
O
N H
N
H
O
N
O
N
O
i)
KC_01                                                 KC_09  
 
i) 4(2-aminoethyl morpholine, DCC, DCM. 
 
To a solution of KC_01 (0.10 g, 0.41 mmol) in DCM (2 mL) was added DCC (0.10 g, 0.46 mmol). 
To the reaction mixture was added the amine (0.06 mL, 0.46 mmol). The reaction mixture was 
stirred for 4 h. The insoluble urea side product was filtered and the solvent was removed in vacuo. 
The crude was purified by flash column chromatography (0-10% MeOH in DCM). The product 
KC_09 (60 mg, 34%) was isolated as a pale yellow oil.  
 
Data for KC_09: 
 
1H NMR (300 MHz, CDCl3) δ ppm 8.89 (s, 1 H), 7.23 (t, J= 8.4 Hz, 1 H), 6.67 (d, J= 8.4 Hz, 1 
H), 6.30 (d, J= 8.2 Hz, 1 H), 4.70 (s, 2 H), 3.69 (t, J= 4.7 Hz, 4 H), 3.61 (t, J= 6.1 Hz, 2 H),  3.56 
(t, J= 4.7 Hz, 4 H), 3.44-3.35 (m, 2 H),  2.63 (t, J= 6.2 Hz, 2 H), 2.52 (t, J= 4.7 Hz, 4 H), 2.42 (t, 
J= 6.2 Hz, 2 H), 2.34 (t, J= 4.7 Hz, 4 H) 
 
13C NMR + DEPT (75 MHz, CDCl3) δ ppm 169.5 (C), 167.0 (C), 164.6 (C), 156.8 (C), 133.2 
(CH),  113.0  (CH),  104.6 (C),  102.0  (CH),  68.3  (CH2),  67.0 (CH2),  66.8  (CH2),  56.7 (2  CH2 
coincident signals), 53.4 (CH2), 53.2 (CH2), 36.0 (CH2), 35.3 (CH2)  
 
 ES
+ MS m/z (%) 437 ([M+H]
+ 100%), 459 ([M+Na]
+  20%) 
 
IR (neat) 3357 (w), 3243 (br), 2850 (w), 1652 (m), 1633 (m), 1591 (s), 1531 (m), 1448 (m) cm
-1 
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N-(2-Acetylamino-ethyl)-2-(2, 2-dimethyl-4-oxo-4H-1, 3-benzodioxin-5-
yloxy)-acetamide (KC_10) 
 
O
O
O
O
OH
O
O
O
O
O
N
H
O
N
H
O i)
KC_01                                                   KC_10  
 
i) N-(2-aminoethyl)-acetamide, DCC, HOBt, DCM 
 
To a solution of KC_01 (93.3 mg, 0.38 mmol) in DCM (2.0 mL) was added DCC (88.7 mg, 0.43 
mmol), HOBt (57 mg, 0.42 mmol) and N-(2-aminoethyl)-acetamide (0.04 mL, 0.42 mmol). The 
reaction mixture was stirred for 2 h. The insoluble urea side product was filtered and the solvent 
was removed in vacuo. The crude was purified by flash column chromatography (0-10% MeOH in 
DCM). The product (KC_10) was isolated as a white solid (25 mg, 20 %).  
 
Data for KC_10: 
 
1H NMR (300 MHz, CDCl3) δ ppm 8.54 (s, 2 H), 7.51 (t, J= 8.4 Hz, 1 H), 6.66 (d, J= 8.3 Hz, 1 
H), 6.55 (d, J= 8.4 Hz, 1 H), 4.58 (s, 2 H), 3.54-3.44 (m, 4 H), 2.01 (s, 3 H), 1.75 (s, 6 H) 
 
13C NMR + DEPT (75 MHz, CDCl3) δ ppm 170.6 (C), 168.1 (C), 159.6 (C), 158.7 (C), 157.9 (C), 
137.4 (CH), 110.7 (CH), 106.8 (CH), 106.2 (C), 101.8 (C), 67.9 (CH2), 39.9 (CH2), 39.0 (CH2), 
25.6 (CH3), 23.2 (CH3) 
 
ES
+ MS m/z (%) 337 ([M+H]
+ 35%), 359 ([M+Na]
+ 100%), 695 ([2M+Na]
+ 22%) 
 
M.P 122 – 124 °C 
 
IR (neat) 3308 (br), 2926 (w), 2359 (w), 1716 (m), 1656 (s), 1607 (m), 1546 (m), 1478 (s) cm
-1 
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2-[(2-Acetylamino-ethylcarbamoyl)-methoxy]-6-hydroxy-benzoic acid 
(KC_11) 
 
O
OH
O
OH
N
H
O
N
H
O
O
O
O
O
N
H
O
N
H
O i)
KC_10                                                                 KC_11  
 
i) aq LiOH, THF, 0°C 
 
The acetonide KC_10 (31.4 mg, 0.09 mmol) was dissolved in THF (4.5 mL) and cooled to 0 °C. 
To this solution, LiOH (4.6 mg, 0.19 mmol) in H2O (0.45 mL) was added dropwise. The reaction 
mixture was warmed to RT and was stirred for 5 h. The solvent was removed in vacuo to leave an 
oily  crude  precipitate.  The  crude  was  washed  with  CHCl3.  The  remaining  solid  product  was 
dissolved in MeOH and the LiOH solid was removed by filtration. The filtrate was concentrated in 
vacuo to yield KC_11 as a solid product (37 mg, 135 %, absorbs moisture).  
 
Data for KC_11: 
 
1H NMR (300 MHz, MeOD, mixed rotamers) δ ppm 7.10 (t, J= 8.2 Hz, 1 H), 6.96 (t, J= 8.2 Hz, 1 
H), 6.46 (d, J= 8.4 Hz, 1 H), 6.39 (dd, J= 8.4, 0.7 Hz, 1 H), 6.31 (d, J= 8.4 Hz, 1 H), 6.12 (d, J= 7.3 
Hz, 1 H), 4.36 (s, 2 H) 4.51 (s, 2 H), 3.22 (t, J= 6.2 Hz, 1 H), 3.15 (m, 2 H), 1.95 (s, 1 H) 2.71 (t, J= 
6.2 Hz, 1 H), 1.94 (s, 1 H), 1.93 (s, 1 H), 1.92 (s, 3 H)  
 
13C NMR + DEPT (75 MHz, MeOD) δ ppm 173.8 (C), 173.0 (C), 167.8 (C), 159.5 (C), 158.3 (C), 
131.0 (CH), 115.2 (CH), 113.4 (C), 100.9 (CH), 69.3 (CH2), 40.0 (CH2), 39.8 (CH2), 22.9 (CH2) 
 
ES
- MS m/z (%) 295 ([M-H]
- 21.2 %) 
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2-Hydroxy–6-octyloxy-benzoic acid (KC_15) 
 
O
OH
O O
O
OH O
OH
i), ii)
 
 
i) 20% KOH, EtOH, reflux, ii) H
+ work up 
 
The acetonide (KC_14) (0.10 g, 0.33 mmol) was dissolved in THF (16 mL) and cooled to 0 °C. To 
this solution was added LiOH (16.3 mg, 0.65 mmol) in H2O (1.6 mL) dropwise. The reaction 
mixture was warmed to RT and was stirred for 20 h. The solvent was removed in vacuo to yield a 
white solid (0.11 g). The crude was purified by flash column chromatography (0-10 % EtOAc in 
Hexane) and the product KC_15 was isolated as colourless oil (31 mg, 35 %). 
 
Data for KC_15: 
 
1H NMR (400 MHz, CDCl3) δ ppm 12.16 (s, 1 H), 11.61 (s, 1 H), 7.39 (t, J= 8.4 Hz, 1 H), 6.71 
(dd, J= 8.5, 0.8 Hz, 1 H), 6.48 (d, J= 8.4 Hz, 1 H), 4.23 (t, J= 6.9 Hz, 2 H), 1.97 – 1.85 (m, 2 H), 
1.55 – 1.43 (m, 2 H), 1.42 – 1.24 (m, 8 H), 0.90 (t, J= 6.8 Hz, 3 H) 
 
13C NMR + DEPT (100 MHz, CDCl3) δ ppm 171.4 (C), 164.7 (C), 158.4 (C), 136.0 (CH), 112.5 
(CH), 102.6 (CH), 102.1 (C), 71.2 (CH2), 32.1 (CH2), 29.5 (CH2), 29.5 (CH2), 29.2 (CH2), 26.2 
(CH2), 23.0 (CH2), 14.5 (CH3) 
 
ES
- MS m/z (%), 265 ([M-H]
- 100 %) 
 
IR (neat) 3204 (br), 2953 (w), 2919 (br), 2853 (w), 1689 (s), 1618 (m), 1580 (m) cm
-1 
 
Known compound but no spectroscopic data reported in the literature
110  
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2-Hydroxy-6-tetradecyloxy-benzoic acid methyl ester (KC_18)  
 
OH
OH
O
O OH
O(CH2)13CH3
O
O
i)
 (1)                                                   KC_18  
i) 1-tetradecanol, Ph3P, DIAD, THF 
Synthesised according to literature procedure
110, 131 
 
To a solution of 1 (0.20 g, 1.2 mmol), Ph3P (0.31 g, 1.2 mmol) and 1-tetradecanol (0.23 g, 1.2 
mmol) in dry THF (1.0 mL), a solution of DIAD (0.23 mL, 1.2 mmol) in dry THF (1.4 mL) was 
added dropwise. The reaction was stirred at RT for 24 h. The solvent was removed in vacuo to 
leave a yellow crude oil which was triturated with cold ether to remove insoluble by products. 
After  removing  the  ether  in  vacuo,  the  remaining  yellow  crude  oil  was  purified  by  column 
chromatography (hexane/DCM 1:1). Two white crystalline solids were isolated KC_18 (0.16 g, 
37%) and a di–substituted product (0.18 g, 27%). 
 
Data for KC_18: 
 
1H NMR (300 MHz, CDCl3) δ ppm 11.51 (s, 1 H), 7.31 (t, J = 8.4 Hz, 1 H), 6.58 (dd, J = 8.2, 0.9 
Hz, 1 H), 6.40 (d, J = 8.4, 1 H), 3.99 (t, J = 6.4 Hz, 2 H), 3.94 (s, 3 H), 1.88-1.74 (m, 2 H), 1.57-
1.44 (m, 2 H), 1.42 – 1.20 (m, 20 H), 0.93 – 0.84 (m, 3 H) 
13C NMR + DEPT (75 MHz, CDCl3) δ ppm 171.8 (C), 163.5 (C), 160.5 (C), 135.1 (CH), 109.7 
(CH), 103.1 (CH), 68.9 (CH2), 52.2 (CH3), 31.9 (CH2), 29.7 (6 CH2 coincidence signals), 29.3 (2 
CH2 coincident signals), 29.2 (CH2), 26.0 (CH2), 22.7 (CH2), 14.1 (CH3)  
 
ES
+ MS m/z (%) 387 ([M+Na]
+, 100%) 
 
M.P 34 - 36 °C, reported M.P 43 - 44 °C
142 
 
The 
1H spectra of KC_18 corresponded to the reported data
142. No 
13C NMR data is recorded for 
KC_18
142. 
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2-Hydroxy-6-tetradecyloxy-benzoic acid (KC_19)  
 
OH
O(CH2)13CH3
O
O OH
O(CH2)13CH3
OH
O
KC_18                                       KC_19
i)
 
 
i) 20% KOH, EtOH, reflux 
Synthesised according to literature procedure
110, 131 
 
A solution of KC_18 (32 mg, 0.14 mmol) in 20% KOH in EtOH (2 mL) was refluxed overnight for 
16 h. The reaction was quenched with 6 M HCl (aq) (2 mL) and the aqueous solution was extracted 
with  EtOAc  (2  x  2  mL).  The  combined  organic  phases  were  washed  with  water  and  brine 
respectively and dried over MgSO4. After removal of the solvent in vacuo, the orange crude oil was 
purified by column chromatography (1– 25% EtOAc in Hexane) to yield a white crystalline solid 
(22 mg, 74%). 
 
Data for KC_19: 
 
1H NMR (300 MHz, CDCl3) δ ppm 12.16 (s, 1 H), 11.60 (br. s, 1 H), 7.39 (t, J = 8.2 Hz, 1 H), 6.71 
(dd, J = 8.4, 0.7 Hz, 1 H), 6.48 (d, J = 8.1 Hz, 1 H), 4.24 (t, J = 6.6 Hz, 2 H), 1.99-1.82 (m, 2 H), 
1.54-1.41 (m, 2 H), 1.41 – 1.21 (m, 20 H), 0.89 (t, J = 6.6 Hz, 3 H) 
 
13C NMR + DEPT (75 MHz, CDCl3) δ ppm 169.9 (C), 163.3 (C), 157.1 (C), 134.5 (CH), 111.2 
(CH), 101.2 (CH), 100.8 (C), 69.8 (CH2), 30.9 (CH2), 28.6 (4 CH2 coincident signals), 28.5 (CH2), 
28.4 (CH2), 28.3 (CH2), 28.2 (CH2), 27.8 (CH2), 24.8 (CH2), 21.7 (CH2), 13.1 (CH3)  
 
ES
- MS m/z (%) 349 ([M-H]
-, 67%) 
 
M.P 49 - 51 °C (hexane), reported M.P 51 – 52 °C
110 
 
Known compound but no spectroscopic data reported in the literature
110.  
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2, 2–Dimethyl-5–tetradecyloxy-1, 3–benzodioxin-4-one (KC_20) 
 
OH
O
O O
O
O O
O i)
(7)                                      KC_20  
 
i) 1-tetradecanol, DIAD, Ph3P, THF, RT. 
 
To a solution of 7 (0.40 g, 2.06 mmol) in THF (21 mL) was added 1-tetradecanol (0.66 g, 3.09 
mmol) and Ph3P (0.81 g, 3.09 mmol). This was followed by dropwise addition of DIAD (0.61 mL, 
3.09 mmol) in THF (10 mL) and the reaction mixture became yellow in colour. After continuous 
stirring at RT for 5h, the solvent was removed in vacuo to yield a yellow crude solid (1.43 g). The 
crude  was  purified  by  flash  column  chromatography  (0-50%  DCM  in  Hexane).  The  product 
KC_20 was isolated as a white crystalline solid (0.57 g, 71%).  
 
Data for KC_20: 
 
1H NMR (300 MHz, CDCl3) δ ppm 7.41 (t, J= 8.4 Hz, 1 H), 6.60 (d, J= 8.4 Hz, 1 H), 6.52 (dd, 
J=8.2, 0.8 Hz, 1 H), 4.07 (t, J= 6.8 Hz, 2 H), 1.95 - 1.83 (m, 2 H), 1.70 (s, 6 H), 1.58 - 1.42 (m, 2 
H), 1.41 - 1.13 (m, 20 H), 0.97 - 0.78 (m, 3 H) 
 
13C NMR + DEPT (75 MHz, CDCl3) δ ppm 161.1 (C), 158.0 (C), 157.7 (C), 136.2 (CH), 108.8 
(CH), 106.4 (CH), 105.1 (C), 103.5 (C), 69.4 (CH2), 31.9 (CH2), 29.7 (4 CH2 coincident signals), 
29.6 (CH2), 29.3 (2 CH2 coincident signals), 28.9 (CH2), 25.6 (2 CH2 coincident signals), 22.7 
(CH2), 14.1 (CH3)  
 
ES
+ MS m/z (%), 391 ([M+H]
+ 100 %), 413 ([M+Na]
+ 17 %) 
 
IR (neat) 2915 (s), 2847 (s), 1727 (s), 1599 (m), 1576 (s), 1455 (m) cm
-1 
 
M.P 48 - 50 °C 
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2, 2–Dimethyl -5 –pentyloxy-1, 3-benzodioxin-4-one (KC_21) 
 
OH
O
O O
O
O O
O (i)
(7)                                       KC_21  
 
i) 1-pentanol, DIAD, Ph3P, THF, RT. 
 
To a solution of 7 (0.20 g, 1.03 mmol) in THF (10 mL) was added 1-pentanol (0.17 mL, 1.55 
mmol) and Ph3P (0.41 g, 1.55 mmol). This was followed by dropwise addition of DIAD (0.30 mL, 
1.55 mmol) in THF (5 mL) and the reaction mixture became yellow in colour. After continuous 
stirring at RT for 5 h, the solvent was removed in vacuo to yield a yellow crude solid (1.32 g). The 
crude was purified by flash column chromatography (EtOAc/Hexane 1:9). The product KC_21 was 
isolated as yellow oil (0.26 g, 99 %).  
 
Data for KC_21: 
 
1H NMR (300 MHz, CDCl3) δ ppm 7.41 (t, J=8.4 Hz, 1 H), 6.60 (d, J=8.4 Hz, 1 H), 6.52 (d, J=8.2 
Hz, 1 H), 4.07 (t, J=6.8 Hz, 2 H), 1.95 - 1.83 (m, 2 H), 1.70 (s, 6 H), 1.55 - 1.32 (m, 4 H), 0.93 (t, 
J=7.18 Hz, 3 H) 
 
13C NMR + DEPT: (75 MHz, CDCl3) δ ppm 161.1 (C), 158.0 (C), 157.7 (C), 136.2 (CH), 108.8 
(CH), 106.4 (CH), 105.0 (C), 103.4 (C), 69.3 (CH2), 28.6 (CH2), 28.0 (CH2), 25.6 (CH3), 22.4 
(CH2), 14.0 (CH3) 
 
ES
+ MS: m/z (%), 265 ([M+H]
+ 26 %), 551 ([M+Na]
+ 100 %) 
 
IR (neat) 2933 (m), 2877 (m), 1735 (s), 1603 (m), 1580 (s), 1467 (m) cm
-1 
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2-Hydroxy-6-pentyloxy-benzoic acid (KC_22) 
 
O
O O
O
O
OH OH
O i) ii)
KC_21                                                         KC_22  
 
i) aq LiOH, THF, 0 °C, ii) H
+ work up 
 
The acetonide KC_21 (0.12 g, 0.46 mmol) was dissolved in THF (3.6 mL) and cooled to 0 °C. To 
this solution, LiOH (0.022 g, 0.93 mmol) in H2O (1.2 mL) was added dropwise. The reaction 
mixture was warmed to RT and was stirred for 20 h. The reaction mixture was quenched with H2O 
(5 mL) and acidified to pH 2 using 2M aq HCl. The organic product was extracted with EtOAc (2x 
10 mL) and the organic extracts were washed with brine (2 x 10 mL) and dried (MgSO4). The 
solvent was removed in vacuo to yield the product KC_22 as yellow oil (93 mg, 90%). No further 
purification was needed. 
 
Data for KC_22: 
 
1H NMR (300 MHz, CDCl3) δ ppm 12.16 (s, 1 H), 11.60 (br. s., 1 H), 7.39 (t, J=8.4 Hz, 1 H), 6.70 
(d, J=8.5 Hz, 1 H), 6.5 (d, J=8.3 Hz, 1 H), 4.23 (t, J=6.6 Hz, 2 H), 1.98 - 1.86 (m, 2 H), 1.54 - 1.34 
(m, 4 H), 0.95 (t, J=7.0 Hz, 3 H) 
 
13C NMR + DEPT (75 MHz, CDCl3) δ ppm 170.9 (C), 164.2 (C), 158.0 (C), 135.5 (CH), 112.1 
(CH), 102.1 (CH), 101.6 (C), 70.7 (CH2), 28.5 (CH2), 27.9 (CH2), 22.2 (CH2), 13.8 (CH3) 
 
ES
- MS m/z (%), 224 ([M-H]
- 58 %) 
 
IR (neat) 3213 (w), 2933 (m), 1682 (s), 1618 (m), 1584 (m), 1452 (s), 1414 (m) cm
-1 
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5-Hexyloxy-2, 2-dimethyl-1, 3-benzodioxin-4-one (KC_23) 
 
O O
OH
O
O O
O
O i)
(7)                                          KC_23  
 
i) 1-hexanol, DIAD, Ph3P, THF, RT. 
 
To a solution of acetonide 7 (0.4 g, 2.10 mmol) in THF (21 mL) was added 1-hexanol (0.39 mL, 
3.10 mmol) and Ph3P (0.81 g, 3.10 mmol). This was followed by dropwise addition of DIAD (0.61 
mL, 3.10 mmol) in THF (10 mL). After continuous stirring at RT in the dark for 5h, the solvent 
was removed in vacuo to yield a yellow crude oil (2.45 g). The crude was purified by flash column 
chromatography (DCM). The product KC_23 was isolated as a white solid (0.56 g, 98%). 
 
Data for KC_23: 
 
1H NMR (300 MHz, CDCl3) δ ppm 7.41 (t,  J= 8.4 Hz, 1 H), 6.60 (d, J= 8.5 Hz, 1 H),  6.52 (dd, J= 
8.2, 0.8 Hz, 1 H), 4.07 (t, J= 6.8 Hz, 2 H), 1.94 - 1.82 (m, 2 H), 1.70 (s, 6 H), 1.57 - 1.45 (m, 2 H), 
1.35 (dq, J= 7.2, 3.6 Hz, 4 H), 0.94 - 0.85 (m, 3 H) 
 
13C NMR + DEPT (75 MHz, CDCl3) δ ppm 161.5 (C), 158.0 (C), 57.7 (C), 136.2 (CH), 108.8 
(CH), 106.4 (CH), 105.0 (C), 103.4 (C), 69.4(CH2), 31.5(CH2), 28.9 (CH2), 25.6 (CH3), 25.5 
(CH2), 22.5 (CH2), 14.0 (CH3) 
 
ES
+ MS m/z (%), 301 ([M+Na]
+ 100 %) 
 
IR (neat) 2926 (w), 2862 (w), 1739 (s), 1610 (s), 1580 (s), 1486 (m), 1474 (m) cm
-1 
 
M.P 38 - 40 °C 
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2-Hexyloxy-6-hydroxyl benzoic acid (KC_24) 
 
O
OH
O
OH O O
O
O i) ii)
KC_23                                                    KC_24  
 
i) aq LiOH, THF, 0 °C; ii) H
+ work up 
 
The acetonide KC_23 (0.20 g, 0.72 mmol) was dissolved in THF (5.4 mL) and cooled to 0 °C. This 
was followed by dropwise addition of LiOH (0.034 g, 1.44 mmol) in H2O (1.8 mL). The reaction 
mixture was warmed to RT and was stirred for 20 h. The reaction mixture was quenched with H2O 
(10 mL) and acidified to pH 2 with 2M aq HCl. The organic product was extracted with EtOAc (2x 
10 mL) and the organic extracts were washed with brine (2 x 10 mL) and dried (MgSO4). The 
solvent was removed in vacuo to yield colourless oil (0.15 g). The crude was purified by flash 
column  chromatography  (0-5  %  EtOAc  in  Hexane)  and  the  product  (KC_24)  was  isolated  as 
colourless oil (82 mg, 48 %). 
 
Data for KC_24: 
 
1H NMR (300 MHz, CDCl3) δ ppm 12.16 (s, 1 H), 11.62 (s, 1 H), 7.39 (t, J= 8.4 Hz, 1 H), 6.71 
(dd, J=8.5, 0.7 Hz, 1 H), 6.48 (d, J= 8.2 Hz, 1 H), 4.24 (t, J= 6.6 Hz, 2 H), 1.98 - 1.85 (m, 2 H), 
1.56 - 1.41 (m, 2 H), 1.40 - 1.30 (m, 4 H), 0.92 (t, J= 7.0 Hz, 3 H) 
 
13C NMR + DEPT (75 MHz, CDCl3) δ ppm 170.9 (C) 164.2 (C), 158.0 (C), 135.5 (CH), 112.1 
(CH), 102.1 (CH), 101.7 (C), 70.7 (CH2), 31.3 (CH2), 28.8 (CH2), 25.5 (CH2), 22.4 (CH2), 13.9 
(CH3) 
 
ES
- MS m/z (%), 237 ([M-H]
- 24 %) 
 
IR (neat) 3194 (br), 2928 (w), 1693 (s), 1584 (m), 1459 (s), 1410 (m) cm
-1 
  
 
130 
5-Heptyloxy-2, 2–dimethyl –benzo [1, 3] dioxin-4-one (KC_25) 
 
OH
O
O O
O
O O
O i)
(7)                                       KC_25  
 
i) 1-heptanol, DIAD, Ph3P, THF, RT. 
 
To a solution of 7 (0.20 g, 1.03 mmol) in THF (10 mL) was added 1-heptanol (0.22 mL, 1.55 
mmol) and Ph3P (0.41 g, 1.55 mmol). This was followed by dropwise addition of DIAD (0.30 mL, 
1.55 mmol) in THF (5 mL) and the solution became yellow in colour. After continuous stirring at 
RT for 5h, the solvent was removed in vacuo to yield a yellow crude solid (1.43 g). The crude was 
purified by flash column  chromatography (0-50%  DCM in Hexane). The product KC_25 was 
isolated as a white solid (0.23 g, 77 %).  
 
Data for KC_25: 
 
1H NMR (300 MHz, CDCl3) δ ppm 7.41 (t, J=8.4 Hz, 1 H), 6.60 (d, J= 8.5 Hz, 1 H), 6.52 (dd, J= 
8.2, 0.6 Hz, 1 H), 4.07 (t, J= 6.7 Hz, 2 H), 1.95 - 1.82 (m, 2 H), 1.70 (s, 6 H), 1.56 - 1.44 (m, 2 H), 
1.40 - 1.27 (m, 6 H), 0.84 - 0.93 (m, 3 H)  
 
13C NMR + DEPT (75 MHz, CDCl3) δ ppm 161.1 (C), 158.0 (C), 157.7 (C), 136.2 (CH), 108.8 
(CH), 106.4 (CH), 105.1 (C), 103.4 (C), 69.4 (CH2), 31.7 (CH2), 29.0 (CH2), 28.9 (CH2), 25.8 
(CH2), 25.6 (CH3), 22.6 (CH2), 14.1 (CH3) 
 
ES
+ MS m/z (%), 293 ([M+H]
+ 38 %), 607 ([M+Na]
+ 100 %) 
 
IR (neat) 2933 (m), 2858 (m), 1739 (s), 1603 (m), 1584 (s), 1459 (m) cm
-1 
 
M.P 40 - 43 °C 
  
 
131 
2-Heptyloxy-6-hydroxy-benzoic acid (KC_26) 
 
O
O O
O
O
OH OH
O i) ii)
KC_25                                                         KC_26  
 
i) aq LiOH, THF, 0°C; ii) H
+ work up 
 
The acetonide KC_25 (0.15 g, 0.51 mmol) was dissolved in THF (3.8 mL) and cooled to 0 °C. 
Followed by dropwise addition of LiOH (0.024 g, 1.02 mmol) in H2O (1.3 mL). The solution was 
warmed to RT and was stirred for 20 h. The reaction mixture was quenched with H2O (5 mL) and 
acidified to pH 2 using 2M aq HCl. The organic product was extracted with EtOAc (2x 10 mL) and 
the organic extracts were washed with brine (2 x 10 mL) and dried (MgSO4). The solvent was 
removed in vacuo to yield a yellow crude oil (0.14 g). The crude was purified by flash column 
chromatography (EtOAc/Hexane 1:19) and the product KC_26 was isolated as a yellow oil (0.12 g, 
95 %). 
 
Data for KC_26: 
 
1H NMR (300 MHz, CDCl3) δ ppm 12.17 (s, 1 H), 11.61 (br. s., 1 H), 7.39 (t, J= 8.4 Hz, 1 H), 6.71 
(d, J= 8.5 Hz, 1 H), 6.48 (d, J=8.3 Hz, 1 H), 4.23 (t, J= 6.6 Hz, 2 H), 1.99 - 1.85 (m, 2 H), 1.56 - 
1.24 (m, 8 H), 0.96 - 0.83 (m, 3 H) 
 
13C NMR + DEPT (75 MHz, CDCl3) δ ppm 170.9 (C), 164.2 (C), 158.0 (C), 135.5 (CH), 112.1 
(CH), 102.1 (CH), 101.7 (C), 70.7 (CH2), 31.6 (CH2), 28.8 (CH2), 25.8 (CH2), 22.5 (CH2), 14.0 
(CH2)  
 
ES
- MS m/z (%), 251 ([M-H]
- 57 %) 
 
IR (neat) 3206 (w), 2930 (m), 1682 (m), 1622 (m), 1584 (m) cm
-1  
 
132 
2-Octyloxy-benzoic acid methyl ester (KC_27) 
 
O
O
O
O
O
O
i)
methyl salicylate                        KC_27  
 
i) 1-Octanol, DIAD, Ph3P, THF, RT. 
 
To a solution of methyl salicylate (0.43 mL, 3.30 mmol) in THF (33 mL) was added 1-octanol 
(0.78 mL, 4.90 mmol) and Ph3P (1.29 g, 4.90 mmol). This was followed by dropwise addition of 
DIAD (0.97 mL, 4.90 mmol) in THF (16 mL) and the solution became yellow in colour. After 
continuous stirring at RT for 5h, the solvent was removed in vacuo to yield a yellow crude oil (4.23 
g). The crude was purified by flash column chromatography (DCM/Hexane 1:1). The fractions 
were collected and the solvent was removed in vacuo to yield KC_27 (0.62 g, 71%) as a yellow oil. 
 
Data for KC_27: 
 
1H NMR (300 MHz, CDCl3) δ ppm 7.78 (dd, J= 7.9, 1.8 Hz, 1 H), 7.44 (ddd, J= 8.5, 7.4, 1.8 Hz, 1 
H), 6.99 - 6.93 (m, 2 H), 4.04 (t, J= 6.5 Hz, 2 H), 3.89 (s, 3 H), 1.89 - 1.77 (m, 2 H), 1.56 - 1.46 (m, 
2 H), 1. 40 - 1.24 (m, 8 H), 0.96 - 0.83 (m, 3 H) 
 
13C NMR + DEPT (75 MHz, CDCl3), δ ppm 167.0 (C), 158.6 (C), 133.3 (CH), 131.5 (CH), 120.5 
(C), 113.2 (CH), 68.9 (CH2), 51.9 (CH3), 31.8 (CH2), 29.3 (CH2), 29.2 (CH2), 29.1 (CH2), 25.9 
(CH2), 22.7 (CH2), 14.1 (CH3) 
 
ES
+ MS m/z (%), 265 ([M+H]
+ 48 %), 287 ([M+Na]
+ 100 %), 328 ([M+CH3CN+Na]
+, 92 %), 551 
([2M+Na]
+ 81 %). 
 
The 
1H and 
13C NMR spectra corresponded to the reported data
143.   
 
133 
2-Octyloxy benzoic acid (KC_28) 
 
O
O
O
O
O
OH
i), ii)
KC_27                                                             KC_28  
 
i) 20% KOH, EtOH, reflux, ii) H
+ work up 
 
KC_27 (0.20 g, 0.76 mmol) was dissolved in 20 % KOH solution in EtOH (15 mL). The solution 
was warmed to reflux and stirred overnight. The reaction mixture was quenched with water (20 
mL) and acidified to pH 2 with 2M aq HCl. The organic product was extracted with EtOAc (2x 20 
mL). The combined organic extracts were washed with brine (2x 40 mL) and dried (MgSO4). The 
solvent was removed in vacuo to yield a brown crude oil (0.21 g). The crude was purified by flash 
column chromatography (EtOAc/Hexane 1:4) and the product KC_28 was isolated as orange oil 
(64 mg, 33 %). 
 
Data for KC_28: 
 
1H NMR (300 MHz, CDCl3) δ ppm 11.04 (br. s., 1 H), 8.20 (dd, J= 7.9, 1.8 Hz, 1 H), 7.56 (ddd, 
J=8.4, 7.4, 1.8 Hz, 1 H), 7.18 - 7.10 (m, 1 H), 7.05 (d, J= 8.3 Hz, 1 H), 4.26 (t, J= 6.6 Hz, 2 H), 
1.98 - 1.87 (m, 2 H), 1.57 - 1.44 (m, 2 H), 1.44 - 1.22 (m, 8 H), 0.95 - 0.82 (m, 3 H) 
 
13C NMR + DEPT (75 MHz, CDCl3) δ ppm 165.4 (C), 157.6 (C), 135.0 (CH), 133.8 (CH), 122.1 
(CH), 117.7 (C), 112.5 (CH), 70.3 (CH2), 31.7 (CH2), 29.1 (CH2), 29.1 (CH2), 28.9 (CH2), 25.8 
(CH2), 22.6 (CH2), 14.0 (CH3) 
 
ES
- MS m/z (%), 249 ([M-H]
- 100 %) 
 
The 1H and 13C NMR spectra corresponded to the reported data
143. 
  
 
134 
3-Octyloxy-phenol (KC_29) 
 
OH
OH
O
OH
i)
resorcinol                         KC_29  
 
i) 1-Octanol, DIAD, Ph3P, THF, RT. 
 
To a solution of resorcinol (0.50 g, 4.50 mmol) in THF (45 mL) was added 1-octanol (1.10 mL, 
6.80 mmol) and Ph3P (1.79 g, 6.80 mmol). This was followed by dropwise addition of DIAD (1.70 
mL,  6.80  mmol)  in  THF  (23  mL)  and  the  reaction  mixture  became  yellow  in  colour.  After 
continuous stirring at RT for 5h, the solvent was removed in vacuo to yield crude yellow oil (5.49 
g). The crude was purified by flash column chromatography (DCM/Hexane 1:9). The fractions 
were collected and the solvent was removed in vacuo to yield KC_29 (136 mg, 13%) as a yellow 
oil. 
 
Data for KC_29: 
 
1H NMR (300 MHz, CDCl3) δ ppm 7.12 (t, J= 8.5 Hz, 1 H) 6.50 (ddd, J= 8.3, 2.2, 0.9 Hz, 1 H) 
6.44 - 6.41 (m, 1 H) 6.41 (s, 1 H) 3.93 (t, J= 6.6 Hz, 2 H) 1.83 - 1.71 (m, 2 H) 1.57 - 1.33 (m, 4 H) 
1.32 - 1.28 (m, 6 H) 0.93 - 0.87 (m, 3 H) 
 
13C NMR + DEPT (75 MHz, CDCl3), δ ppm 160.5 (C), 156.7 (C), 130.1 (CH), 107.5 (CH), 107.1 
(CH), 102.0 (CH), 68.1 (CH2), 31.8 (CH2), 29.3 (CH2), 29.2 (2 CH2 coincident signals), 26.0 
(CH2), 22.7 (CH2), 14.1 (CH3) 
 
ES
- MS m/z (%), 221 ([M-H]
- 100 %) 
 
IR (neat) 2926 (m), 2850 (m), 1588 (s), 1580 (s), 1497 (m), 1463 (m) cm
-1 
 
Known compound but no reported spectroscopic data in the literature
144.  
 
135 
5-Hydroxy-7-methoxy-2, 2-dimethyl-1, 3-benzodioxin-4-one (KC_30) 
 
OH
O
O O
O H OH
O
O O
O
i)
(9)                                             KC_30  
 
i) MeOH, DIAD, Ph3P, THF, RT. 
 
To a solution of (9) (1.07 g, 5.09 mmol) in THF (15 mL) was added MeOH (0.23 mL, 5.60 mmol) 
and Ph3P (1.47 g, 5.60 mmol). This was followed by dropwise addition of DIAD (1.10 mL, 5.60 
mmol) in THF (4 mL) and the reaction mixture became yellow in colour. After continuous stirring 
at RT for 5h, the solvent was removed in vacuo to yield a yellow crude solid (3.05 g). The crude 
was purified by flash column chromatography (EtOAc/Hexane 1:9). The fractions were collected 
and the solvent was removed in vacuo to yield KC_30 as a white crystalline solid (0.59 g, 52 %). 
 
Data for KC_30: 
 
1H NMR (300 MHz, CDCl3) δ ppm 10.45 (s, 1 H), 6.15 (d, J=2.3 Hz, 1 H), 6.01 (d, J=2.3 Hz, 1 
H), 3.82 (s, 3 H), 1.73 (s, 6 H) 
 
13C NMR + DEPT (75 MHz, CDCl3) δ ppm 167.7 (C), 165.1 (C), 163.1 (C), 156.8 (C), 106.9 (C), 
95.7 (CH), 94.6 (CH), 93.1 (C), 55.7 (CH3), 25.6 (CH3) 
 
ES
+ MS m/z (%), 225 ([M+H]
+ 12 %), 247 ([M+Na]
+ 38 %).  
 
M.P 96 - 99 °C, reported M.P 108 – 109 °C
145. 
 
The 
1H and 
13C NMR spectra corresponded to the reported data
145, 146.  
 
136 
7-Methoxy-2, 2-dimethyl-5-octyloxy-1, 3-benzodioxin-4-one (KC_31) 
 
OH
O
O O
O O
O O
O
O
i)
KC_30                                         KC_31  
 
i) 1-octanol, DIAD, Ph3P, THF, RT. 
 
To a solution of KC_30 (0.19 g, 0.85 mmol) in THF (8.5 mL) was added 1-octanol (0.20 mL, 1.28 
mmol) and Ph3P (0.33 g, 1.28 mmol). This was followed by dropwise addition of DIAD (0.25 mL, 
1.28 mmol) in THF (4.2 mL) which turned the reaction mixture yellow in colour. After continuous 
stirring at RT for 5h, the solvent was removed in vacuo to yield a yellow crude oil (1.35 g). The 
crude was purified by flash column chromatography (EtOAc/Hexane 1:9). The product KC_31 was 
isolated as colourless oil (0.18 g, 63 %).  
 
Data for KC_31: 
 
1H NMR (300 MHz, CDCl3) δ ppm 6.12 (d, J=2.2 Hz, 1 H), 6.04 (d, J=2.2 Hz, 1 H), 4.02 (t, J=6.8 
Hz, 2 H), 3.82 (s, 3 H), 1.94 - 1.82 (m, 2 H), 1.69 (s, 6 H), 1.49 (qd, J=7.2, 7.0 Hz, 2 H), 1.39 - 1.21 
(m, 8 H), 0.93 - 0.80 (m, 3 H) 
 
13C NMR + DEPT (75 MHz, CDCl3) δ ppm 166.2 (C), 162.4 (C), 159.3 (C), 157.9 (C), 104.8 (C), 
96.9 (C), 94.4 (CH), 93.2 (CH), 69.3 (CH2), 55.6 (CH3), 31.2 (CH2), 29.3 (CH2), 29.2 (CH2), 28.8 
(CH2), 25.8 (CH2), 25.6 (CH3), 22.6 (CH2), 14.1 (CH3) 
 
ES
+ MS m/z (%), 337 ([M+H]
+ 23 %), 359 ([M+Na]
+ 47 %), 696 ([2M+Na]
+ 100 %) 
 
IR (neat) 2930 (m), 2854 (m), 1731 (s), 1610 (m), 1576 (s), 1493 (m), 1436 (m) cm
-1 
  
 
137 
2-Hydroxy-4-methoxy-6-octyloxy-benzoic acid (KC_32) 
 
O
O O
O
O O
OH OH
O
O
i) ii)
KC_31                                                                     KC_32  
 
i) aq LiOH, THF, 0 °C, ii) H
+ work up 
 
The acetonide KC_31 (0.14 g, 0.42 mmol) was dissolved in THF (3.2 mL) and cooled to 0 °C. This 
was followed by dropwise addition of LiOH (0.020 g, 0.83 mmol) in H2O (1.1 mL). The reaction 
mixture was warmed to RT and was stirred for 20 h. The reaction mixture was quenched with H2O 
(5 mL) and acidified to pH 2 using 2M aq HCl. The organic product was extracted with EtOAc (2x 
5 mL) and the organic extracts were washed with brine (2 x 10 mL) and dried (MgSO4). The 
solvent was removed in vacuo to yield a pale yellow crude oil (0.069, 99.9%). The crude was 
purified  by  flash  column  chromatography  (EtOAc/Hexane  1:9).  The  product  KC_32  was 
recrystallised from hexane to give white needles (43 mg, 35 %). 
 
Data for KC_32: 
 
1H NMR (400 MHz, CDCl3) δ ppm 12.47 (s, 1 H), 11.25 (s, 1 H), 6.19 (d, J= 2.3 Hz, 1 H), 6.02 (d, 
J= 2.3 Hz, 1 H), 4.18 (t, J= 6.6 Hz, 2 H), 3.83 (s, 3 H), 1.95 - 1.85 (m, 2 H), 1.53 - 1.42 (m, 2 H), 
1.42 - 1.25 (m, 8 H), 0.90 (t, J= 6.9 Hz, 3 H)  
 
13C NMR + DEPT (100 MHz, CDCl3) δ ppm 170.9 (C), 166.3 (C), 165.6 (C), 159.2 (C), 95.3 (C), 
94.5 (CH), 92.1 (CH), 70.6 (CH2), 55.7 (CH3), 31.7 (CH2), 29.1 (CH2), 29.0 (CH2), 28.7 (CH2), 
25.8 (CH2), 22.6 (CH2), 14.0 (CH3) 
 
ES
- MS: m/z (%), 296 ([M-H]
- 100 %) 
 
IR (neat) 2922 (w), 2359 (m), 1610 (m), 1516 (s), 1448 (m), 1402 (m) cm
-1 
 
 
  
 
138 
2, 2–Dimethyl -5 –phenethyloxy-1, 3-benzodioxin-4-one (KC_33) 
 
OH
O
O O
O
O O
O i)
(7)                                       KC_33  
 
i) (2-bromoethyl)-benzene, K2CO3, NaI, DMF, reflux  
 
To a 0 °C suspension of 7 (0.20 g, 1.03 mmol), K2CO3 (0.16 g, 1.13 mmol) and NaI (0.060 g, 0.41 
mmol) in DMF (1 mL) was added (2-bromoethyl)-benzene (0.15 mL, 1.13 mmol). The mixture was 
stirred for 30 mins and was warmed to reflux overnight. The reaction mixture was quenched with 
water (2 mL) and acidified to pH 2 using 2M aq HCl. The organics were extracted with EtOAc (2x 
5  mL),  and  then  the  combined  organic  layers  were  washed  with  brine  (2x  10  mL)  and  dried 
(MgSO4). The solvent was removed in vacuo to yield a brown crude oil (0.41 g). The crude was 
purified by flash column chromatography (EtOAc/Hexane 1:9). The product KC_33 was isolated 
as yellow oil (73 mg, 24 %). 
 
Data for KC_33: 
 
1H NMR (300 MHz, CDCl3) δ ppm 7.33 - 7.11 (m, 6 H), 6.48 (d, J= 8.5 Hz, 1 H), 6.44 (d, J= 8.2 
Hz, 1 H), 4.16 (t, J= 7.1 Hz, 2 H), 3.12 (t, J= 7.2 Hz, 2 H), 1.61 (s, 6 H)  
 
13C NMR + DEPT (75 MHz, CDCl3) δ ppm 160.7 (C), 158.0 (C), 157.8 (C), 138.0 (C), 136.2 
(CH), 129.3 (CH), 128.5 (CH), 126.6 (CH), 109.2 (CH), 106.4 (CH), 105.1 (C), 103.5 (C), 70.2 
(CH2), 35.6 (CH2), 25.6 (CH3) 
 
ES
+ MS m/z (%), 299 ([M+H]
+ 28 %), 321 ([M+Na]
+ 100 %), 619 ([2M+Na]
+ 92 %) 
 
IR (neat) 1735 (s), 1607(m), 1584(s), 1478 (m), 1463 (m) cm
-1 
 
 
  
 
139 
2-Hydroxy-6-phenethyloxy-benzoic acid (KC_34) 
 
O
O O
O
O
OH OH
O i) ii)
KC_33                                                          KC_34  
 
i) aq LiOH, THF, 0 °C, ii) H
+ work up 
 
The acetonide KC_33 (0.034 g, 0.11 mmol) was dissolved in THF (0.08 mL) and cooled to 0 °C. 
To this solution, LiOH (0.0055 g, 0.23 mmol) in H2O (0.03 mL) was added dropwise. The reaction 
mixture was warmed to RT and was stirred for 20 h. The reaction mixture was quenched with H2O 
(1 mL) and acidified to pH 2 using 2M aq HCl. The organic product was extracted with EtOAc (2x 
2 mL) and the organic extracts were washed with brine (2 x 5 mL) and dried (MgSO4). The solvent 
was removed in vacuo to yield the product KC_34 as a pale yellow solid (28 mg, 99.9%). No 
purification was needed.  
 
Data for KC_34: 
 
1H NMR (300 MHz, CDCl3) δ ppm 12.11 (s, 1 H), 7.49 - 7.08 (m, 6 H), 6.65 (d, J=8.4 Hz, 1 H), 
6.42 (d, J=8.3 Hz, 1 H), 4.42 (t, J=6.6 Hz, 2 H), 3.16 (t, J=6.63 Hz, 2 H)  
 
13C NMR + DEPT (75 MHz, CDCl3) δ ppm 170.8 (C), 164.2 (C), 157.7 (C), 136.1 (C), 135.5 
(CH), 129.1 (CH), 128.6 (CH), 127.3 (CH), 112.3 (CH), 102.0 (CH), 101.6 (C), 70.9 (CH2), 35.3 
(CH2) 
 
ES
- MS m/z (%), 257 ([M-H]
- 100 %) 
 
IR (neat) 3213 (br), 2843 (w), 1686 (s), 1622 (m), 1588 (m), 1455 (s), 1406 (m) cm
-1 
 
M.P 87 - 90 °C  
 
140 
8-Octyloxy-quinoline (KC_35) 
N
OH
N
O
i)
8-hydroxyquinoline                  KC_36  
 
i) 1-octanol, DIAD, Ph3P, THF, RT. 
 
To a solution of 8-hydroxyquinoline (0.50 g, 3.44 mmol) in THF (34 mL) was added 1-octanol 
(0.81 mL, 5.17 mmol) and Ph3P (1.36 g, 5.17 mmol). This was followed by dropwise addition of 
DIAD (1.02 mL, 5.17 mmol) in THF (18 mL) and the reaction mixture became yellow in colour. 
After continuous stirring at RT in the dark for 5h, the solvent was removed in vacuo to yield a 
brown  crude  solid  (4.10  g).  The  crude  was  purified  by  flash  column  chromatography 
(EtOAc/Hexane 1:9). The product KC_35 was isolated as colourless oil (86 mg, 10%). 
 
Data for KC_35: 
 
1H NMR: (300 MHz, CDCl3) δ ppm 8.95 (dd, J= 4.2, 1.7 Hz, 1 H), 8.11 (dd, J= 8.3, 1.7 Hz, 1 H), 
7.52 - 7.31 (m, 3 H), 7.05 (dd, J= 7.6, 1.1 Hz, 1 H), 4.23 (t, J= 7.1 Hz, 2 H), 2.03 (qd, J= 7.4, 7.2 
Hz, 2 H), 1.61 - 1.45 (m, 2 H), 1.46 - 1.20 (m, 8 H), 0.96 - 0.81 (m, 3 H)  
 
13C NMR + DEPT: (75 MHz, CDCl3) δ ppm 154.8 (C), 149.2 (CH), 140.4 (C), 135.8 (CH), 129.4 
(C), 126.6 (CH), 121.4 (CH), 119.3 (CH), 108.5 (CH), 69.0 (CH2), 31.8 (CH2), 29.4 (CH2), 29.2 
(CH2), 28.9 (CH2), 26.0 (CH2), 22.6 (CH2), 14.1 (CH3) 
 
EI MS: m/z (%) 257 ([M]
+˙, 2%), 172 (16%), 158 (100%), 145 (55%) 
 
IR (neat) 2926 (m), 2854 (m), 1565 (m), 1501 (s), 1463 (s) cm
-1 
 
Known compound but no spectroscopic data in the literature
147.  
 
141 
8-Octyloxy-1-benzopyran-2-one (KC_36) 
 
OH
O O
O
O O
i)
 
 
i) 1-octanol, DIAD, Ph3P, THF, RT. 
 
To a solution of 8-hydroxycoumarin (0.20 g, 1.23 mmol) in THF (12 mL) was added 1-octanol 
(0.30 mL, 1.85 mmol) and Ph3P (0.49 g, 1.85 mmol). This was followed by dropwise addition of 
DIAD (0.36 mL, 1.85 mmol) in THF (7 mL) and the reaction mixture became yellow in colour. 
After continuous stirring at RT for 5h, the solvent was removed in vacuo to yield orange crude oil 
(1.40  g).  The  crude  was  purified  by  flash  column  chromatography  (EtOAc/Hexane  1:9).  The 
isolated product (KC_36) was recrystallised from hexane to give white crystalline needles (0.22 g, 
65 %). 
 
Data for KC_36: 
 
1H NMR (300 MHz, CDCl3) δ ppm 7.64 (d, J= 9.5 Hz, 1 H), 7.24 (s, 1 H), 7.10 (dd, J= 9.1, 2.9 
Hz, 1 H), 6.91 (d, J= 2.8 Hz, 1 H), 6.42 (d, J= 9.5 Hz, 1 H), 3.97 (t, J= 6.5 Hz, 2 H), 1.85 - 1.74 (m, 
2 H), 1.52 - 1.41 (m, 2 H), 1.37 - 1.26 (m, 8 H), 0.89 (t, J= 6.6 Hz, 3 H) 
 
13C NMR + DEPT (75 MHz, CDCl3) δ ppm 161.0 (C), 155.6 (C), 148.3 (C), 143.2 (CH), 119.9 
(CH), 119.1 (C), 117.8 (CH), 117.0 (CH), 110.7 (CH), 68.7 (CH2), 31.8 (CH2), 29.3 (CH2), 29.2 
(CH2), 29.2 (CH2), 26.0 (CH2), 22.6 (CH2), 14.1 (CH3) 
 
ES
+ MS m/z (%), 275 ([M+H]
+ 11 %), 297 ([M+Na]
+ 21 %), 571 ([2M+Na]
+ 88 %) 
 
IR (neat) 2915 (m), 2854 (m), 1705 (m), 1565 (s), 1470 (m), 1448 (m) cm
-1 
 
M.P 64 - 66 °C  
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2, 2-Dimethyl-5-(4-phenyl-butoxy)-1, 3-benzodioxin-4-one (KC_37) 
O O
OH
O
O O
O
O
i)
(7)                                         KC_37  
 
i) 4-phenyl-1-butanol, DIAD, Ph3P, THF, RT. 
 
To a solution of 7 (0.10 g, 0.52 mmol) in THF (10.4 mL) was added 4-phenyl-1-butanol (0.12 mL, 
0.77 mmol) and Ph3P (0.20 g, 0.77 mmol). This was followed by dropwise addition of DIAD (0.15 
mL,  0.77  mmol)  in  THF  (5  mL)  and  the  reaction  mixture  became  yellow  in  colour.  After 
continuous stirring at RT for 5h, the solvent was removed in vacuo to yield a yellow crude oil (0.76 
g). The crude was purified by flash column chromatography (EtOAc/Hexane 1:9). The product 
KC_37 was isolated as viscous oil (0.13 g, 77 %). 
 
Data for KC_37: 
 
1H NMR (400 MHz, CDCl3) δ ppm 7.41 (t, J= 8.4 Hz, 1 H), 7.32 - 7.14 (m, 5 H), 6.58 (d, J= 8.4 
Hz, 1 H), 6.53 (dd, J= 8.2, 0.8 Hz, 1 H), 4.09 (t, J= 6.0 Hz, 2 H), 2.72 (t, J= 7.0 Hz, 2 H), 1.99 - 
1.84 (m, 4 H), 1.71 (s, 6 H) 
 
13C NMR + DEPT (100 MHz, CDCl3) δ ppm 161.0 (C), 157.9 (C), 157.8 (C), 142.2 (C), 136.2 
(CH), 128.4 (CH), 128.3 (CH), 125.7 (CH), 108.9 (CH), 106.4 (CH), 105.1 (C), 103.5 (C), 69.1 
(CH2), 35.5 (CH2), 28.5 (CH2), 27.5 (CH2), 25.6 (CH3) 
 
ES
+ MS m/z (%), 349 ([M+Na]
+ 100 %), 675 ([2M+Na]
+ 68 %) 
 
IR (neat) 2937 (w), 1735 (s), 1603 (s), 1580 (s), 1486 (m), 1459 (m) cm
-1 
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2-Hydroxy-6-(4-phenyl-butoxy)-benzoic acid (KC_38) 
 
O
O O
O
O
OH OH
O i) ii)
KC_37                                                                     KC_38  
 
i) LiOH, THF, 0 °C, ii) H
+ work up 
 
The acetonide KC_37 (80 mg, 0.25 mmol) was dissolved in THF (3.75 mL) and cooled to 0 °C. To 
this solution was added LiOH (12 mg, 0.49 mmol) in H2O (1.25 mL) was added dropwise. The 
reaction mixture was warmed to RT and was stirred for 20 h. The reaction mixture was quenched 
with H2O (2 mL) and acidified to pH 2 using 2M aq HCl. The organic product was extracted with 
EtOAc (2x 4 mL) and the organic extracts were washed with brine (2 x 8 mL) and dried (MgSO4). 
The solvent was removed in vacuo to yield the product KC_38 as a white solid (48 mg, 67%). No 
further purification was needed.  
 
Data for KC_38: 
 
1H NMR (300 MHz, CDCl3) δ ppm 12.17 (1H, s), 11.57 (1H, s) 7.43-7.16 (m, 6 H), 6.71 (dd, 
J=8.5, 0.8 Hz, 1 H), 6.45 (d, J= 8.3 Hz, 1 H), 4.23 (t, J= 6.4 Hz, 2 H), 2.73 (t, J= 7.3 Hz, 2 H),  
2.03 – 1.90 (m, 2H), 1.90 – 1.77 (m, 2H) 
 
13C NMR + DEPT (75 MHz, CDCl3) δ ppm 170.9 (C), 164.2 (C), 157.9 (C), 141.2 (C), 135.6 
(CH), 128.5 (CH), 128.3 (CH), 126.1 (CH), 112.2 (CH), 102.1 (CH), 101.6 (C), 70.5 (CH2), 35.3 
(CH2), 28.3 (CH2), 27.5 (CH2) 
 
ES
- MS m/z (%), 285 ([M-H]
- 100 %) 
 
IR (neat) 3198 (w), 2945 (w), 1690 (s), 1622 (m), 1580 (m), 1459 (s), 1410 (m) cm
-1 
 
M.P 68 - 69 °C 
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5-[2-(1H-Indol-3-yl)-ethoxy]-2, 2-dimethyl-1, 3-benzodioxin-4-one 
(KC_39) 
O O
OH
O
O O
O
O
N
H
i)
(7)                                       KC_39  
 
i) 3(2-hydroxyethyl)-indole, DIAD, Ph3P, THF, RT 
 
To a solution of 7 (0.1 g, 0.52 mmol) in THF (10.4 mL) was added 3(2-hydroxyethyl)-indole (0.12 
g, 0.77 mmol) and Ph3P (0.20 g, 0.77 mmol). This was followed by dropwise addition of DIAD 
(0.15 mL, 0.77 mmol) in THF (5 mL) and the reaction mixture became yellow in colour. After 
continuous stirring at RT for 5h, the solvent was removed in vacuo to yield a yellow crude oil (0.74 
g). The crude was purified by flash column chromatography (EtOAc/Hexane 1:9). The product 
KC_39 was isolated as colourless oil (13 mg, 7 %). 
 
Data for KC_39: 
 
1H NMR: (300 MHz, CDCl3) δ ppm 8.12 (br. s. 1H), 7.66 (d, J= 7.7 Hz, 1 H), 7.44 - 7.35 (m, 3 H), 
7.25 – 7.10 (m, 2H), 6.60 (d, J= 8.4 Hz, 1 H), 6.55 (dd, J= 8.1, 0.7 Hz, 1 H), 4.32 (t, J= 7.0 Hz, 2 
H), 3.38 (t, J= 6.8 Hz, 2 H), 1.72 (s, 6 H)  
 
13C NMR + DEPT: (75 MHz, CDCl3) δ ppm 160.8 (C), 158.3 (C), 157.7 (C), 136.3 (CH), 136.0 
(C), 127.3 (C), 123.5 (CH), 121.8 (CH), 119.3 (CH), 118.5 (CH), 111.6 (C), 111.2 (CH), 109.0 
(CH), 106.3 (CH), 105.2 (C), 103.3 (C), 69.4 (CH2), 25.6 (CH3), 24.8 (CH2)  
 
ES
+ MS: m/z (%), 338 ([M+H]
+ 20 %), 360 ([M+Na]
+ 63 %), 697 ([2M+Na]
+ 100 %). 
 
IR (neat) 3387 (w), 2937 (w), 1724 (s), 1607 (s), 1580 (s), 1489 (m), 1455 (m) cm
-1 
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2-Hydroxy-6-[2-(1H-indole-3yl)-ethoxy]-benzoic acid (KC_40) 
 
O
O O
O N
H
O
OH OH
O N
H
i) ii)
KC_39                                                              KC_40  
 
i) LiOH, THF, 0 °C, ii) H
+ work up 
 
The acetonide KC_39 (10 mg, 0.030 mmol) was dissolved in THF (1.5 mL) and cooled to 0 °C. To 
this solution was added LiOH (14 mg, 0.060 mmol) in H2O (0.5 mL) was added dropwise. The 
reaction mixture was warmed to RT and was stirred for 20 h. The reaction mixture was quenched 
with H2O (1 mL) and acidified to pH 2 using 2M aq HCl. The organic product was extracted with 
EtOAc (2x 2 mL) and the organic extracts were washed with brine (2 x 4 mL) and dried (MgSO4). 
The solvent was removed in vacuo to yield a yellow crude oil (89 mg) which was purified by flash 
chromatography (DCM). The product KC_40 was isolated as white viscous oil (29 mg, 33%).   
 
Data for KC_40: 
 
1H NMR (300 MHz, CDCl3) δ ppm 12.15 (s, 1 H), 11.41 (br. s., 1 H), 8.13 (br. s., 1 H), 7.60 (d, J= 
7.8 Hz, 1 H), 7.42 (d, J= 8.1 Hz, 1 H), 7.37 (t, J= 8.4 Hz, 1 H), 7.24 (dd, J= 8.0, 1.1 Hz, 1 H), 7.16 
(dt, J= 7.4, 1.0 Hz, 2 H), 6.69 (dd, J= 8.5, 0.7 Hz, 1 H), 6.48 (d, J= 8.3 Hz, 1 H), 4.54 (t, J= 6.5 Hz, 
2 H), 3.40 (t, J= 6.4 Hz, 2 H) 
 
13C NMR + DEPT (100 MHz, CDCl3) δ ppm 170.9 (C), 164.3 (C), 157.9 (C), 136.6 (C), 135.5 
(CH), 126.7 (C), 122.7 (CH), 122.6 (CH), 119.8 (CH), 118.2 (CH), 112.2 (CH), 111.6 (CH), 110.4 
(C), 102.1 (CH), 101.7 (C), 69.8 (CH2), 25.4 (CH2) 
 
ES
- MS m/z (%), 296 ([M-H]
- 24 %) 
 
IR (neat) 3410 (w), 3206 (w), 1678 (s), 1614 (m), 1599 (m), 1452 (s) cm
-1 
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5-[2-(4-Methoxy-phenyl)-ethoxy)-2,2-dimethyl-benzo-[1,3]-dioxin-4-one 
(KC_41)  
 
O O
OH
O
O O
O
O
O i)
(7)                                       KC_41  
 
i) 4-methoxyphenethyl-alcohol, DIAD, Ph3P, THF, RT. 
 
To a solution of 7 (0.10 g, 0.52 mmol) in THF (10.4 mL) was added 4-methoxyphenethyl-alcohol 
(0.12 g, 0.77 mmol) and Ph3P (0.20 g, 0.77 mmol). This was followed by dropwise addition of 
DIAD (0.15 mL, 0.77 mmol) in THF (5 mL) and the reaction mixture became yellow in colour. 
After continuous stirring at RT for 5h, the solvent was removed in vacuo to yield a yellow crude oil 
(0.70  g).  The  crude  was  purified  by  flash  column  chromatography  (EtOAc/Hexane  1:9).  The 
product KC_41 was isolated as a white crystalline solid (0.13g, 76 %). 
 
Data for KC_41: 
 
1H NMR (400 MHz, CDCl3) δ ppm 7.39 (t, J= 8.4 Hz, 1 H), 7.32 (d, J= 8.5 Hz, 2 H), 6.87 (d, J= 
8.6 Hz, 2 H), 6.57 (d, J= 8.4 Hz, 1 H), 6.53 (d, J= 8.2 Hz, 1 H)  4.22 (t, J= 7.0 Hz, 2 H), 3.80 (s, 3 
H), 3.16 (t, J= 7.0 Hz, 2 H), 1.71 (s, 6 H) 
 
13C NMR + DEPT (100 MHz, CDCl3) δ ppm 160.8 (C), 158.4 (C), 158.0 (C), 157.8 (C), 136.2 
(CH), 130.4 (CH), 130.0 (C), 113.9 (CH), 109.1 (CH), 106.4 (CH), 105.1 (C), 103.5 (C), 70.4 
(CH2), 55.2 (CH3), 34.7 (CH2), 25.7 (CH3) 
 
ES
+ MS m/z (%), 351 ([M+Na]
+ 67 %), 679 ([2M+Na]
+ 100 %) 
 
IR (neat) 2945 (w), 1735 (s), 1607 (s), 1580 (s), 1512 (s), 1478 (m), 1463 (m) cm
-1 
 
M.P 97 - 99 °C  
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2-Hydroxy-6-[2-(4-methoxy-phenyl)-ethoxy]-benzoic acid (KC_42) 
 
O
O O
O
O
O
OH OH
O
O i) ii)
KC_41                                                                   KC_42  
 
i) LiOH, THF, 0 °C, ii) H
+ work up 
 
The acetonide KC_41 (82 mg, 0.25 mmol) was dissolved in THF (3.75 mL) and cooled to 0 °C. To 
this solution was added LiOH (12 mg, 0.49 mmol) in H2O (1.25 mL) was added dropwise. The 
reaction mixture was warmed to RT and was stirred for 20 h. The reaction mixture was quenched 
with H2O (2 mL) and acidified to pH 2 using 2M aq HCl. The organic product was extracted with 
EtOAc (2x 4 mL) and the organic extracts were washed with brine (2 x 8 mL) and dried (MgSO4). 
The solvent was removed in vacuo to yield the product KC_42 as a white solid (70 mg, 97%). No 
further purification was needed.  
 
Data for KC_42: 
 
1H NMR (300 MHz, CDCl3) δ ppm 12.16 (s, 1 H), 11.25 (s, 1 H), 7.38 (t, J= 8.4 Hz, 1 H), 7.18 (d, 
J= 8.6 Hz, 2 H), 6.90 (d, J= 8.7 Hz, 2 H), 6.70 (dd, J= 8.5, 0.8 Hz, 1 H), 6.47 (d, J= 8.2 Hz, 1 H), 
4.43 (t, J= 6.6 Hz, 2 H), 3.81 (s, 3 H), 3.16 (t, J= 6.6 Hz, 2 H) 
 
13C NMR + DEPT (75 MHz, CDCl3) δ ppm 170.8 (C), 164.2 (C), 158.8 (C), 157.8 (C), 135.5 
(CH), 129.6 (CH), 128.0 (C), 114.5 (CH), 112.3 (CH), 102.0 (CH), 101.6 (C), 71.1 (CH2), 55.3 
(CH3), 34.4 (CH2) 
 
ES
- MS m/z (%), 287 ([M-H]
- 100 %) 
 
IR (neat) 3213 (w), 2956 (w), 1686 (s), 1618 (m), 1588 (m), 1516 (s), 1455(s), 1402 (m) cm
-1 
 
M.P 113 - 115 °C 
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1-Ethoxy-3-octyloxy-benzene (KC_43) 
 
O
OH
O
O
i)
KC_29                                                                 KC_43  
 
i) Iodoethane, NaH, THF.  
 
To a solution of NaH (27 mg, 0.67 mmol) in THF (1.0 mL) was added dropwise the phenol KC_29 
(40 mg, 0.17 mmol) in THF (0.7 mL). Once the initial exothermic reaction subsided, iodoethane 
(0.02  mL,  0.25  mmol)  was  added  dropwise,  and  the  reaction  mixture  was  stirred  in  the  dark 
overnight. The solvent was removed in vacuo to yield a yellow crude oil (49 mg). The crude was 
purified  by  flash  column  chromatography  (EtOAc/Hexane  1:9)  and  the  product  KC_43  was 
isolated as colourless oil (12 mg, 27 %).  
 
Data for KC_43: 
 
1H NMR: (300 MHz, CDCl3) δ ppm 7.16 (t, J= 8.1 Hz, 1 H), 6.50 (br. s, 1 H), 6.49 - 6.45 (m, 2 H), 
4.02 (q, J= 7.0 Hz, 2 H), 3.94 (t, J= 6.6 Hz, 2 H), 1.83 - 1.72 (m, 2 H), 1.41 (t, J=7.0 Hz, 3 H), 1.27 
(s, 10 H), 0.92 - 0.83 (m, 3 H) 
 
13C NMR + DEPT: (100 MHz, CDCl3) δ ppm 160.4 (C), 160.2 (C), 129.8 (CH), 106.8 (CH), 
106.6 (CH), 101.5 (CH), 68.0 (CH2), 63.4 (CH2), 31.8 (CH2), 29.7 (CH2), 29.4 (CH2), 29.3 (CH2), 
26.1 (CH2), 22.7 (CH2), 14.8 (CH3), 14.1 (CH3) 
 
EI MS: m/z (%) 250 ([M]
+˙, 22%), 138 (100%), 110 (93%) 
 
IR (neat) 2918 (s), 2854 (s), 1614 (m), 1595 (m), 1489 (m), 1467 (m) cm
-1 
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2-Ethoxy-6-octyloxy-benzoic acid ethyl ester (KC_44) 
 
OH OH
O
O
O O
O
O i)
KC_15                                                                    KC_44  
 
i) DES, K2CO3 , dry acetone 
 
To solution of KC_15 (0.013 g, 0.049 mmol) in dry acetone (1 mL) was added K2CO3 (0.027 g, 
0.20 mmol). DES (13.0 µL, 0.098 mmol) was added dropwise. After complete addition the reaction 
mixture was warmed to reflux and maintained for 4 h. The reaction mixture was quenched with 
water (1 mL) and the product was extracted with EtOAc (2x 2 mL). The organic layer was washed 
with water (2 x 4mL), brine (2x 4 mL) and dried (MgSO4). The solvent was removed in vacuo to 
yield a colourless crude oil (21 mg) which was purified by flash chromatography (EtOAc/Hexane 
1:3). The product KC_44 was isolated as colourless oil (12 mg, 76%).  
 
Data for KC_44: 
 
1H NMR (400 MHz, CDCl3) δ ppm 7.22 (t, J= 8.3 Hz, 1 H), 6.52 (d, J= 8.4 Hz, 2 H), 4.39 (q, J= 
7.2 Hz, 2 H), 4.06 (q, J= 7.0 Hz, 2 H), 3.97 (t, J= 6.5 Hz, 2 H), 1.79 – 1.70 (m, 2 H), 1.37 (t, J= 7.2 
Hz, 6 H), 1.34 - 1.26 (m, 10 H), 0.89 (t, J=6.8 Hz, 3 H)  
 
13C NMR + DEPT (100 MHz, CDCl3) δ ppm 166.5 (C), 156.8 (C), 156.6 (C), 130.7 (CH), 114.2 
(C), 104.9 (CH), 68.8 (CH2), 64.4 (CH2), 61.0 (CH2), 31.8 (CH2), 29.3 (CH2), 29.2 (CH2), 29.1 
(CH2), 25.9 (CH2), 22.7 (CH2), 14.7 (CH3), 14.3 (CH3), 14.1 (CH3) 
 
ES
+ MS m/z (%), 323 ([M+H]
+ 19 %), 345 ([M+Na]
+ 29%), 386 ([M+CH3CN+Na]
+ 15 %), 668 
([2M+Na]
+ 100 %) 
 
IR (neat) 2930 (w), 1739 (s), 1591 (s), 1478 (s), 1459 (s) cm
-1 
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Biological Studies of Anacardic Acid & Analogues 
 
A  range  of  in  vitro  experiments  were  carried  out,  predominately  investigating  the  effect  of 
anacardic acid, followed by further studies with the newly synthesised compounds. The aim of 
these experiments was to establish whether the compounds exhibited any reasonable potency and 
explore their effect on histone acetylation. The four main experiments carried out to explore these 
aims were growth inhibition, enzyme inhibition, western blotting and a p21 reporter gene assay. 
The biological studies also include two small in vitro studies to determine the potency of the 
azumamides and their effect on histone acetylation. 
 
Cellular Assays 
 
Cell Culture 
All cells used were supplied by ATCC, Manassas, USA. Cell culture and passage was carried out 
in a 37 °C incubator supplied with 10 % CO2 (Hera cell, Heraeus). Cells were maintained in a 
CELLSTAR
® T175 (175 cm
2) tissue culture flask (Greiner Bio-One Ltd, Gloucestershire, UK) and 
supplemented with complete Dulbecco's Modified Eagle Medium (DMEM, see Appendix A).  
 
Cell passage was carried out every three days at a ratio of 1:4. The adherent cells were detached 
with a Trypsin-Versene
® EDTA mixture (Lonza Group Ltd). Cells were incubated with Trypsin-
Versene
® EDTA mixture (5 ml) for 5 minutes maximum. Complete DMEM (15 mL) was added to 
inactivate the Trypsin and cells were transferred to a falcon tube. The required dilution of cells was 
added back to the tissue culture flask.  
 
Cells required for experiments were also taken during cell passage. The number of cells required 
for seeding was determined with the use of a haemocytometer. For the experiments, cells were 
either seeded in 96-well plates with flat bottoms and a lid (Greiner
® Cellstar
®) or 6-well plates with 
flat bottoms and a lid (Greiner
® Cellstar
®). 
 
Growth Inhibition 
Growth  inhibition  experiments  were  carried  out  to  evaluate  the  potency  of  anacardic  acid, 
anacardic acid analogues and the azumamides using an in vitro cell assay. The potency of these 
compounds was investigated by analyzing inhibition of cell growth using a CyQUANT® Cell 
Proliferation Assay Kit (Molecular Probes
®
, USA). This assay provides a simple procedure for 
measuring the density of adherent cells in culture by measuring the fluorescence emitted from 
green CyQUANT GR dye which intercalates to nucleic acids. The fluorescence emitted from the  
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green dye is indicative of the cell number. A dose response can be plotted by comparison of the 
number of treated cells to untreated cells.  
 
Growth Inhibition Procedure 
This applies to all adherent cell lines. Cells (1 x 10
3 /100 µL/well) from the chosen cell line were 
seeded in a 96-well plate in duplicate for each drug treatment and control. Cells were left to adhere 
to the wells (5 h at 37 °C) before being treated with compound solution (100 µl/ well). After 
treatment the cells were left to incubate at 37 °C for six days. On the sixth day, the growth medium 
was removed by blotting and the cells were gently washed with phosphate buffered saline (PBS, 
Appendix A). The plate was frozen immediately at -70 °C for a minimum of one hour.  
 
To measure the effect of the treatment conditions, the CyQUANT® Cell Proliferation Assay Kit 
for cells in culture was used. The cells were thawed and CyQuant GR dye/cell-lysis buffer (200 
µL) made according to the manufacturer’s instructions was added to the microplate wells. The plate 
was left to incubate at room temperature for 5 mins in the dark. The sample fluorescence was 
measured using Cytofluor II Fluorescence Multiwell Plate Reader and Cytofluor II software with 
filters at 480 nm for excitation and 520 nm for emission maxima.  
 
The percentage cell number was obtained by expressing the fluorescence values as a percentage of 
the  fluorescence  values  obtained  for  untreated  cells.  The  average  cell  number  for  each 
concentration is then plotted as a sigmoidal dose response curve using GraphPad Prism software 
version 4.03.  
 
Growth Inhibition Conditions 
 
Cell Line Evaluation 
A  range  of  cell  lines  from  different  origins  were  investigated.  The  cell  lines  included  MCF7 
(breast),  PANC1  (pancreas),  PC3  (prostate)  and  HCT116  (colorectal)  cells.  The  potency  of 
anacardic acid towards all four cell lines was assessed and the most sensitive cell line was selected 
for further experiments.  
 
Anacardic acid (Appendix A) concentrations used were 1000, 500, 250, 125, 62.5, 31.3, 15.6, 7.8, 
3.9, 2.0 and 0.9 µM (100 µL /well) and these were prepared by making serial dilutions in DMEM. 
Two controls were also carried out in duplicate, untreated cells and one in which the cells were 
treated with the maximum amount of DMSO used in a given sample. 
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Compound Screening of Anacardic acid analogues 
The growth inhibition experiment was carried out in the more sensitive MCF7 cell line to screen 
anacardic acid and analogues at a single concentration.  
 
Up to eighteen compounds were tested in triplicate per plate. Two controls per plate were also 
carried out, one where the cells were left untreated and the second where the cells were treated with 
maximum amount of DMSO used in a given sample. The treatment dosage for all the compounds 
except KC_20 was 250 µM which could was only soluble in DMSO at 10 mM and not 100 mM. 
Solutions were prepared by dissolving 4 µL of 50 mM stock solution (Appendix A) in 400 µL 
DMEM to give 500 µM. The cells were treated (100 µL /well) to give a final concentration of 250 
µM. The treatment dosage for KC_20 was 50 µM; since the most concentrated stock available was 
10 mM and the conditions require that the percentage of DMSO is kept consistent. 
 
IC50 Determination of Anacardic acid analogues 
Growth  inhibition  experiments  were  carried  out  to  determine  the  IC50  of  the  compounds  that 
resulted in more than 50 % growth inhibition at a concentration of 250 µM as determined from 
previous compound screening experiment. Each experiment was repeated to give an average IC50.  
 
Treatment dosages used were taken from the range 1000 to 1.0 µM and these were prepared by 
making serial 2 or 4 fold dilutions of the compound (100 mM aliquots, Appendix A) in DMEM. 
Two controls were also carried out in duplicate, one where the cells were left untreated and the 
second where the cells were treated with maximum amount of DMSO used in a given sample. 
 
IC50 Determination of the Azumamides 
Growth inhibition experiments were carried out to determine the IC50 of the azumamides.  
 
Equipotent azumamide treatments were used and these were prepared by making serial dilutions 
using 100 mM stock aliquots (Appendix A). The concentration ranged from 100 µM to 10 nM of 
which 10 concentration points were tailored for each azumamide. Two controls were also carried 
out in duplicate, one where the cells were left untreated and the second where the cells were treated 
with the maximum amount of DMSO used in a given sample. 
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Western Blotting 
To explore the effect of anacardic acid and analogues at the protein level, western blotting was 
employed to detect acetylated proteins in MCF7 cells. Using this method, specific proteins related 
to histone acetylation can be identified from the total cell lysate by separating proteins according to 
molecular weight on a polyacrylamide gel. The proteins are transferred (blotted) onto nitrocellulose 
membrane for easier handling and manipulation. After blotting, the target protein is labelled with a 
primary antibody designed to bind to the protein of interest. Secondary antibodies conjugated to an 
enzyme called horse radish peroxidise (HRP) are used to bind to the primary antibody-protein 
complex. The HRP conjugate reacts with a detection reagent to generate chemiluminescence which 
is  amplified  by  an  enhancer.  An  image  acquisition  system  can  be  used  to  detect  the 
chemiluminescent signal and hence determines qualitatively the expression levels of the target 
protein in the experimental samples.  
 
Western Blotting Procedure 
After treatment using the defined experimental conditions the growth media was removed from the 
wells. PBS (1 mL) was added to each well. The cells were harvested by scraping the adherent cells 
of the well surface. The cell samples were transferred to 1.5 ml eppendorfs and centrifuged for 1 
min at 4 °C in a Heraeus
® FRESCO Microcentrifuge (3427 g). The lysate supernatant was removed 
and  the  cell  pellets  were  re-suspended  in  1x  sample  buffer  containing  DTT  (Cell  Signalling 
Technology, Danvers, MA). The cell pellets were sonicated (Soniprep 150 MSE) and the cell 
debris boiled at 94 ºC for 5 minutes along with the protein marker (#P7709, New England BioLabs, 
Ipswich, MA). 
 
Polyacrylamide Gel Electrophoresis (PAGE) and Blotting 
Ready made 4-15% Tris-HCl polyacrylamide 12 lane gels (BioRad) were assembled into a Mini-
PROTEAN 3 Cell unit (BioRad) and submerged with 1x running buffer (Appendix A). The protein 
samples (15 µl) was loaded into the wells alongside protein marker (5 µl) flanking the side of the 
well. Gel electrophoresis was carried out at 200 V for 40 minutes. At the end of the electrophoresis 
run, the gel was laid over Protran nitrocellulose blocking membrane (Schleicker and Schuell) and 
sandwiched  between  two layers  of  Whatmann  paper  (Whatmann  PLC,  Kent,  UK)  and  sponge 
(BioRad Laboratories). 
 
The whole sandwich was assembled into the Mini-PROTEAN 3 Cell unit and filled with protein 
transfer buffer (Appendix A). Protein transfer was carried out at 100 V for 1 hour. At the end of the 
run the nitrocellulose membrane was removed and washed with distilled H2O. 
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Labelling 
An  anti-acetyl-histone  H4  antibody  probe  was  used  to  test  for  histone  acetylation  and  a 
proliferating cell nuclear antigen (PCNA) antibody probe was used as a standard. Before blocking 
the specific antibody binding sites, the nitrocellulose membrane was cut into two pieces at approx 
25 kDa. The piece of nitrocellulose membrane containing proteins above 25 kDa was used to blot 
for PCNA. The second piece of nitrocellulose membrane containing proteins below 25 kDa was 
used to blot for acetylated histone H4.  
 
Saturation of non-specific antibody sites was achieved by incubating the nitrocellulose membrane 
with 3-5 % (w/v) solution non fat milk (Marvel) in 5 ml of TSTween20 (TST, Appendix A) or PBS 
for 30 minutes. The antibodies and their corresponding blocking agent are listed in Appendix A. 
After blocking each nitrocellulose membrane piece was incubated with its corresponding primary 
antibody overnight at 4 °C i.e. the > 25 kDa nitrocellulose membrane was incubated with PC10 in 
3% TS milk for PCNA.  
 
Before incubation with the secondary antibodies, the nitrocellulose membranes were washed. PBS 
milk was washed off twice with distilled H2O. TST milk was washed off thrice with TSTween20. 
Incubation with the corresponding secondary antibodies was then carried out in their respective 
non-fat milk solutions (Appendix A) for 1 hour. After 1 hour, the membrane was washed according 
to the antibody solution. PBS milk was then washed away five times with distilled H2O, once with 
PBSTween20 (Appendix A) and a final five times with distilled H2O. TST milk was washed off 3 
times with TSTween20 for 5 minutes a time.  
 
Detection 
In  order  to  detect  the  bound  immuno-complexes,  a  Supersignal  West  Pico  Chemiluminescent 
solution (Pierce, Thermo Fisher Scientific Inc, Rockford, IL) of peroxide (2 ml) and enhancer (2 
ml) was prepared using the manufacturer’s kit. The nitrocellulose membranes were soaked in the 
Supersignal solution for 5 minutes. The chemiluminescence was detected using the Flour-S Max 
MultiImager and an image of the blot was taken using the BioRad Quantity One program. A 
qualitative assessment of acetylated protein levels was then made from the digital images. 
 
Western Blotting Conditions 
 
HDAC inhibitor Concentration 
An experiment was set up to determine the minimum concentration of SAHA needed to observe 
acetylated histone H4 on a western blot.  
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Seven wells were seeded with MCF7s (1x10
6 cells/ 2 mL growth medium/ well). The cells were 
left to adhere to the wells for 5 h at 37 °C.  Two control wells were set aside for 0.5 % DMSO 
treatment  and  untreated  MCF7  cells.  The  remainder  of  the  cells  were  treated  with  decreasing 
concentrations of SAHA. The concentrations of SAHA used were, 5, 4, 2, 1 and 0.5 µM. The cells 
were treated for a total of two hours at 37 °C. 
 
Effect of SAHA and Anacardic Acid on Histone Acetylation 
An experiment was set up to investigate whether HAT inhibitor and HDAC inhibitor antagonise 
each other. A fixed concentration of SAHA was used in each sample along with varying amounts 
of the HAT inhibitor anacardic acid.  
 
Eight wells were seeded with MCF7s (5x10
5 cells/ 2 mL growth medium/ well). The cells were left 
to adhere to the wells for 5 h at 37 °C.  Four control wells were established, one untreated, one 
DMSO treated, 0.5 µM SAHA, and 100 µM anacardic acid. The remaining wells were subjected to 
an anacardic acid dose response in a fixed concentration of SAHA. The concentrations of anacardic 
acid used were 100, 50, 25 and 12.5 µM. Twice concentrated compound stocks were prepared in 
DMEM media and diluted 2-fold into the experimental wells. The cells were treated for a total of 
two hours at 37 °C. 
 
p21 Promoter Assay 
It has been demonstrated that the HDAC inhibitor SAHA induces cell cycle arrest and apoptosis in 
MCF7 cells via up-regulation of the cyclin-dependent kinase (CDK) inhibitor p21
136. The purpose 
of this experiment was to investigate whether anacardic acid and analogues also influences p21 
programmed cell cycle arrest. In this assay, MCF7 breast cancer cells were transfected with a 
luciferase reporter vector coupled with a p2l promoter to enhance the level of p21 expression to the 
extent that p21 presence is artificial but measurable. The Bright-Glo
TM luciferase assay system 
(Promega)  was  used  in  conjunction  with  the  p21  promoter  assay  in  order  to  quantify  p21 
expression (Figure 4.1).  
 
The luciferase reporter vector carries the luciferase gene (luc) followed by the SV40 intron and 
early polyadenylation (polyA) signals. Transcription enzyme sites in the vector allow the gene of 
choice to be inserted and in this experiment the p21 promoter gene was inserted into a pGL2 vector 
to create the p21 del BST plasmid
137. Transfection of the plasmid in MCF7 cells was performed 
with Transfast™ transfection reagent, a cationic liposome designed for transporting DNA to the 
cell nucleus. After successful transfection the cells are incubated with a HDAC inhibitor, a HAT 
inhibitor or both. The HDAC inhibitor SAHA is expected to induce p21 expression with respect to 
background level of p21. After overnight treatment, the Bright-Glo™ Luciferase Assay System 
was used to measure the level of p21 present in the MCF7 cells. Firefly luciferase is a commonly  
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used  bioluminescence  reporter.  The  enzyme  catalyses  a  two  step  oxidation  reaction  of  beetle 
luciferin into oxyluciferin which also yields a short burst of light. This enzymatic reaction produces 
a sustained level of luminescence which can be detected by a luminometer. 
 
 
  
Figure 4.1: A schematic diagram portraying the p21 promoter assay 
 
p21 Assay Procedure 
The  Transfast™  transfection  reagent  (Promega)  and  Bright-Glo™  Luciferase  Assay  System 
(Promega) were used according to the manufacturer’s instructions. White flat bottomed 96 well 
plates (Greiner Bio-One Ltd) were used for seeding the transfected cells, and to carry out the 
Bright-Glo
TM Luciferase assay. The outside wells of the plate are not used as evaporation affects 
the assay. Assay controls included a non-transfection control which involved adding transfection 
reagent and no DNA during the transfection step. The positive controls in the assay can include any 
known HDAC inhibitor, such as TSA, SAHA or FK288. Plasmid p21 del BST (aka WWP-luc) was 
supplied by Vogelstein B, The Oncology Centre and Program in Human Genetics and Molecular 
Biology, Johns Hopkins University School of Medicine, Baltimore
137. 
 
Transfection 
MCF7 cells (3x10
6/ 15 mL) were plated in two greiner cellstar 10 cm dishes and incubated at 37 ºC 
overnight. The Transfast™ transfection reagent must be diluted with nuclease free water according 
light 
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to the manufacturer’s instructions the day before transfection and stored at – 20 °C overnight. The 
following day, the cells were transfected with the luciferase reporter vector; p21 del BST or pGL2 
(Promega, UK). A transfection mixture of serum free media (6 ml), plasmid (4 µg DNA) and 
Transfast
TM  transfection  reagent  (90  µl)  was  prepared  by  mixing  the  reagents  together  and 
incubating at RT for 12 minutes. For the non-transfected control cells, a solution of serum free 
media (6 ml) and Transfast
TM transfection reagent (90 µl) was prepared.  The cells are washed with 
serum free media before the transfection reagent was added to the cells and incubated for 2 hours at 
37 ºC.  The transfection reagent was removed and replaced with 15 ml complete media and the 
cells were incubated for 24 hours at 37 ºC.  
 
Treatment 
The following day, untreated and p21/pGL2 transfected MCF7 cells (2000/ 50 µl) were plated in 
white 96 well plates. The cells were left to adhere for 5 hours at 37 °C.  The cells were treated with 
their respective sample solutions (50 µL) for 24 hours.  
 
Luciferase Reporter Assay 
The firefly luciferase activity was quantified by adding Bright-Glo™ (100 µL) to the experimental 
wells. The plate was shaken for 2 minutes and then incubated in the dark for 10 minutes before the 
luminescence was measured using the luminometer (VARIOSKAN FLASH READER). 
 
p21 Assay Conditions 
 
Compound Screening of Anacardic acid and analogues 
An experiment was designed to investigate whether the known HAT inhibitors anacardic acid and 
KC_19 can repress expression of p21 in the presence or absence of SAHA. SAHA induces p21 
expression and in turn causes apoptosis. Anacardic and KC_19 both inhibit the HAT PCAF and 
exhibit cytotoxic effects. These two compounds were chosen to investigate whether the cytotoxic 
effects observed are linked to p21 regulation. In addition to KC_19 a selection of analogues that do 
not inhibit the histone acetyltransferase PCAF at 100 µM but inhibit MCF7 cell growth were also 
profiled.  
 
The  compounds  profiled  were  KC_21,  KC_23,  KC_39,  and  KC_41.  Two  different  treatment 
dosages of 100 µM compound and 100 µM compound plus 1.0 µM SAHA were used. The 100 µM 
compound sample solutions in growth media were prepared from 50 mM stocks (Appendix A) to 
give 200 µM which was then diluted 2-fold in the experimental well. The 100 µM compound plus 
1.0 µM SAHA sample solutions were prepared from 50 mM stocks diluted in 2.0 µM SAHA 
solution  to  give  200  µM.  SAHA  solutions  were prepared  from  1  mM  aliquots (Appendix  A). 
Control experimental wells consisted of 1.0 µM SAHA control and a 0.6 % DMSO control.  
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Dose Response Profile of Anacardic Acid 
A dose response profile of anacardic acid in the presence of 1 µM SAHA was developed to assess 
whether  p21  expression  fluctuates  with  a  change  in  anacardic  acid  concentration.  The  dose 
response profile was evaluated in p21 del BST transfected MCF7 cells. An identical experiment 
was conducted in pGL2 transfected cells as a control. The dose response ranged from 100 µM to 1 
nM anacardic acid. The treatment solutions in growth media were prepared by making serial 10-
fold dilutions into 2 µM SAHA. A 1.0 µM SAHA control and a 0.6 % DMSO control were also 
included. 
 
Enzyme Assays 
 
Radioactive HAT Assay 
An in vitro radioactive HAT flash plate assay was used to investigate inhibition of the HAT PCAF 
by anacardic acid and analogues
132. The assay utilizes scintillation proximity counting to measure 
the level of acetylated histone. The flash-plate is coated with a solid scintillant which is excited 
when tritium molecules are in close proximity (Figure 4.2). The assay is very straightforward, 
histone substrate, [
3H]-acetyl-CoA, and PCAF are incubated with or without compound for 30 
minutes at room temperature. After the enzyme has catalysed the transfer of [
3H]-acetyl groups to 
the  histone  molecules,  a  scintillation  signal  is  generated.  Unreacted  [
3H]-acetyl-CoA  does  not 
generate a scintillation event, hence the total activity of the enzyme can be assessed.  
 
 
 
Figure 4.2:  A schematic diagram portraying the basics for a scintillation event in the 
radioactive flash plate HAT assay   
 
Radioactive HAT Assay Procedure 
This experimental procedure is based on the published conditions provided by Aherne et al
132. All 
reagents were procured from Sigma Aldrich unless otherwise stated. The radioactive HAT flash 
plate assay was modified for use in basic 96-well flash-plates (SMP200, Perkin Elmer Life 
Sciences) with a total assay volume of 40 µL/ well. The GST-tagged PCAF HAT domain was 
synthesised by Patrick Duriez, Cancer Research UK Clinical centre, University of Southampton 
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Medical School. The prepared enzyme was provided as 1 mg/ml aliquots in HAT assay buffer 
(Appendix A) and stored at – 70 ºC.   
 
The enzyme concentration required for optimum conditions was determined before use by running 
a series of experiments to measure the total activity for a range of enzyme concentrations. The 
concentration of histone and acetyl-CoA has been previously optimised by Rowlands, M et al. and 
are the approx Km values
132.  
 
To each flash plate well was added compound (10 µL in 4 % DMSO solution), histone extract (10 
µL, 2.5µg Sigma Type III-S) and acetyl-CoA (10 mL, 1.48 µM & 0.015µCi, Perkin Elmer Life 
Sciences). The reaction was started by the addition of the PCAF protein (10 µL, 1µg protein) and 
the plate incubated at room temperature for 30 mins. The reaction was stopped by adding 150 µL 
of assay buffer and after mixing, the plate was read on a microplate scintillation counter (A9912V 
TOPCOUNT, PACKARD). 
 
Radioactive HAT Assay Conditions  
 
Compound Screening of Anacardic acid and analogues 
A  screening  experiment  was  carried  out  to  screen  the  forty  four  anacardic  acid  analogues  in 
triplicate at 10 µM and 100 µM and compare to anacardic acid.  
 
Anacardic acid and the analogues were dissolved in DMSO to give a concentration of 10 mM and 
dilutions were made in the assay buffer to give 40 and 400µM solutions in 4% DMSO (v/v). These 
were subsequently diluted four-fold in the experimental well.   
 
IC50 Determination 
Experiments  were  carried  out  to  determine  the  IC50  of  compounds  that  showed  significant 
inhibition of PCAF at 10 µM.  Each compound was tested at a concentration range of 400 µM to 1 
µM depending on the compounds potency. Anacardic acid and the analogues were dissolved in 
DMSO to give a concentration of 20 mM and dilutions were made in the assay buffer to give 800 
µM solutions followed by subsequent 2-fold dilutions in 4% DMSO (v/v) to give a concentration 
range.  
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Xanthine Oxidase Assay 
This assay measures the generation of superoxide anion via the reduction of yellow nitro blue 
tetrazolium dye to an insoluble blue formazan (Figure 4.3). The superoxide anions are generated 
via  the  xanthine  oxidase  oxidation  of  xanthine  to  uric  acid.  The  assay  is  simple  to  execute, 
xanthine, bovine serum albumin, nitro blue tetrazolium dye are added in assay buffer to a plastic 
cuvette or 96-well plate. The enzyme reaction is initiated by the addition of xanthine oxidase at 
room temperature. The change in absorbance at 560 nm is then measured for 90 seconds
117.  
 
 
 
Figure 4.3:  A diagram showing the reduction of tetrazolium to formazan by the superoxide 
anion. 
 
Xanthine Oxidase Assay Procedure 
This is experimental assay is based on a procedure published by Masuoka et al
117. All reagents 
were procured from Sigma Aldrich unless otherwise stated.  
 
Xanthine oxidase (20 mg / ml) was dissolved in assay buffer (Appendix A) and aliquots were 
stored at -70°C. Xanthine substrate aliquots (10 mM) were prepared by dissolving in 1M NaOH 
(50 mg / ml) and sterile water. Nitro blue tetrazolium tablets were dissolved in sterile water to 
prepare a stock solution (10 mg tablet/ mL) which could be kept at 4° C for one week. The BSA 
was prepared fresh each time by dissolving in assay buffer.   
 
Cuvettes 
To a plastic cuvette was added assay buffer (1350 µL), xanthine (30 µL, 10mM), sample solution 
in DMSO (30 µL), 0.5 % bovine serum albumin (15 µL) and nitro blue tetrazolium (15 µL, 2.5 
mM). The background colour of the cuvette was subtracted before addition of xanthine oxidase (60 
µL). The total reaction volume was 1.5 ml. A kinetics profile was set up to measure the absorbance 
at 560 nm at 5 second intervals for 90 seconds on the UV spectrometer (UV-1700 PharmaSpec). 
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Control  experiments  were  carried  out  by  replacing  sample  solution  with  the  same  amount  of 
DMSO. 
 
96 well plate 
For each experimental well a reaction mixture of assay buffer (405 µL), xanthine (9 µL, 10 mM), 
sample solution in DMSO (9 µL), 0.5 % bovine serum albumin (4.5 µL) and nitro blue tetrazolium 
(2.5  µL,  4.5  mM)  was  prepared.  The  enzyme,  xanthine  oxidase  (8  µL)  was  added  to  each 
experimental well apart from the experimental blanks to which assay buffer (9 µL) was added. The 
reaction mixture was added to each well to initiate the enzyme reaction. A kinetics profile was set 
up using SkanIt Software 2.4.3 RE to shake the plate for 5 seconds before recording the absorbance 
at 560 nm at regular intervals during a fixed time period on the UV spectrometer (Varioskan 
Flash).  
 
Xanthine Oxidase Assay Conditions  
 
Reaction Volume 
The first experiment investigated the optimum reaction volume. First the reaction was trialled in a 
plastic cuvette and then it was scaled down six-fold for use in a 96-well plate.  
 
The experiment was carried out as described in the assay protocols using xanthine oxidase (3.33 
mg /mL) and DMSO was used in place of the sample solutions. The change in absorbance of blue 
formazan was measured over a 90 second time period.  
 
Enzyme Concentration 
This  experiment  was  designed  to  measure  the  total  activity  of  xanthine  oxidase  at  a  range  of 
concentrations at 30 second intervals over a time period of 900 seconds.  
 
The enzyme concentrations used were 2 mg/ml, 1 mg/ml, 0.5 mg/ml and 0.25 mg/ml. The enzyme 
solutions were prepared by diluting the xanthine oxidase (20 mg/ml) stock aliquot in assay buffer. 
DMSO was used in place of the sample solutions. A blank control with no added enzyme was also 
included. Each sample was carried out in duplicate and the average change in absorbance for each 
concentration was plotted against time. The data was fixed using a linear line of regression to 
calculate the slope which equates to the change in absorbance. The velocity was calculated from 
the change in absorbance of blue formazan (560 nm) over 900 seconds for each concentration of 
enzyme. 
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Compound Screening 
A screening experiment was carried out to screen the forty four analogues plus anacardic acid at 
100 µM.  
 
Anacardic  acid  and  analogues  (10  mM,  appendix  A)  were  dissolved  in  DMSO  to  give  a 
concentration of 5 mM of which 9 µL diluted 50 fold in the reaction mixture to give 100 µM. The 
concentration of xanthine oxidase used was 2 mg/ml. The change in absorbance of blue formazan 
(560 nm) was measured at 10 second intervals over 300 seconds for each sample. To minimize 
experimental error, four compounds were screened a row at a time alongside a total activity and a 
blank control. Each sample was carried out in triplicate and the average change in absorbance for 
each concentration was plotted against time. The data was fixed using a linear line of regression to 
calculate the slope which equates to the change in absorbance. The inverse reciprocal of the slope 
was  calculated  for  each  sample  and  was  expressed  relative  to  the  total  enzyme  activity.  The 
anacardic acid used was supplied by AXXORA. For each compound to be tested, aliquots of 50 
mM were prepared in DMSO and stored at -70°C. 
 
IC50 Determination 
The dose response of anacardic acid and any potential analogues on the total activity of xanthine 
oxidase was investigated for a range of concentrations. A maximum of eight concentration points 
with 1.2-fold intervals were used. The concentration range for both compounds was 120 to 33.5 
µM. Compounds were dissolved in DMSO to give a concentration of 6 mM and 50 fold dilutions 
were made into the reaction mixture to give 120 µM solutions followed by subsequent 1.2-fold 
dilutions to give a concentration range. The anacardic acid used was supplied by AXXORA. For 
each compound to be tested, aliquots of 50 mM were prepared in DMSO and stored at -70°C. To 
minimise experimental error, four concentration points were screened in duplicate a row at a time 
alongside a total activity and a blank control.  
 
Luciferase Counter Screen 
A  luciferase  screen  was  undertaken  to  identify  whether  anacardic  acid  or  analogues  inhibits 
luciferase and hence exhibits non specific activity.  A simple counter screen was set up to measure 
firefly luciferase activity by use of yellow luminescence. The yellow luminescence is a result of the 
oxidation  of  a  luciferyl-adenylate  intermediate  formed  from  the  luciferase  catalysed 
phosphorylation of luciferin. All reagents were supplied by Sigma Aldrich unless stated.  
 
Luciferase from firefly (1 mg / ml) was dissolved in luciferase storage buffer (Appendix A) and 
aliquots were stored at -70°C for six weeks maximum. The luciferase assay reagent (Promega, UK) 
was used as supplied by the manufacturer.   
  
 
163 
Luciferase Counter Screen Procedure 
Luciferase (10 µL of 10 µg/ml) was incubated in the presence or absence of compound (10 µL in 
lysis  buffer)  for  five  minutes  before  the  addition  of  luciferase  assay  reagent  (100  µL).  The 
luciferase activity was measured as luminescence in a luminometer (Varioskan Plate Reader). The 
average  luminescence  was  calculated  for  each  sample  and  expressed  as  a  percentage  of  the 
luminescence observed for the total enzyme activity with no added inhibitor. 
 
Luciferase Counter Screen Conditions 
A screening experiment was carried out to screen forty four compounds plus anacardic acid in 
duplicate at 100 µM alongside a total enzyme activity and DMSO control. Anacardic acid and 
analogues (50 mM, Appendix A) were dissolved in luciferase lysis buffer to give a concentration of 
200 µM which was diluted 2 fold in the reaction mixture to give 100 µM. The maximum amount of 
DMSO present in the assay at any time was 1 % (v/v).  
 
HDAC Fluor de Lys
® Fluorescent Assay 
This  assay  is  designed  to  measure  inhibition  of  histone  deacetylase  activity  from  HeLa  cell 
extracts. The HDAC fluorescent activity assay kit (BIOMOL
®, Exeter, UK) contains a unique 
Fluor  de  Lys
®  substrate  and  developer  combination.  Deacetylation  of  the  histone  substrate  by 
HDAC enzymes contained within the provided HeLa extract sensitises the histone substrate to the 
developer which then generates a fluorophore (Figure 4.4). The fluorophore is excited upon contact 
with light and the emitted light frequency is detected on a fluorometric plate reader. Introducing an 
HDAC inhibitor to the assay will inhibit deacetylation of the histone substrate and hence reduce the 
fluorescence signal. 
 
Figure  4.4:    A  schematic  diagram  explaining the  principles  of the HDAC  Fluor  de  Lys
® 
Fluorescent Assay 
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HDAC Fluor de Lys
® Fluorescence Assay Procedure 
The in vitro assay was performed according to the manufacturer’s instructions. All reagents and 
buffers were supplied with the assay kit unless otherwise stated. HeLa nuclear extract was prepared 
by 30 fold dilution in assay buffer. The Fluor de Lys
® substrate was diluted 100 fold in assay buffer 
to make a 2x concentration of 500 µM.  The azumamide solutions were prepared in assay buffer. 
The HDAC assay reactions were stopped using an excess of trichostatin A (TSA), a potent HDAC 
inhibitor contained within the developer. To prepare the developer solution, the Fluor de Lys
® 
developer solution was diluted 20-fold in assay buffer, followed by 100 fold dilution of trichostatin 
A (0.2 mM) into the developer solution.  All reagents were kept on ice until use.   
 
The assay was performed by adding the reagents in the following order; azumamide or DMSO 
solution (10 µL) was added to relevant wells apart from the HeLa and blank wells. HeLa extract 
(15 µL) was added to all the wells except blank wells. To equalise the reaction volumes, assay 
buffer (10 µL) was added to the HeLa weeks and 25 µL of buffer was added to the blank wells. 
The plates were incubated at 37°C for 15 minutes before addition of Fluor de Lys
® substrate (25 
µL) to each well. The assay plate was incubated for a further hour at 37°C. The reaction was 
stopped by addition of developer solution (50 µL). The plate was incubated for 10 minutes to allow 
development of the fluorophores at room temperature and the fluorescence signal was detected 
using a fluorometric plate reader with 360/460 filters. Inhibition of HDAC activity was determined 
for mean values of duplicate samples as a percentage of untreated samples. Non-linear regression 
was performed using GraphPad Prism Software version 4.03 to determine an IC50. 
 
HDAC Fluor de Lys
® Fluorescence Assay Conditions 
 
IC50 Determination 
In vitro experiments were carried out to assess the potency of the azumamides towards HDACs and 
hence derive the IC50. A dose response profile containing five concentration points was tested for 
each  azumamide.  The  concentrations  used  were  determined  by  trial  experiments  to  a  find  the 
optimum concentration range that includes the IC50. The maximum azumamide concentration used 
was 10 µM and compounds which did not cause more than 50 % HDAC inhibition were deemed 
not potent.  
 
Azumamide  solutions  were  prepared  from  10  mM  stock  aliquots  (Appendix  A)  which  were 
dissolved in assay buffer to create solutions 5x more concentrated than the final experimental 
concentration. A DMSO control was also run using the maximum amount of DMSO used for each 
dose response profile. Other controls included a HeLa control with no added treatment and a blank 
control containing no HeLa or compound or DMSO.  
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Appendix A 
 
Compounds 
Anacardic acid was supplied by AXXORA, UK. Aliquots of 100, 50, 20 10 and 1 mM were 
prepared in DMSO and stored at -70 °C. 
 
SAHA was supplied by Alexis Biochemicals, now Enzo Life Sciences. Aliquots of 1 mM were 
prepared in DMSO and stored at -70 °C. 
 
The azumamides were synthesised by Wen et al
138.  Aliquots of 100 mM and 10 mM were prepared 
in DMSO and stored at -70 °C. 
 
Anacardic acid analogues were synthesised as outlined in the synthesis section. Aliquots of 100 
mM, 20 mM and 10 mM were prepared in DMSO and stored at -70 °C. 
 
All antibodies were obtained from Millipore formerly Upstate cell signalling solutions. 
 
Media and Buffers 
All materials provided by Sigma Aldrich unless otherwise stated.  
 
Complete Dulbecco’s modified Eagle’s medium (DMEM) 
•  500 ml DMEM (Lonza Group Ltd) 
•  50 ml Fetal Calf Serum (FCS, PAA Laboratories) 
•  2 mM L-Glutamine (Lonza Group Ltd) 
•  50 U/ml Penicillin (Lonza Group Ltd) 
•  50 U/ml Streptomycin (Lonza Group Ltd) 
 
Phosphate Buffered Saline (PBS) 
•  125 mM NaCl 
•  16 mM Na2HPO4 
•  10 mM KH2PO4 
•  pH 7.3 
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HAT assay buffer 
•  50 mM Tris 
•  150 mM NaCl 
•  10 % glycerol 
•  pH 8.0 
 
SDS Sample Buffer 
•  500 µl 3x SDS Sample Buffer Red (Cell Signalling Technology)  
•  50 µl DTT (Cell Signalling Technology) 
•  950 µl deionised H2O  
 
10 x Protein Running Buffer 
•  1 L solution in deionised H2O 
•  30.2 g Tris-base 
•  144 g glycine 
•  10 g SDS 
 
1 x Protein Running Buffer 
•  200 ml 10x protein running buffer 
•   1800 ml deionised H2O 
 
Protein Transfer Buffer 
•  1 L solution in deionised H2O 
•  200 ml 10 x protein running buffer 
•  500 ml EtOH 
 
PBS Tween20 
•  PBS + 0.1% v/v Tween 20 
 
TS Tween20 (TST) 
•  TS buffer + 0.005% v/v Tween 20 
 
TS Buffer 
•  10   mM Tris-HCl 
•  150 mM NaCl 
•  pH 8  
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Xanthine Oxidase assay buffer 
•  0.1 mM EDTA 
•  40 mM Na2CO3 
•  pH 10 
 
Luciferase Lysis Buffer 
•  10 mM Tris-HCl 
•  1 mM EDTA 
•  150 mM NaCl 
•  0.65 % (w/v) IGEPAL 
•  pH 8.0 
 
Luciferase Storage Buffer 
•  100 µg/ml BSA 
•  0.05 M Tricine Buffer 
•  10 mM MgSO4 
•  1 mM EDTA 
•  1 mM DTT 
 
Tricine Buffer 
•  1 M Tricine 
•  1 M MgSO4 
•  0.5 M EDTA 
•  1.25 M DTT (Cell Signalling Technology) 
•  1 mg/ml BSA 
 
HDAC assay buffer (BIOMOL
®) 
•  50mM Tris-HCl 
•  137mM NaCl 
•  2.7mM KCL 
•  1 mM MgCl2 
•  pH 8.0  
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Antibodies 
 
All antibodies were obtained from Millipore formerly Upstate cell signalling solutions. 
 
Protein 
 
Primary Antibody  Dilution  Secondary Antibody  Dilution  Buffer 
PCNA  PC10  1:1000  Anti-mouse  1:5000  3% TST milk 
Ac Histone H4  Anti Ac H4  1:1000  Goat-anti rabbit  1:5000  5% PBS milk 
 
A table containing the antibodies used for Western blotting, their respective dilutions and buffers 
 
Appendix B 
 
1H NMR spectra of all novel compounds are shown in the following section. NMR data were 
recorded on a Bruker AV300/1 NMR spectrometer (operating at 300 MHz for 
1H and at 75 MHz 
for 
13C)  or  a  Bruker  DPX400/1  NMR  spectrometer  (400  MHz  for  1H).  NMR  samples  were 
dissolved in CDCl3 or MeOD with tetramethylsilane as an internal standard. Each spectrum was 
processed using ACD/1D NMR Manager (ACD Labs, Version 12.01). 2-Benzyl-6-pentadecyl-benzoic acid methyl ester (5)
Acquisition Time (sec) 1.9923 Comment KC4494-49P1 Date 14 Mar 2006 20:35:12
Date Stamp 14 Mar 2006 20:35:12 File Name E:\The Last Hurdle\QR1 to TR NMR files\ma1406lw1\ma1406lw1_010000fid
Frequency (MHz) 400.13 Nucleus 1H Number of Transients 16 Origin spect Original Points Count 16384
Owner jms Points Count 65536 Pulse Sequence zg Receiver Gain 57.00 SW(cyclical) (Hz) 8223.68
Solvent CHLOROFORM-d Spectrum Offset (Hz) 2413.3662 Sweep Width (Hz) 8223.56 Temperature (degree C) 27.000
O
O
O
ma1406lw1_HNMR.esp
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y(2, 2-Dimethyl-4-oxo-4H-1,3-benzodioxin-5-yloxy)-acetic acid (KC_01)
Acquisition Time (sec) 2.7329 Comment KC/4494/73_P1 Date 22 Jan 2007 13:47:44
Date Stamp 22 Jan 2007 13:47:44
File Name D:\KRYSTLE CAREY\MY DOCUMENTS\THE LAST HURDLE\CHEMISTRY DATA\QR1 TO TR NMR FILES\JA2207KLC1\10\PDATA\1\1r
Frequency (MHz) 300.13 Nucleus 1H Number of Transients 16 Origin av300
Original Points Count 16384 Owner nmr Points Count 16384 Pulse Sequence zg30
Receiver Gain 645.10 SW(cyclical) (Hz) 5995.20 Solvent CHLOROFORM-d Spectrum Offset (Hz) 1497.8611
Spectrum Type STANDARD Sweep Width (Hz) 5994.84 Temperature (degree C) 27.160
O O
O
CH3 C H3
O
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O
JA2207KLC1 HNMR.esp
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y(2,2-Dimethyl-4-oxo-4H-1,3-benzodioxin-5-yloxy)-acetic acid methyl ester (KC_02)
Acquisition Time (sec) 2.7329 Comment KC/4494/84_P Date 28 Feb 2007 02:59:12
Date Stamp 28 Feb 2007 02:59:12
File Name d:\Krystle Carey\My Documents\The Last Hurdle\Data\Chemistry Data\2007 NMR Files\fe2707klc2\10\PDATA\1\1r
Frequency (MHz) 300.13 Nucleus 1H Number of Transients 16 Origin av300
Original Points Count 16384 Owner nmr Points Count 16384 Pulse Sequence zg30
Receiver Gain 645.10 SW(cyclical) (Hz) 5995.20 Solvent CHLOROFORM-d
Spectrum Offset (Hz) 1497.8611 Spectrum Type STANDARD Sweep Width (Hz) 5994.84 Temperature (degree C) 27.160
O O
O
O
O
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O
CH3 C H3
fe2707klc2 HNMR.esp
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y2-Hydroxy-6-methoxycarbonylmethoxy-benzoic acid (KC_03)
Acquisition Time (sec) 2.7329 Comment KC/4494/88_P1 Date 19 Mar 2007 19:35:28
Date Stamp 19 Mar 2007 19:35:28
File Name D:\KRYSTLE CAREY\MY DOCUMENTS\THE LAST HURDLE\DATA\CHEMISTRY DATA\2007 NMR FILES\MA1907KLC1\10\PDATA\1\1r
Frequency (MHz) 300.13 Nucleus 1H Number of Transients 16 Origin av300
Original Points Count 16384 Owner nmr Points Count 16384 Pulse Sequence zg30
Receiver Gain 512.00 SW(cyclical) (Hz) 5995.20 Solvent CHLOROFORM-d Spectrum Offset (Hz) 1497.8613
Spectrum Type STANDARD Sweep Width (Hz) 5994.84 Temperature (degree C) 27.160
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MA1907KLC1 HNMR.esp
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y2-Hydroxy-6-(3-methoxycarbonyl-propoxy)-benzoic acid methyl ester (KC_04)
Acquisition Time (sec) 2.7329 Comment KC4494:94.P1 Date 13 Apr 2007 21:22:24
Date Stamp 13 Apr 2007 21:22:24
File Name D:\KRYSTLE CAREY\MY DOCUMENTS\THE LAST HURDLE\DATA\CHEMISTRY DATA\2007 NMR FILES\AP1307LS2\10\PDATA\1\1r
Frequency (MHz) 300.13 Nucleus 1H Number of Transients 16 Origin av300
Original Points Count 16384 Owner nmr Points Count 16384 Pulse Sequence zg30
Receiver Gain 512.00 SW(cyclical) (Hz) 5995.20 Solvent CHLOROFORM-d Spectrum Offset (Hz) 1497.8611
Spectrum Type STANDARD Sweep Width (Hz) 5994.84 Temperature (degree C) 27.160
OH
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CH3
AP1307LS2.010.001.1r.esp
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y4-(2, 2-Dimethyl-4-oxo-4H-1,3-benzodioxin-5-yloxy)-butyric acid ethyl ester (KC_05)
Acquisition Time (sec) 2.7329 Comment KC/4494/92_P2 Date 30 Mar 2007 04:29:04
Date Stamp 30 Mar 2007 04:29:04
File Name d:\Krystle Carey\My Documents\The Last Hurdle\Data\Chemistry Data\2007 NMR Files\ma2907klc2\10\PDATA\1\1r
Frequency (MHz) 300.13 Nucleus 1H Number of Transients 16 Origin av300
Original Points Count 16384 Owner nmr Points Count 16384 Pulse Sequence zg30
Receiver Gain 203.20 SW(cyclical) (Hz) 5995.20 Solvent CHLOROFORM-d
Spectrum Offset (Hz) 1497.8611 Spectrum Type STANDARD Sweep Width (Hz) 5994.84 Temperature (degree C) 27.160
O
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O
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CH3 C H3
ma2907klc2 HNMR.esp
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yHydroxy-6-(3-methoxycarbonyl-propoxy)-benzoic acid (KC_06)
Acquisition Time (sec) 2.7329 Comment KC/4494/94 Date 12 Apr 2007 20:33:20
Date Stamp 12 Apr 2007 20:33:20
File Name d:\Krystle Carey\My Documents\The Last Hurdle\Data\Chemistry Data\2007 NMR Files\ap1207klc2\10\PDATA\1\1r
Frequency (MHz) 300.13 Nucleus 1H Number of Transients 16 Origin av300
Original Points Count 16384 Owner nmr Points Count 16384 Pulse Sequence zg30
Receiver Gain 574.70 SW(cyclical) (Hz) 5995.20 Solvent CHLOROFORM-d
Spectrum Offset (Hz) 1497.8612 Spectrum Type STANDARD Sweep Width (Hz) 5994.84 Temperature (degree C) 27.160
OH
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ap1207klc2 HNMR.esp
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y2- (2, Dimethyl-4-oxo-4H-1, 3-benzodioxin-5-yloxy)-N-(2-morpholin-4-yl-ethyl)-acetamide (KC_07)
Acquisition Time (sec) 2.7329 Comment KC/4494/79_P Date 06 Feb 2007 10:35:44
Date Stamp 06 Feb 2007 10:35:44
File Name D:\KRYSTLE CAREY\MY DOCUMENTS\THE LAST HURDLE\DATA\CHEMISTRY DATA\THESIS NMR FILES\FE0607KLC1\10\PDATA\1\1r
Frequency (MHz) 300.13 Nucleus 1H Number of Transients 16 Origin av300
Original Points Count 16384 Owner nmr Points Count 16384 Pulse Sequence zg30
Receiver Gain 181.00 SW(cyclical) (Hz) 5995.20 Solvent CHLOROFORM-d Spectrum Offset (Hz) 1504.6903
Spectrum Type STANDARD Sweep Width (Hz) 5994.84 Temperature (degree C) 27.160
O
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N
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CH3 C H3
FE0607KLC1 HNMR.esp
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y2-Hydroxy-6-[(2-morpholin-4-yl-ethylcarbamoyl)-methoxy]-benzoic acid (KC_08)
Acquisition Time (sec) 2.7329 Comment KC/4494/95 Date 04 Apr 2007 14:00:48
Date Stamp 04 Apr 2007 14:00:48
File Name d:\Krystle Carey\My Documents\The Last Hurdle\Data\Chemistry Data\2007 NMR Files\ap0407klc1\10\PDATA\1\1r
Frequency (MHz) 300.13 Nucleus 1H Number of Transients 16 Origin av300
Original Points Count 16384 Owner nmr Points Count 16384 Pulse Sequence zg30
Receiver Gain 287.40 SW(cyclical) (Hz) 5995.20 Solvent METHANOL-d4 Spectrum Offset (Hz) 1496.0190
Spectrum Type STANDARD Sweep Width (Hz) 5994.84 Temperature (degree C) 27.160
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y2-Hydroxy-N-(2-morpholin-4-yl-ethyl)-6-[(2-morpholin-4-yl-ethylcarbamoyl)-methoxy]-benzamide (KC_09)
Acquisition Time (sec) 2.7329 Comment KC/4494/77_P Date 01 Feb 2007 14:53:52
Date Stamp 01 Feb 2007 14:53:52
File Name d:\Krystle Carey\My Documents\The Last Hurdle\Data\Chemistry Data\Thesis NMR files\fe0107klc1\10\PDATA\1\1r
Frequency (MHz) 300.13 Nucleus 1H Number of Transients 16 Origin av300
Original Points Count 16384 Owner nmr Points Count 16384 Pulse Sequence zg30
Receiver Gain 322.50 SW(cyclical) (Hz) 5995.20 Solvent CHLOROFORM-d
Spectrum Offset (Hz) 1497.8611 Spectrum Type STANDARD Sweep Width (Hz) 5994.84 Temperature (degree C) 27.160
OH
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N
O
fe0107klc1.010.001.1r.esp
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yN-(2-Acetylamino-ethyl)-2-(2,2-dimethyl-4-oxo-4H-1,3-benzodioxin-5-yloxy)-acetamide (KC_10)
Acquisition Time (sec) 2.7329 Comment KC/4494/80_P2 Date 09 Feb 2007 22:00:32
Date Stamp 09 Feb 2007 22:00:32
File Name d:\Krystle Carey\My Documents\The Last Hurdle\Data\Chemistry Data\QR1 to TR NMR files\fe0907klc2\10\PDATA\1\1r
Frequency (MHz) 300.13 Nucleus 1H Number of Transients 16 Origin av300
Original Points Count 16384 Owner nmr Points Count 16384 Pulse Sequence zg30
Receiver Gain 574.70 SW(cyclical) (Hz) 5995.20 Solvent CHLOROFORM-d
Spectrum Offset (Hz) 1497.8611 Spectrum Type STANDARD Sweep Width (Hz) 5994.84 Temperature (degree C) 27.160
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fe0907klc2 HNMR.esp
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y2-[(2-Acetylamino-ethylcarbamoyl)-methoxy]-6-hydroxy-benzoic acid (KC_11)
Acquisition Time (sec) 2.7329 Comment KC/4494/97 Date 17 May 2007 02:29:36
Date Stamp 17 May 2007 02:29:36
File Name d:\Krystle Carey\My Documents\The Last Hurdle\Chemistry Data\2007 NMR Files\my1607klc1\10\PDATA\1\1r
Frequency (MHz) 300.13 Nucleus 1H Number of Transients 16 Origin av300
Original Points Count 16384 Owner nmr Points Count 16384 Pulse Sequence zg30
Receiver Gain 362.00 SW(cyclical) (Hz) 5995.20 Solvent METHANOL-d4 Spectrum Offset (Hz) 1496.0189
Spectrum Type STANDARD Sweep Width (Hz) 5994.84 Temperature (degree C) 25.160
O O H
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OH O
my1607klc1 HNMR.esp
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y2-Hydroxy-6-octyloxy-benzoic acid (KC_15)
Acquisition Time (sec) 1.9923 Comment KC4494:P8-P3 Date 21 May 2007 17:29:36
Date Stamp 21 May 2007 17:29:36 File Name d:\Krystle Carey\My Documents\PhD Project\Chemistry\Q8\NMR Data\my2107th2\1\fid
Frequency (MHz) 400.13 Nucleus 1H Number of Transients 16 Origin spect
Original Points Count 16384 Owner jms Points Count 16384 Pulse Sequence zg30
Receiver Gain 228.10 SW(cyclical) (Hz) 8223.68 Solvent CHLOROFORM-d
Spectrum Offset (Hz) 2454.4438 Spectrum Type STANDARD Sweep Width (Hz) 8223.18 Temperature (degree C) 27.000
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my2107th2.001.esp
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y2, 2-Dimethyl-5-tetradecyloxy-1, 3-benzodioxin-4-one (KC_20)
Acquisition Time (sec) 2.7329 Comment KC-4960-05 Date 16 Aug 2007 19:03:44
Date Stamp 16 Aug 2007 19:03:44
File Name d:\Krystle Carey\My Documents\The Last Hurdle\Data\Chemistry Data\2007 NMR Files\au1607klc1\10\PDATA\1\1r
Frequency (MHz) 300.13 Nucleus 1H Number of Transients 16 Origin av300
Original Points Count 16384 Owner nmr Points Count 16384 Pulse Sequence zg30
Receiver Gain 322.50 SW(cyclical) (Hz) 5995.20 Solvent CHLOROFORM-d
Spectrum Offset (Hz) 1497.4950 Spectrum Type STANDARD Sweep Width (Hz) 5994.84 Temperature (degree C) 25.160
O
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O
C H3 CH3
CH3
au1607klc1.010.001.1r.esp
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y2, 2-Dimethyl -5 -pentyloxy-1, 3-benzodioxin-4-one (KC_21)
Acquisition Time (sec) 2.7329 Comment KC4960:10 Date 28 Aug 2007 14:26:08
Date Stamp 28 Aug 2007 14:26:08
File Name C:\DOCUMENTS AND SETTINGS\KRYSTLE CAREY\DESKTOP\PHD PROJECT\CHEMISTRY\Q8\NMR DATA\AU2807KC1\AU2807KC1_010000FID
Frequency (MHz) 300.13 Nucleus 1H Number of Transients 16 Origin av300
Original Points Count 16384 Owner nmr Points Count 65536 Pulse Sequence zg30
Receiver Gain 287.40 SW(cyclical) (Hz) 5995.20 Solvent CHLOROFORM-d Spectrum Offset (Hz) 1497.3687
Sweep Width (Hz) 5995.11 Temperature (degree C) 25.160
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AU2807KC1_HNMR.esp
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y2-Hydroxy-6-pentyloxy-benzoic acid (KC_22)
Acquisition Time (sec) 2.7329 Comment KC-4960-16 Date 06 Sep 2007 21:56:16
Date Stamp 06 Sep 2007 21:56:16
File Name C:\DOCUMENTS AND SETTINGS\KRYSTLE CAREY\DESKTOP\PHD PROJECT\CHEMISTRY\Q8\NMR DATA\SE0607KLC1\SE0607KLC1_010000FID
Frequency (MHz) 300.13 Nucleus 1H Number of Transients 16 Origin av300
Original Points Count 16384 Owner nmr Points Count 65536 Pulse Sequence zg30
Receiver Gain 322.50 SW(cyclical) (Hz) 5995.20 Solvent CHLOROFORM-d Spectrum Offset (Hz) 1497.3688
Sweep Width (Hz) 5995.11 Temperature (degree C) 25.160
OH
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SE0607KLC1_HNMR.esp
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y5-Hexyloxy-2,2-dimethyl-1,3-benzodioxin-4-one (KC_23)
Acquisition Time (sec) 2.7329 Comment KC/4494/100_P Date 25 Jul 2007 00:06:24
Date Stamp 25 Jul 2007 00:06:24
File Name C:\DOCUMENTS AND SETTINGS\KRYSTLE CAREY\DESKTOP\PHD PROJECT\CHEMISTRY\Q8\NMR DATA\JY2407KLC1\JY2407KLC1_010000FID
Frequency (MHz) 300.13 Nucleus 1H Number of Transients 16 Origin av300
Original Points Count 16384 Owner nmr Points Count 65536 Pulse Sequence zg30
Receiver Gain 287.40 SW(cyclical) (Hz) 5995.20 Solvent CHLOROFORM-d Spectrum Offset (Hz) 1497.4602
Sweep Width (Hz) 5995.11 Temperature (degree C) 25.160
O
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CH3
JY2407KLC1_HNMR.esp
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y2-Hexyloxy-6-hydroxyl benzoic acid (KC_24)
Acquisition Time (sec) 2.7329 Comment KC-4960-03 Date 03 Aug 2007 16:00:00
Date Stamp 03 Aug 2007 16:00:00
File Name C:\DOCUMENTS AND SETTINGS\KRYSTLE CAREY\DESKTOP\PHD PROJECT\CHEMISTRY\Q8\NMR DATA\AU0307KLC1\AU0307KLC1_010000FID
Frequency (MHz) 300.13 Nucleus 1H Number of Transients 16 Origin av300
Original Points Count 16384 Owner nmr Points Count 65536 Pulse Sequence zg30
Receiver Gain 322.50 SW(cyclical) (Hz) 5995.20 Solvent CHLOROFORM-d Spectrum Offset (Hz) 1497.4603
Sweep Width (Hz) 5995.11 Temperature (degree C) 25.160
OH
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O CH3
AU0307KLC1_HNMR.esp
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y5-Heptyloxy-2,2-dimethyl -benzo[1,3] dioxin-4-one (KC_25)
Acquisition Time (sec) 2.7329 Comment KC-4960-09 Date 22 Aug 2007 18:05:52
Date Stamp 22 Aug 2007 18:05:52
File Name C:\DOCUMENTS AND SETTINGS\KRYSTLE CAREY\DESKTOP\PHD PROJECT\CHEMISTRY\Q8\NMR DATA\AU2207KLC2\AU2207KLC2_010000FID
Frequency (MHz) 300.13 Nucleus 1H Number of Transients 16 Origin av300
Original Points Count 16384 Owner nmr Points Count 65536 Pulse Sequence zg30
Receiver Gain 287.40 SW(cyclical) (Hz) 5995.20 Solvent CHLOROFORM-d Spectrum Offset (Hz) 1497.4603
Sweep Width (Hz) 5995.11 Temperature (degree C) 25.160
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AU2207KLC2_HNMR.esp
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y2-Heptyloxy-6-hydroxy-benzoic acid (KC_26)
Acquisition Time (sec) 2.7329 Comment KC-4960-15 Date 13 Sep 2007 11:16:16
Date Stamp 13 Sep 2007 11:16:16
File Name C:\DOCUMENTS AND SETTINGS\KRYSTLE CAREY\DESKTOP\PHD PROJECT\CHEMISTRY\Q8\NMR DATA\SE1307KLC1\SE1307KLC1_010000FID
Frequency (MHz) 300.13 Nucleus 1H Number of Transients 16 Origin av300
Original Points Count 16384 Owner nmr Points Count 65536 Pulse Sequence zg30
Receiver Gain 362.00 SW(cyclical) (Hz) 5995.20 Solvent CHLOROFORM-d Spectrum Offset (Hz) 1497.4603
Sweep Width (Hz) 5995.11 Temperature (degree C) 25.160
OH
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SE1307KLC1_HNMR.esp
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y7-Methoxy-2,2-dimethyl-5-octyloxy-1,3-benzodioxin-4-one (KC_31)
Acquisition Time (sec) 2.7329 Comment KC-4960-18 Date 10 Sep 2007 23:08:48
Date Stamp 10 Sep 2007 23:08:48
File Name C:\DOCUMENTS AND SETTINGS\KRYSTLE CAREY\DESKTOP\PHD PROJECT\CHEMISTRY\Q8\NMR DATA\SE1007KLC2\SE1007KLC2_010000FID
Frequency (MHz) 300.13 Nucleus 1H Number of Transients 16 Origin av300
Original Points Count 16384 Owner nmr Points Count 65536 Pulse Sequence zg30
Receiver Gain 287.40 SW(cyclical) (Hz) 5995.20 Solvent CHLOROFORM-d Spectrum Offset (Hz) 1497.3687
Sweep Width (Hz) 5995.11 Temperature (degree C) 25.160
O
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O
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CH3
SE1007KLC2_HNMR.esp
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y2-Hydroxy-4-methoxy-6-octyloxy-benzoic acid (KC_32)
Acquisition Time (sec) 1.9923 Comment KC4960:19.P Date 23 Nov 2007 22:26:08
Date Stamp 23 Nov 2007 22:26:08
File Name C:\DOCUMENTS AND SETTINGS\KRYSTLE CAREY\DESKTOP\PHD PROJECT\CHEMISTRY\Q9\NMR\NV2307LS1\NV2307LS1_010000FID
Frequency (MHz) 400.13 Nucleus 1H Number of Transients 32 Origin spect
Original Points Count 16384 Owner jms Points Count 65536 Pulse Sequence zg30
Receiver Gain 406.40 SW(cyclical) (Hz) 8223.68 Solvent CHLOROFORM-d Spectrum Offset (Hz) 2454.6501
Sweep Width (Hz) 8223.56 Temperature (degree C) 27.000
OH
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NV2307LS1_HNMR.esp
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y2,2-Dimethyl -5 -phenethyloxy-1,3-benzodioxin-4-one (KC_33)
Acquisition Time (sec) 2.7329 Comment KC-4960-11 Date 29 Aug 2007 23:10:56
Date Stamp 29 Aug 2007 23:10:56
File Name C:\DOCUMENTS AND SETTINGS\KRYSTLE CAREY\DESKTOP\PHD PROJECT\CHEMISTRY\Q8\NMR DATA\AU2907KLC1\AU2907KLC1_010000FID
Frequency (MHz) 300.13 Nucleus 1H Number of Transients 16 Origin av300
Original Points Count 16384 Owner nmr Points Count 65536 Pulse Sequence zg30
Receiver Gain 362.00 SW(cyclical) (Hz) 5995.20 Solvent CHLOROFORM-d Spectrum Offset (Hz) 1466.7230
Sweep Width (Hz) 5995.11 Temperature (degree C) 25.160
O
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AU2907KLC1_HNMR.esp
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y2-Hydroxy-6-phenethyloxy-benzoic acid (KC_34)
Acquisition Time (sec) 2.7329 Comment KC-4960-17 Date 10 Sep 2007 23:00:16
Date Stamp 10 Sep 2007 23:00:16
File Name C:\DOCUMENTS AND SETTINGS\KRYSTLE CAREY\DESKTOP\PHD PROJECT\CHEMISTRY\Q8\NMR DATA\SE1007KLC1\SE1007KLC1_010000FID
Frequency (MHz) 300.13 Nucleus 1H Number of Transients 16 Origin av300
Original Points Count 16384 Owner nmr Points Count 65536 Pulse Sequence zg30
Receiver Gain 512.00 SW(cyclical) (Hz) 5995.20 Solvent CHLOROFORM-d Spectrum Offset (Hz) 1481.1769
Sweep Width (Hz) 5995.11 Temperature (degree C) 25.160
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y8-Octyloxy-1-benzopyran-2-one (KC_36)
Acquisition Time (sec) 2.7329 Comment KC-4960-24_P Date 29 Oct 2007 18:44:16
Date Stamp 29 Oct 2007 18:44:16
File Name C:\DOCUMENTS AND SETTINGS\KRYSTLE CAREY\DESKTOP\PHD PROJECT\CHEMISTRY\Q9\NMR\OC2907KLC1\OC2907KLC1_010000FID
Frequency (MHz) 300.13 Nucleus 1H Number of Transients 16 Origin av300
Original Points Count 16384 Owner nmr Points Count 65536 Pulse Sequence zg30
Receiver Gain 322.50 SW(cyclical) (Hz) 5995.20 Solvent CHLOROFORM-d Spectrum Offset (Hz) 1496.7428
Sweep Width (Hz) 5995.11 Temperature (degree C) 25.160
O
O O
CH3
OC2907KLC1_HNMR.esp
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y2, 2-Dimethyl-5-(4-phenyl-butoxy)-1,3-benzodioxin-4-one (KC_37)
Acquisition Time (sec) 1.9923 Comment KC4960:26_P (ex AV300/1 position 4) Date 20 Nov 2007 11:14:08
Date Stamp 20 Nov 2007 11:14:08
File Name C:\DOCUMENTS AND SETTINGS\KRYSTLE CAREY\DESKTOP\PHD PROJECT\CHEMISTRY\Q9\NMR\NV2007KC2\NV2007KC2_001000FID
Frequency (MHz) 400.13 Nucleus 1H Number of Transients 16 Origin spect
Original Points Count 16384 Owner jms Points Count 65536 Pulse Sequence zg30
Receiver Gain 228.10 SW(cyclical) (Hz) 8223.68 Solvent CHLOROFORM-d Spectrum Offset (Hz) 2454.5247
Sweep Width (Hz) 8223.56 Temperature (degree C) 27.000
O
O O
CH3 C H3
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y2-Hydroxy-6-(4-phenyl-butoxy)-benzoic acid (KC_38)
Acquisition Time (sec) 2.7329 Comment KC-4960-32-P Date 10 Dec 2007 22:17:36
Date Stamp 10 Dec 2007 22:17:36
File Name C:\DOCUMENTS AND SETTINGS\KRYSTLE CAREY\DESKTOP\PHD PROJECT\CHEMISTRY\Q9\NMR\DC1007KLC2\DC1007KLC2_010000FID
Frequency (MHz) 300.13 Nucleus 1H Number of Transients 16 Origin av300
Original Points Count 16384 Owner nmr Points Count 65536 Pulse Sequence zg30
Receiver Gain 645.10 SW(cyclical) (Hz) 5995.20 Solvent CHLOROFORM-d Spectrum Offset (Hz) 1497.3689
Sweep Width (Hz) 5995.11 Temperature (degree C) 19.160
O
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y5-[2-(1H-Indol-3-yl)-ethoxy]-2,2-dimethyl-1,3-benzodioxin-4-one (KC_39)
Acquisition Time (sec) 2.7329 Comment KC-4960-27-P2 Date 12 Dec 2007 19:01:20
Date Stamp 12 Dec 2007 19:01:20
File Name C:\DOCUMENTS AND SETTINGS\KRYSTLE CAREY\DESKTOP\PHD PROJECT\CHEMISTRY\Q9\NMR\DC1207KLC1\DC1207KLC1_010000FID
Frequency (MHz) 300.13 Nucleus 1H Number of Transients 16 Origin av300
Original Points Count 16384 Owner nmr Points Count 65536 Pulse Sequence zg30
Receiver Gain 724.10 SW(cyclical) (Hz) 5995.20 Solvent CHLOROFORM-d Spectrum Offset (Hz) 1497.3689
Sweep Width (Hz) 5995.11 Temperature (degree C) 20.160
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y2-Hydroxy-6-[2-(1H-indole-3yl)-ethoxy]-benzoic acid (KC_40)
Acquisition Time (sec) 2.7329 Comment KC-4960-34-P Date 19 Dec 2007 11:39:44
Date Stamp 19 Dec 2007 11:39:44
File Name C:\DOCUMENTS AND SETTINGS\KRYSTLE CAREY\DESKTOP\PHD PROJECT\CHEMISTRY\Q9\NMR\DC1907KLC1\DC1907KLC1_010000FID
Frequency (MHz) 300.13 Nucleus 1H Number of Transients 16 Origin av300
Original Points Count 16384 Owner nmr Points Count 65536 Pulse Sequence zg30
Receiver Gain 1625.50 SW(cyclical) (Hz) 5995.20 Solvent CHLOROFORM-d Spectrum Offset (Hz) 1497.2771
Sweep Width (Hz) 5995.11 Temperature (degree C) 25.160
O
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y5-[2-(4-Methoxy-phenyl)-ethoxy)-2,2-dimethyl-benzo-[1,3]-dioxin-4-one (KC_41)
Acquisition Time (sec) 1.9923 Comment kc4960:28_P (ex AV300/1 position 4) Date 28 Nov 2007 14:02:40
Date Stamp 28 Nov 2007 14:02:40
File Name C:\DOCUMENTS AND SETTINGS\KRYSTLE CAREY\DESKTOP\PHD PROJECT\CHEMISTRY\Q9\NMR\NV2807KC1\NV2807KC1_001000FID
Frequency (MHz) 400.13 Nucleus 1H Number of Transients 16 Origin spect
Original Points Count 16384 Owner jms Points Count 65536 Pulse Sequence zg30
Receiver Gain 322.50 SW(cyclical) (Hz) 8223.68 Solvent CHLOROFORM-d Spectrum Offset (Hz) 2454.7756
Sweep Width (Hz) 8223.56 Temperature (degree C) 27.000
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NV2807KC1_HNMR.esp
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y2-Hydroxy-6-[2-(4-methoxy-phenyl)-ethoxy]-benzoic acid (KC_42)
Acquisition Time (sec) 2.7329 Comment KC-4960-33-P Date 30 Nov 2007 22:32:32
Date Stamp 30 Nov 2007 22:32:32
File Name C:\DOCUMENTS AND SETTINGS\KRYSTLE CAREY\DESKTOP\PHD PROJECT\CHEMISTRY\Q9\NMR\NV3007KLC3\NV3007KLC3_010000FID
Frequency (MHz) 300.13 Nucleus 1H Number of Transients 16 Origin av300
Original Points Count 16384 Owner nmr Points Count 65536 Pulse Sequence zg30
Receiver Gain 574.70 SW(cyclical) (Hz) 5995.20 Solvent CHLOROFORM-d Spectrum Offset (Hz) 1497.4602
Sweep Width (Hz) 5995.11 Temperature (degree C) 25.160
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y1-Ethoxy-3-octyloxy-benzene (KC_43)
Acquisition Time (sec) 2.7329 Comment KC-4960-20-IMP Date 22 Sep 2007 13:56:16
Date Stamp 22 Sep 2007 13:56:16
File Name C:\DOCUMENTS AND SETTINGS\KRYSTLE CAREY\DESKTOP\PHD PROJECT\CHEMISTRY\Q9\NMR\SE2107KLC1\SE2107KLC1_010000FID
Frequency (MHz) 300.13 Nucleus 1H Number of Transients 16 Origin av300
Original Points Count 16384 Owner nmr Points Count 65536 Pulse Sequence zg30
Receiver Gain 322.50 SW(cyclical) (Hz) 5995.20 Solvent CHLOROFORM-d Spectrum Offset (Hz) 1497.4603
Sweep Width (Hz) 5995.11 Temperature (degree C) 25.160
O
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y2-Ethoxy-6-octyloxy-benzoic acid ethyl ester (KC_44)
Acquisition Time (sec) 1.9923 Comment KC4960:31-P Date 30 Nov 2007 19:09:52
Date Stamp 30 Nov 2007 19:09:52
File Name C:\Documents and Settings\Krystle Carey\Desktop\PhD Project\Chemistry\Q9\NMR\nv3007th2\nv3007th2_001000fid
Frequency (MHz) 400.13 Nucleus 1H Number of Transients 16 Origin spect
Original Points Count 16384 Owner jms Points Count 65536 Pulse Sequence zg30
Receiver Gain 228.10 SW(cyclical) (Hz) 8223.68 Solvent CHLOROFORM-d
Spectrum Offset (Hz) 2454.5247 Sweep Width (Hz) 8223.56 Temperature (degree C) 27.000
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